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1. Summary
Pancreatic ?-cell death is the fundamental cause of type 1 and type 2 diabetes (T1/T2D). 
Loss of function and survival signals and the activation of pro-apoptotic mediators are 
characteristic for diabetic ?-cells. Strategies to prevent ?-cell apoptosis and restore ?-cell 
survival are currently unavailable; thus in urgent need and critical for an effective treatment 
???????????????????????????????????-cell death in a diabetic milieu are complex and not 
well defined; multiple triggering factors have been identified, which initiate a variety of 
?????????? ????????? ??? ?-cells that affect the expression of apoptotic genes and the 
????????????-cell failure. T?????????????????????????????????????????????-cell apoptosis 
offers novel therapeutic targets for the treatment of diabetes. Mammalian sterile 20-like 
kinase 1 (MST1) is a serine threonine kinase, which mediates apoptosis in response to 
cytotoxic stress. MST1 is both, cleaved and activated by caspases, and also serves as an 
activator of caspases to amplify the apoptotic signaling pathways. In search for a common 
pro-apoptotic pathway, I investigated whether MST1 ??????????-cell death in diabetes. In 
the present thesis, I explored the possible patho-?????????????????????????????????????-cells 
under diabetic conditions and its downstream signaling, which may be a major common 
???????? ??? ?-cell death in diabetes. My data establish MST1 as a master regulator of 
???????????-cell death.
??????? ????????????????????????????????? ????-cells under diabetogenic conditions in vitro
and in vivo. MST1 cleavage & phosphorylation was increased in human and mouse 
primary islets and in the ?-cell line INS-1E cells when exposed to a complex diabetic 
milieu. This correlated with the activation of known MST1 targets (H2B, JNK), increased ?-
cell apoptosis and impaired insulin secretion. Notably, MST1 activation and ?-cell 
apoptosis were profoundly increased in diabetic islets from T2D patients, obese diabetic 
Leprdb/db mice as well as hyperglycemic high fat/ high sucrose fed mice. My data suggest a 
potential crosstalk between MST1 and pro-survival PI3K/AKT signaling pathways. MST1 
and AKT negatively regulated each other and constitute a stress-sensitive survival 
pathway. Under acute stress conditions, AKT promoted cell survival by inhibiting MST1, but 
prolonged stress decreased AKT, which allowed pro-apoptotic MST1 signaling.
Overexpression of MST1 itself increased ?-cell apoptosis and impaired function indicating 
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that MST1 alone is sufficient to promote ?-cell failure. MST1 overexpression decreased 
antiapoptotic PDX1, Bcl-2 and Bcl-xL and increased proapoptotic Bax, Bim and 
cytochrome c release and activation of caspase-9 and -3 indicating activation of the 
mitochondrial (intrinsic) pathway of cell death. 
?????-cell transcription factor pancreatic duodenal homeobox-1 (PDX1) was identified as a 
novel MST1 substrate. MST1 overexpression in ?-cells strongly decreased PDX1 without 
changes in PDX1 mRNA levels; this demonstrates that the decrease in PDX1 expression 
was regulated at the post-transcriptional level and related to its reduced stability. MST1 
directly phosphorylated PDX1 at Thr11, resulting in its ubiquitination and degradation and 
subsequent reduction in PDX1 target genes and loss of glucose-stimulated insulin 
secretion. Amazingly, PDX1-phosho-deficient mutant (T11-PDX1) restored PDX1 function 
and insulin secretion. This suggests (1) that MST1-induced PDX1 phosphorylation at T11 
leads directly to PDX1 de-stabilization and impaired ?-cell function and (2) that PDX1 is a 
?????????????????????????????????????????????-cell function. MST1 deficiency restored ?-cell 
function and survival in human and rodent cells. MST1-knock down in ?-cells protected 
them from cell death induced by multiple diabetic stimuli. Importantly, detailed in vivo
studies show that MST1 deficient mice did not develop diabetes.
Together, my work shows that MST1 acts as an essential apoptotic molecule in the 
presence of diabetic stimuli and is a common component in the diverse signaling pathways 
????????????-cell apoptosis. My results suggest that MST1 is a critical mediator of impaired
?-cell function and apoptosis. Inhibiting the MST1-pathway could be an important strategy 
????????????-cell apoptosis.
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1.Zusammenfassung
Sowohl im autoimmun induzierten Typ 1 Diabetes (T1D), als auch im Übergewicht-
????????????? ???? ?? ????????? ?????? ???? ???? ?????????? ???? ??????????????? ?-Zellen die 
grundlegende Ursache für das Ausbrechen der Krankheit. Proapoptotische 
??????????????? ????? ????????????????? ???? ???????????? ?-Zellen, induzieren deren 
Funktionsverlust und führen letztendlich zur verringerten Lebenszeit der Zellen. Die 
???????????????????????????????-Zelltods und eine Verbesserung der Überlebensrate sind 
wichtige Ansatzpunkte für eine wirksame Behandlung des Diabetes, jedoch noch nicht 
????????????????????????????????-Zelltods im diabetischen Milieu sind komplex und nicht 
vollständig aufgeklärt; es wurden verschiedene Faktoren identifiziert, die eine Vielzahl von 
???????????? ?????? ????? ??? ???? ?-Zelle auslösen und damit die Expression von pro-
?????????????? ?????? ???? ???? ?????????????? ?-Zellen-Zerstörung bewirken. Die genaue 
Kenntnis dieser Signalwege ist ein Sch???????????????????????????-Zellapoptose und bietet 
neue therapeutische Ansatzpunkte für die Behandlung von Diabetes. 
Mammalian Sterile 20-like Kinase 1 (MST1) ist eine Serin-Threonin-Kinase, die Apoptose 
in Abhängigkeit von zytotoxischem Stress direkt vermittelt. Apoptotische Signalwege 
werden durch MST1 sowohl initiiert, als auch amplifiziert: die wichtige Effektor-Caspase 3 
wird angeschaltet, um dann rückwirkend selbst MST1 wieder zu aktivieren. Auf der Suche 
nach einem allgemeingültigen Apoptoseweg während des Ausbruchs des Diabetes 
???????????? ????? ??? ????? ???????????? ???? ????? ??????????????? ???? ???? ?-Zelltod unter 
diabetogenen Bedingungen ist und ob MST1 selbst die Zerstörung der ?-Zelle auslöst.
Die Ergebnisse meiner Arbeit etablieren MST1 als Hauptr????????? ???? ?????????????? ?-
Zelltods im Diabetes. Unter diabetogenen Bedingungen nahm sowohl die Spaltung, als 
??????????????????????????????????????-Zellen in vitro und in vivo zu. Nach Inkubation in 
einem komplexen diabetischen Milieu konnte dies in menschlichen Inselzellen, in 
??????????? ???? ??? ???? ?-Zelllinie INS1E gezeigt werden. Dies korrelierte mit der 
???????????? ?????????? ????? ???????? ?????? ?????? ????????? ?-Zellapoptoserate und 
beeinträchtigter Insulinsekretion. In Inselzellen von T2D Patienten konnte MST1-
???????????? ???? ? ?-Zell-Apoptose  beobachtet werden. Dies zeigte sich auch in 
diabetischen Mausmodellen,  z.B.  in  leptindefizienten übergewichtigen Leprdb/db Mäusen 
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und in hyperglykämischen Mäusen, die mit einer zucker- und fetthaltigen Diät gefüttert 
wurden. 
Meine Daten deuten auf eine mögliche Interaktion von pro-apoptotischen MST1- und pro-
überlebens-PI3K/AKT kontrollierten Signalwegen hin, dadurch wird ein stress-sensitiver 
Überlebensweg gebildet. Dosis facit venenum: unter akuten Stressbedingungen fördert 
AKT das Überleben der Zelle durch Hemmung von MST1, anhaltender Stress verringert 
jedoch AKT und erlaubt die pro-apoptotische MST1 Initialisierung. Überexpression von 
???????????? ??????? ?-Zell-????????????? ?????? ??????? ????????????????? ??????????? ????-
Zellen in einen diabetischen Phenotyp umzuwandeln. MST1 Überexpression verringert 
anti-apoptotische Regulatoren wie PDX1, Bcl-2 und Bcl-xL und induzierte die Expression 
der pro-apoptotischen Gene Bax und Bim, sowie Cytochrom c-Freisetzung aus den 
Mitochondrien ins Zytosol. Die daraus erfolgende Aktivierung von Caspase-9 und -3 zeigt 
Beteiligung des mitochondrialen (intrinsischen) Zelltod-Weges.
?????-zellspezifische Transkriptionsfaktor Duodenal-Homeobox-1 (PDX1) wurde als neues 
MST1-????????? ??????????????? ????? ??????????????? ??? ?-Zellen verminderte das Protein 
PDX1, ohne jedoch die mRNA Levels zu beeinträchtigen. Dies zeigt, dass der Verlust an 
PDX1 auf post-transkriptioneller Ebene reguliert wurde und ein Resultat verminderter 
Stabilität ist. Ich identifizierten die genaue Phosphorylierungsstelle von PDX1: Threonin 11 
(T11). PDX-1 Phosphorylierung an T11 führte zur Ubiquitinierung und Degradierung mit 
anschließender Reduktion der PDX1 nachgeschalteten Gene und zum Verlust der 
Glucose-stimulierten Insulinsekretion. Die PDX1-phosho-Mutante T11-PDX1 zeigte keine 
beeinträchtigte Insulinsekretion und bestätigte damit unsere Ergebnisse. Dies legt nahe, 
dass (1) MST1-induzierte Phosphorylierung von PDX1 an T11 direkt zu PDX1-
????????????????? ???? ????????????????? ???? ?-Zellfunktion führt und dass (2) PDX1 ein 
???????????????????????????????????????????????????????-Zellfunktion darstellt.
Das Ausschalten von MST1 führte zu verb????????? ?????????? ???? ????????? ???? ?-Zelle und 
schützt vor Diabetes,  wie ich durch detaillierte in vivo Studien mit MST1 defizienten Mäuse 
bestätigen konnten. Zusammenfassend zeigt meine Arbeit, dass MST1 als wichtiges pro-
apoptotisches Molekül wirkt, das in Gegenwart von diabetischen Stimuli angeschaltet wird und zu 
?-Zell-Apoptose, Verlust der Insulinsekretion und Diabetes führt. Somit ist die Hemmung des 
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MST1-Signalweges eine wichtige Strategie zum Schutz der ?-Zelle und legt ein neues 
Therapiekonzept zur Behandlung des Diabetes vor.
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2. Introduction
This thesis has established a novel strategy to promote survival of the pancreatic ?-cells, 
whose destruction is a major cause of immune-mediated T1 Diabetes Mellitus (T1D) and a 
contributing factor in obesity associated T2 Diabetes Mellitus (T2D). The following chapter 
will introduce the morphology of the insulin producing ?-cells and their localization in the 
pancreas, mechanisms of hormone secretion to establish normoglycemia, the 
pathophysiology of diabetes, mechanisms of apoptotic cell death and the kinase MST1 as 
a major regulator of cell survival.
2.1. Pancreas: structure and function
The pancreas is a gland organ of the digestive as well as the endocrine systems of 
vertebrates. It is localized posterior to the stomach, anterior to the kidneys, and empties 
into the duodenum portion of the small intestine. Its size differs from 12.5 to 15 cm and 
weighs from 60 to 100 g [1] (Figure1).
Figure 1. The Pancreas (adapted from [1]). The pancreas is located in the abdomen behind the 
stomach. The head of the pancreas is located on the right side of the abdomen, connected to the 
duodenum, the upper end of the small intestine. The narrow part of the pancreas, called the tail, 
extends to the left side of the body.
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It has both exocrine and endocrine functions. The exocrine pancreas consists of acinar 
cells, which produce digestive enzymes such as lipase, protease and amylase. The 
endocrine pancreas consists of the Islets of Langerhans and is responsible for glucose 
homeostasis in the body. There are 4 ?????????? ?????? ??? ?????? ??? ???? ???????? ???? ?-cells 
?????????????????????????-??????????????????????????????-cells secreting somatostatin and the 
PP-cells secreting pancreatic polypeptide (Figure 2). These hormones have several 
anabolic and catabolic effects in order to keep the blood glucose concentration in a narrow 
range. Somatostatin is an inhibitory peptide that regulates the endocrine system by 
suppressing the release of several gastrointestinal and pancreatic hormones, especially of 
insulin. Pancreatic polypeptide is released after meal ingestion and suppresses food intake 
???????????????????????????????????????????????????????????????????????????????????????????-
cells in response to several stimuli mainly elevated blood glucose levels. As an anabolic
hormone, it acts on muscle, adipose tissue and liver by promoting glucose uptake and 
inhibiting glycogen breakdown (glycogenolysis) and the synthesis of glucose from 
gluconeogenic precursors (gluconeogenesis), thus returning high circulating glucose 
concentrations to normal values. If blood glucose levels are low, e.g. after exercise or in-
???????? ??????? ?-cells produce glucagon which acts mainly on the liver. In response,
glucagon as catabolic hormone induces glycogenolysis and gluconeogenesis in hepatic 
cells [2]. The resulting glucose is released into the bloodstream and prevents
hypoglycemia. 
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Figure 2. Cross section of the pancreas (adapted from [3]). Pancreas has both exocrine and 
endocrine functions. Islets of Langerhans make up the exocrine pancreas.
2.2. Insulin and Glucagon 
2.2.1. Insulin: structure, secretion and function
Insulin is a peptide hormone that is synthesized as pro-insulin containing a B-, C- and A-
chain. Proteolytic cleavage removes the C-peptide and produces the mature insulin, which 
consists of 51 amino acids of the B- and A-chain bound together by disulphide bonds. 
??????????????????????????????????????????????????-cells is tightly regulated by blood glucose
[4,5]?? ???? ?-cell responds to blood glucose fluctuations by sensing concentrations of 
glucose. Glucose equilibrates across the plasma membrane via the glucose transporter 
(GLUT) 2 and is phosphorylated by glucokinase, the rate-limiting enzyme of glycolysis. 
?????????? ??????????????????????????????? ??? ?????-cell, enters the mitochondrial TCA cycle 
and provides the link between oxidative metabolism and insulin secretion. The ensuing 
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increase in cellular ATP to ADP ratio is due to electron transfer from the TCA cycle (in the 
form of NADH and FADH2) to the respiratory chain (oxidative phosphorylation). Thereafter, 
membrane depolarization is facilitated through closure of ATP-sensitive K+ channels (KATP), 
resulting in Ca2+ influx through voltage-sensitive Ca2+ channels, and culminating in insulin 
granule exocytosis [6,7,8] (Figure 3). Insulin acts on different organs, including muscle, 
adipose tissue and liver. It promotes glucose uptake, glycogen and lipid synthesis, and it 
inhibits glycogenolysis, gluconeogenesis, and breakdown of lipids and proteins (lipolysis 
and proteolysis) [9,10].
2.2.2. Glucagon: structure, secretion and function
Glucagon is a member of the pituitary adenylate cyclase activating polypeptide (PACAP) 
superfamily of peptide hormones.  The proglucagon gene encoding glucagon, glucagon-
like peptide (GLP)-1 and GLP-2 is expressed as a 2-kb transcript. Pro-hormone convertase 
2 (PC2) contributes to processing pro-????????? ??? ???? ??????????? ?-cell to produce 
glucagon, a single chain 29 amino acid polypeptide with a molecular weight of 3483 kD
[11,12,13]. As the counter-regulatory hormone to insulin, glucagon secretion is suppressed 
in response to glucose, and increased when glucose levels are low. However, contrary to 
glucose-stimulated insulin secretion (GSIS) ??????????-cell, the mechanisms underlying the 
regulation of glucagon secretion by glucose are not as well understood. It is not yet well 
known ???????? ?-cells directly sense and respond to fluctuations in plasma glucose, or 
whether the response to low circulating glucose is mediated by the autonomic nervous 
system and/or the paracrine/endocrine effects of secretory products from other islet 
endocrine cell types. Currently, a large body of research favors the latter 
paracrine/endocrine hypothesis [14,15]. Several hypotheses have been put forward; these 
include paracrine inhibitory actions of Zn
2+ 
or ?-Aminobutyric acid (???????????????????-
cells [16], and paracrine inhibition of glucagon secretion by somatostatin released by 
????????????? ?-cells [17]. A???????? ????????? ??????????? ??? ?-cell activity is certainly 
??????????? ????? ???????????? ?????????? ??? ???? ???????????????????????-cell secretory products 
during hyperglycemia [18]. The key biological actions of glucagon converge on regulation 
of glucose homeostasis through its actions on the liver. The primary effect of glucagon on 
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these metabolic pathways is an increase in hepatic glucose output resulting from increase 
in glycogenolysis, gluconeogenesis, and a decrease in glycolysis [9].
Figure 3. ???????????????????????????????????????-cells (Adapted from [19]). Due to the uptake 
of glucose by the GLUT2 transporter, the glycolytic phosphorylation of glucose causes a rise in the 
ATP to ADP ratio, which inactivates the potassium channel followed by depolarization of the 
membrane, causing the calcium channel to open up allowing calcium ions to flow inward finally, 
leading to the exocytotic release of insulin from their storage granule.
2.3. Diabetes 
Diabetes mellitus is a common endocrine disease comprising a group of metabolic 
disorders characterized by hyperglycemia. According to the World Health Organization 
(WHO), Diabetes affects 346 million people worldwide. In 2004, 3.4 million people died 
from consequences of high blood glucose. The WHO expects that diabetes related deaths 
will double from 2005-2030, with low- and middle income countries being worst affected, 
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with 80% of diabetes related deaths [20]. Diabetes mellitus can be divided into two main 
classes; T1D accounting for approximately 10% and T2D comprising about 90% of all 
cases [20,21] . Both major types of diabetes break out as a result of an interplay of genetic 
as well as environmental factors [21,22]. In recent years, the dramatic world-wide increase
in diabetes is paralleled with other diseases of the metabolic syndrome, e.g. 
arthrosclerosis, hypertension, cardiovascular disease, all associated with obesity [20].
Diabetes is characterized by the failure of ?-cells within the islets of Langerhans in the 
pancreas to secrete sufficient amounts of insulin to maintain normoglycemia [23]. An 
absolute insulin-????????????????????? ??? ????? ????? ???????????? ??? ??????????? ?-cells is 
the cause of T1D [21,24]. T2D is a multi-????????????????????????????????????????????-cells to 
compensate for the increased insulin demand, most commonly in response to insulin 
resistance as a consequence of obesity [25,26]. However, the mechanisms underlying 
???????? ??????????? ???? ?-cell compensation are not clear. As described in detail later, 
genetic and environmental factors may impair insulin signaling causing severe insulin 
???????????? ???? ????????? ??????? ????? ?-cells decompensate, which until recently was 
believed to be the consequence of a “toxic” effect of elevated levels of glucose and free 
fatty acids (FFAs), bu???????????????-cell insulin resistance [27]. More recently, in T1D and 
???? ????????????? ??????????? ????? ????? ????????? ??? ?????? ?-cell dysfunction and 
destruction, where infiltrating immune cells and systemic low-grade inflammation may 
contribute to ?-cell failure [28,29,30,31,32,33].
2.3.1. Type 1 diabetes
T1D is a multifactorial disorder triggered by not fully discovered environmental factors in 
genetically predisposed individuals [21]. The pathogenesis involves immune components 
???????-cells are lost as a consequence of inflammatory processes in the islet. The genetic 
predisposition in T1D patients is caused by variations in multiple genes including human 
leukocyte antigen (HLA), the insulin gene, protein tyrosine phosphatase non-receptor type 
2 (PTPN2), interleukin-2 receptor alpha chain (IL2RA), and cytotoxic T-lymphocyte antigen 
(CTLA) 4 [34]. The earliest signs of autoimmunity are detectable years before the 
appearance of clinical symptoms i.e. auto-??????????? ???????? ?-cells [21]. The most 
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common auto-antibodies are directed against glutamic acid decarboxylase (GAD) 65, islet 
auto-antigen-2 (IA-2), insulin autoantibody (IAA), and zinc-transporter 8 (ZnT8) [21]. Islet 
??????????????????-cell destruction can take years and is associated with the detection of the
auto-antibodies and islet infiltration of CD4+ T-cells, CD8+ T-cells, dendritic cells (DCs), 
macrophages and B-lymphocytes [34,35]. Multiple auto-antibodies are established
diagnostic markers of disease risk [36]. ??????????????????????????????????-cell replication 
is detectable; however the replication is not sufficient to compensate for ?-cell loss during 
the inflammatory destruction [34,35]. ????? ???? ??????????? ?-cell mass is reduced by 60-
90%, clinical symptoms appear [37]. ????????????????- cell function and mass, is evidenced 
by the loss of first-phase secretion in an intravenous glucose challenge, preceding
impaired glucose tolerance [38] as well as the strong correlation of impaired fasting 
glucose levels and ?-cell mass [39,40].
2.3.1.1. Immune cell infiltration in islets
In T1D the islets of Langerhans are infiltrated by immune cells that selectively attack and 
???????? ???? ?-cells, probably by a combination of T-cell mediated mechanisms and by 
secretion of proinflammatory cytokines and reactive oxygen species (ROS). In the early 
phases of T1D, most of the pathological processes take place in the islet microenvironment 
of the pancreatic draining lymph nodes [41]. The first immune cells to infiltrate the islets are 
macrophages and DCs, they probably migrate to the lymph nodes or to the islets
themselves to activate CD4+T-cells (Figure 4) [21]. In the NOD mouse, DCs and 
macrophages first appear in the periphery of the islet around four weeks of age with 
increased insulin secretion and islet neogenesis that may be mediated by low-level 
stimulation exerted by IL-??? [42,43]. This was also observed in a patient with newly 
diagnosed T1D [44]. After 8-12 weeks the islet is infiltrated by a mixture of DCs, 
macrophages, B-lymphocytes, and CD4+ and CD8+ T-??????? ??????????? ????? ?-cell 
dysfunction and destruction [40,45,46].
16 
 
Figure 4. Proposed scheme for the initiation of type 1 diabetes. (adapted from [32]). Naive T 
cells (purple spheres) circulate through the blood and lymphoid organs, including the pancreatic 
lymph nodes (PLNs). In the nodes, they encounter APCs (probably mature DCs) displaying on their 
surface MHC molecules carrying antigens in the form of peptide fragments. In this case, the 
antigens derive from proteins s????????????????????????????????-cells, picked up (in soluble form, as 
cell bits or as apoptotic cells) when the APCs (probably DCs in immature state) resided in the islets. 
A minute fraction of the naive T cells can recognize MHC molecule/!-cell antigen complexes, 
become activated (red asterisks), and then access tissues including the pancreas, where they 
reencounter cognate antigen, and are reactivated and retained. 
2?????????-cell destruction
???? ?????????? ??????????? ??? ?-cell destruction in T1D are not fully understood, but 
probably include Fas/FasL interaction on CD4+ and CD8+ T-cells and islets, perforin-
???????????????????-cell destruction by CD8+ T-cells, and cytokine and NO secretion by 
DCs, macrophages and T-cells [21]?? ????? ?????????????? ????????? ?-cells of genetically 
predisposed individuals start to produce and liberate auto-antigens, which are taken up by 
APCs and presented on the major histocompatibility complex (MHC) class II or presented 
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????????-cell surface on MHC class I, which is recognized by either CD4+ T-cells or CD8+ T-
cells (Figure 5??? ???????????? ??? ?-cells can be divided into two simplified models: a 
“recognition-linked” and an “activation-linked” model [32]. The recognition-linked hypothesis 
??????????????????????????-?????????????????????????????????????????-cell surface, which is 
recognized by CD8+ T-?????? ????? ???????? ???? ?-cell via cell-to-cell interactions through 
Fas/FasL binding and perforin/granzyme system [32]. Upon antigen recognition by the 
CD8+ T-??????? ?????????? ??? ????????? ????? ???? ?-cell membrane generates pores allowing 
granzyme to enter the cytosol, inducing mitochondrial outer membrane pore (MOMP) 
formation by insertion of Bcl-2-associated X protein (Bax) and Bcl-2 homologous 
antagonist/killer (Bak) into the mitochondrial outer membrane, resulting in activation of the 
intrinsic apoptosis pathway [46]????? ???????????????????????-cell by FasL activates the Fas 
associated death domain protein (FADD), and initiates the intrinsic apoptosis pathway by 
inducing MOMP formation, leading to cytochrome c release and caspase activation [33,47].
The activation-linked hypothesis requires liberation of auto-antigens from infected, altered, 
??? ?????? ?-cells presented on MHC class II on APCs. Such liberated auto-antigens are 
taken up by antigen-presenting cells such as DCs, which activate CD4+ and CD8+ T-cells to 
mediate the immune response. Once activated, the immune cells invade the islets and 
???????? ?????? ???????????? ???????? ??? ???? ?-cells through secretion of pro-inflammatory 
cytokines ????? ???????? ?-cells and further activate other immune cells such as 
macrophages to enhance the inflammatory response [32]. In addition to secretion of pro-
inflammatory cytokines the immune cells launch an attack via ROS that further contributes 
????-cell destruction [21]. The two models are likely to work in concert rather than alone
[40].
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Figure 5. Proposed cellular mechanisms of ?-cell death in T1D. (adapted from [32]). According 
to ‘recognition-linked’ mechanisms, the T cell (in this case CD8+ T cell) is activated by direct 
recognition of islet ?-cell antigens (red dots) presented by MHC molecules (in this case class I 
molecules) on !-cells. Activation provokes killing of the ?-cell through cell/cell contact using, for 
example, the Fas/FasL or perforin pathways. b, According to ‘activation-linked’ mechanisms, the T 
cell (either CD4+ or CD8+) recognizes ?-cell antigens presented indirectly by APCs (macrophages, 
DCs) in the vicinity. The resulting activation provokes ?-cell death mediated by surface receptors 
(such as FasL/Fas, TNF-"/TNF-R) (i); cytokines and other soluble death mediators produced by the 
T cell (ii); activation of macrophages and stimulation of their cytocoidal activities (iii); and activation 
of ?-cells and stimulation of their production of cell death mediators (iv).
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2.3.2. Type 2 diabetes 
The pancreatic ?-cell has an enormous capacity to adapt to conditions of increased insulin 
demand (e.g. in obesity, pregnancy or cortisol excess), by increasing its mass and its 
insulin secretion. But under certain circumstances, e.g. continuous weight gain, or genetic
predisposition, this leads to ?-cell failure and progression of T2D in 10-20% of the insulin 
resistant individuals, underlying the causative role of the ?-cell in T2D (Figure 6) [48,49,50].
As T1D, T2D is a multi factorial disorder with a strong genetic predisposition and 
environmental triggers. The prevalence of T2D rises with increased obesity [51,52]. As 
mentioned above, T2D is caused by insulin resistance, and impaired insulin secretion. 
Increased circulating FFAs and low density lipoprotein (LDL) cholesterol, hyperglycemia, 
and low-grade inflammation seems to be important for progression of insulin resistance
?????-cell failure in T2D [53]. Pro-inflammatory cytokines increase adipose tissue lipolysis, 
probably contributing to increased serum fatty acids [54,55]. Insulin resistance is 
associated with hepatic, adipose tissue and hypothalamic inflammation. Hepatic 
inflammation leads to dysfunctional energy homeostasis through decreased hepatic 
glycogen storage, increased gluconeogenesis, and lipogenesis, associated with hepatic 
lipid accumulation [55]. Inflammation in the hypothalamus is associated with dysregulation 
of leptin and insulin signaling, while inflammation inhibits muscle glucose uptake and 
glycogen synthesis [55,56]. Insulin resistance leads to increased demand for insulin to 
????????? ???????????? ?????? ???????? ???????? ?????? ??????? ???? ??????????? ?-cells to 
??????????? ???? ???? ???????? ?????????????? ??????????? ????????????????????? ??????????? ?????-
cell mass [26]. When insulin secretion becomes insufficient to compensate for the 
increased demand, T2D develops [26].
???? ??? ?????????????? ??? ???????????? ?-cell dysfunction starting with abrogation of first-
phase insulin secretion and reduced glucose sensitivity of second-phase insulin secretion, 
??????????????- ???????????????????????????????-cell mass, or a combination of both [57,58].
The defective insulin secretion in T2D is caused by impaired glucose stimulus-secretion 
coupling, perturbed insulin granule exocytosis and a reduction in insulin biosynthesis [58].
In addition to the secretory defects, ???? ??? ??????????? ????? ????? ??? ?-cell mass when 
compared to age- and weight-matched non-diabetic controls [58]??????????????? ????-cell 
mass is approximately 60% measured in pancreases from autopsy in T2D compared to 
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non-diabetic controls, which is due to accelerated apoptosis caused by increased levels of 
FFA, increased glucose concentrations, pro-inflammatory cytokines and adipocytokines, 
?????????-cell regeneration [26,40,58,59].
Figure 6. Adult pancreatic morphology in normal, nondiabetic obesity and type 2 diabetes
(adapted from [50]). The whole pancreas, which is composed primarily of exocrine cells 
(producing enzymes delivered directly to the gut through the pancreatic duct for digestion), retains 
the same shape and size in all of these conditions. The endocrine islets (which produce hormones 
responsible for glucose homeostasis) are more dynamic. Under normal circumstances, these islets 
are scattered throughout the pancreas and comprise about 1% of the total pancreatic population of 
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cells. In normal islets (insert), the ?-cells (brown) tend to populate the core of the islet, representing 
about 70% of the islet endocrine cells. In nondiabetic obesity, the number of islets in the pancreas 
increases and these islets (insert) tend to be larger, primarily because of increased numbers of ?-
cells per islet or in some instances because of increased ?-cell size. As a result, 99% of the islet 
endocrine cells are ?-cells. In type 2 diabetes, the number of islets in the pancreas decreases and 
these islets (insert) are disorganized. There is a marked reduction in the number of ?-cells per islet 
and amyloid plaques (purple) can dominate the islet area. 
2.3.2.1. Current therapies of T2D
Currently, there is no causative therapy for T2D available. Therapeutic options for T2D 
???????? ???????? ?????????????? ??????????????? ???? ??????????????? ?????? ????? ??? ?-cells to 
induce insulin secretion, insulin sensitizers (thiazolidinediones), which improve insulin 
response, Biguanides like metformin, which act primarily to reduce hepatic 
??????????????????????-glucosidase and SGLT2 inhibitors, which reduce carbohydrate re-
absorption from the intestine and kidney. These agents all reduce postprandial 
hyperglycemia [60,61,62,63]. Unfortunately, none of these currently widely used anti-
????????? ??????? ???????? ???? ???????????? ??? ??????????? ?-cell mass [58,64,65,66],
although it has been demonstrated that even a small amount of preserved endogenous 
insulin secretion has great benefits in terms of clinical outcome [67].
Only the intestine hormone Glucagon-like peptide-1 (GLP-1), which stimulates insulin 
secretion after food intake, delays carbohydrate absorption, increases satiety through 
hypothalamic actions and decreases glucagon secretion, was shown to inhibit pancreatic 
?-cell apoptosis in mouse models and human islets [68]. Due to its rapid degradation by 
the enzyme dipeptidyl peptidase-4 (DPP4), it has a very short half-life. Thus longer-acting 
GLP-1 analogs as well as DPP4-inhibitor were developed for therapy [69,70]. DPP4-
analogs were also tested for its possible direct effect on human islets (see appendix). 
Although we found profound effect of DPP4-inhibitors to improve ?-cell function and 
survival, a clinical study could not support any long-term effect of GLP-1 to improve ?-cell 
function directly [71]. Anti-inflammatory strategies, e.g. the neutralization of IL-1? by IL-1Ra 
or neutralizing antibodies to IL-1? [30,72] as well as aspirin analogs [73,74] are a novel as 
well as “ancient” [75] therapeutic concept towards ?-cell protection (see results part 2).
Finding of a target for ?-cell-directed therapies, ?????? ?????? ??? ????? ??? ???????? ?-cell 
???????????????????????????????????????????????????????-cell mass would represent a 
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??????????????????????????????-cells are highly sensitive to apoptotic damages induced by 
multiple stressors such as inflammatory and oxidative assault, due at least in part to their 
low expression levels of cytoprotective enzymes [76,77]. Therefore, the knowledge of the 
??????????????????????????-cell apoptosis offers novel therapeutic targets in the treatment 
of diabetes. 
2.4. Apoptosis 
Programmed cell death, known as apoptosis, is the major form of cellular suicide in various 
physiological processes and regulates the maintenance of homeostasis in multi-cellular 
organisms. Apoptosis differs from other forms of cell death like necrosis by eliminating the 
target cells without eliciting inflammation. Studies in Caenorhabditis elegans, Drosophila 
melanogaster and mammals have shown that it is an evolutionary conserved process that 
is tightly regulated and required for the proper development and homeostasis of multi-
cellular organisms [78,79]. Apoptosis is characterized by a genetic controlled autodigestion
of the cell through the activation of endogenous proteases. This process results in 
cytoskeletal disruption, cell shrinkage, membrane blebbing, nuclear condensation, and 
internucleosomal DNA fragmentation [78,79,80]. Classical apoptosis results from the 
activation of cysteinyl aspartyl proteases (caspases) that then rapidly dismantle the cell. 
Caspases are present as inactive pro-enzymes in healthy cells, poised to drive cellular 
destruction upon receipt of an activating signal. This destruction does not only occur by 
degradation of cellular proteins, but is also driven by signaling events where many caspase 
substrates are themselves activated by cleavage [80]. Based on the order in cell death 
pathways, caspases are divided into two major groups. The subset of caspases that cleave 
selected substrates to produce the typical alteration changes associated with apoptosis are 
known as executioner caspases, which in mammals are caspases-3, -6, and -7. 
Executioner caspases are activated by apical initiator caspases, including caspase-8, -9, 
and -10 [80,81,82] (see result part 3).
Apoptosis occurs through extrinsic and intrinsic apoptotic pathways (Figure 7). ?????????
step involved in each pathway is a caspase cascade, which cleaves regulatory and 
structural molecules, leading to cell death. The death-receptor pathway (extrinsic) of 
apoptosis is activated upon interaction of a death receptor with its cognate death-inducing 
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ligand, resulting in recruitment of the adaptor protein FADD and pro-caspase-8 to the 
intracellular death domain of the receptor. Concomitantly, pro-caspase-8 is proteolytically 
cleaved and activates the effector caspases such as caspase-3 [83,84,85]. In addition, 
caspase-8 can cleave the BH3-only protein Bid, thereby activating a mitochondrial 
amplification loop. The mitochondrial (intrinsic) pathway of apoptosis is controlled by the 
Bcl-2 family of pro- and anti-apoptotic proteins. When activated, the upstream sensors of 
intracellular stress-the BH3-only proteins (e.g. Bid)-associate with the pro-apoptotic Bcl-2
proteins Bax or Bak and translocate to the outer mitochondrial membrane. Subsequently, 
pores are formed in this membrane, resulting in the release of DNases apoptosis inducing 
factor (AIF) and endonuclease G. Both translocate to the nucleus and induce DNA 
fragmentation. In addition, cytochrome c is released from the mitochondria and associates 
with APAF-1 and pro-caspase-9 into the complex which is called apoptosome. In the 
apoptosome, caspase-9 is proteolytically processed into its active form, whereupon effector 
caspases (e.g. caspase-3) can be activated. BH3- only proteins are inhibited by the anti-
apoptotic Bcl-2 proteins, such as Bcl-2 and Bcl-xL, that bind to and inhibit the association
of BH3-only proteins with Bax or Bak [83,86,87]. The balance between survival and 
apoptotic signals must be tightly controlled. Failure of apoptosis control results in severe
pathological conditions. These include situations with too less apoptosis and unwanted cell 
accumulation (cancer) and failure to eradicate aberrant cells (autoimmune diseases) or 
disorders with too high apoptosis and inappropriate loss of cells (cardiovascular and 
neurodegenerative diseases, AIDS and diabetes) [88,89]. Genes which regulate apoptosis 
have often complex functions during development as well as in mature cells. For example, AIF, 
besides its function as inducer of apoptosis, regulates oxidative phosphorylation and mitochondrial 
energy metabolism [90] and plays therefore an important role in metabolic diseases such as 
diabetes (see appendix in part2).
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Figure7. Signal transduction of apoptosis. Two major pathways of apoptosis exist in 
mammalian cells (Adapted from [88]). Left, the extrinsic cell death pathway is mediated by a 
subgroup of the TNF receptor superfamily called the death receptors (CD95, TRAIL-R1/2, and 
TNF-R1). Receptor-mediated cell death is initiated by the recruitment of adapter proteins, like 
FADD, via the DD, which then bind to the death effector domain-containing caspase-8 or -10. 
Formation of this DISC results in the activation of caspase-8, which then directly cleaves and 
activates caspase-3, -6, or -7, the executioner enzymes of apoptosis. Right, in the mitochondrial or 
intrinsic pathway, which is initiated by multiple forms of cellular stress, proapoptotic Bcl-2 family 
members Bax and Bak translocate to the mitochondria. The BH3-only protein Bid activates Bax and 
Bak to mediate the release of cytochrome c in the cytosol. This triggers the assembly of the 
apoptosome (APAF-1 and caspase-9) and subsequent activation of caspase-3 and cell death. IAPs 
bind directly to caspases and inhibit their enzymatic activity. The inhibitory function of IAPs is 
countered by the SMAC.
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2.4.1. Apoptosis and diabetes 
Pancreatic ?-cell death is the fundamental cause of T1D and a contributing factor to the 
???????? ?-cell mass in T2D ??????????? ????? ?-cell death is the critical determinant in the 
pathogenesis of both ???????? ??????????????? ??? ?-cell death in a diabetic milieu are 
complex and not well defined but multiple triggering factors have been identified, which 
initiate ?????????????????????????????????-cells that affect the expression of apoptotic genes, 
which induce the ????????????????????-cell [26,32,44,91,92,93,94].
In T1D, autoimmune destruction of insulin-producing ?-cells and critically diminished ?-cell 
mass are hallmarks of the disease. ?-cell destruction occurs through immune mediated 
processes; mononuclear cell infiltration in the pancreatic islets and interaction between 
antigen presenting cells and T-cells leads to high local concentrations of inflammatory 
cytokines, chemokines, ROS and other apoptotic triggers like perforin and Fas/FasL 
system (Figure 8). Strikingly, Fas-, perforin-, or TNF-deficient non-obese diabetic (NOD)
mice (T1D model) display reduced incidence and delayed onset of diabetes [32]. The initial 
trigger of ?-cell apoptosis remains still unclear, whether the T-cell activation (CD4+ or CD8+)
by direct recognition of islet antigens or presented by antigen presenting cells 
(macrophages, dendritic cells) directly provokes killing of the ?-cell through cell/cell 
contacts mediated by the Fas/FasL, perforin or TNF-?????-R pathways, or whether 
cytokines and other soluble death mediators produced by the activated T-cell or by the 
cytotoxic activities of activated macrophages induce ?-cell death or finally whether the 
activation of the ?-cell itself and production of cell death mediators induce its self-killing
[21,33,44]. Most likely, it is an orchestra of events, which makes the initiation of ?-cell 
death complex and its blockade so hard to successfully achieve in vivo.
In T2D, reduced ?-cell mass and ?-cell dysfunction are the ultimate events leading to the 
development of clinically overt disease in subjects with insulin resistance [26,50]. ???????-
cell failure in type 2 ???????????????????????????????????????????????????-cell consumption 
for insulin resistance. The failure is progressive, particularly after hyperglycemia is 
????????????????????????????????????????????????????????????-cell mass from apoptosis. ?-cell 
toxicity has been linked to stimuli including glucotoxicity, lipotoxicity, proinflammatory 
cytokines, ER stress, and oxidative stress (Figure 8) [23,30,50,95]. High concentrations of 
glucose can induce ?-cell apoptosis and this may be an important mechanism leading to ?-
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cell failure in diabetes. Through the activation of several mechanisms and signaling 
pathways such as oxidative and ER stresses, ?-cell overstimulation and elevated levels of 
Ca2+, inflammation, hexoamine pathway and ?-cell dedifferentiation, high glucose levels 
??????????????????????????????-cell function and survival [50,96,97]. Glucose-induced ?-cell 
apoptosis has been reported in several animal models of T2DM including the Psammomys 
obesus or the ZDF rat [98,99]. Lipotoxicity plays an important role in underlying mechanism 
of type 2 diabetes. Prolonged exposure of pancreatic ?-cells to elevated levels of FFA like 
palmitic acid induces ?-cell apoptosis via activation of a number of relatively separate 
apoptosis-inducing events, including the generation of ceramide and ROS and ER stress 
[92,100,101,102]. Free fatty acids also induce ?-cell apoptosis in the presence of high 
concentrations of glucose, a process called glucolipotoxicity [103]. There are accumulating 
evidences that inflammation is an important mechanism that contributes to the initiation, 
development, and progression of T2D. The proinflammatory cytokines and chemokines 
released by adipose tissue, endothelial cells, and immune cells under diabetic conditions 
are thought to contribute to the inflammatory process in several tissues including the liver 
and pancreatic ?-cells [28,30,104]. Interestingly, IL-???production has been shown to be 
upregulated in human islets cultured in the presence of high glucose levels. This was 
paralleled by increased NF-?B activation, reduced expression of endogenous IL-1 receptor 
antagonist (IL-1Ra), upregulation of the cell death receptor Fas ???????????????-cell death
[105,106,107]. Islet macrophage infiltration and increased expression of IL-??? ????? ?????
been reported in the pancreas sections of patients and animal models of T2D [31,108]. ?-
cells are particularly sensitive to ER stress due to their high rate of proinsulin biosynthesis 
in response to glucose stimulation [109]. Therefore, adequate unfolded protein response 
(UPR) ??? ?????? ???? ???? ???????????? ??? ???? ??????????? ?-cell mass, whereas exaggerated 
activation and/or genetic disruption of the UPR leads to prolonged ER stress, which 
triggers ?-cell apoptosis [109,110]. Interestingly, it has been shown that CHOP (pro-
apoptotic mediator of ER stress) deletion in db/db and HFD mice prevented fasting 
?????????????? ???? ???????? ???????????? ??? ?? ???????????? ??? ????????? ?-cell function,
increased proliferation, and inhibition of apoptosis [111].
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Figure 8. Beta cell apoptosis in type 1 and type 2 diabetes and islet transplantation (adapted 
from [92]). The different cellular and molecular mediators of ?-cell apoptosis are shown for T1DM, 
T2DM and primary non-function of islets after transplantation. After initial graft loss, transplanted 
islets become susceptible to the cellular and molecular mechanisms of apoptosis outlined for T1D 
and T2D.
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2.5. Pancreatic duodenal homeobox-1 (PDX1)
At the molecular level, genetic mutations and/or metabolic disturbances can alter protein 
networks and thereby disrupt downstream signaling pathways that are essential for survival 
???? ??????? ????????? ??? ?-cells. The transcription factor pancreatic duodenal homeobox-1
(PDX1), which has previously been called IPF1, IDX1, STF1, or IUF1 has been well 
established as a key factor in pancreas development and function, with homozygous 
mutations resulting in pancreas agenesis associated with neonatal diabetes [112,113].
During pancreas development, PDX1 expression is maintained in precursor cells, and high-
level expression of PDX1 ???????? ??????????? ??? ??????? ?-cells while PDX1 is 
downregulated to a lower expression level in mature acinar and ductal cells [114,115].
Importantly, heterozygosity for the null mutation, and hence reduced PDX1 expression 
levels, affect insulin expression and secretion and predispose islets to apoptosis 
[112,116,117]. In humans, mutations in PDX1 gene can predispose individuals to develop 
maturity onset diabetes of the young (MODY4) suggesting a critical role for PDX1 in 
????????-cells [118]. It was also reported that PDX1 heterozygous knockout mice (PDX1+/-)
are glucose intolerant, with increased islet apoptosis, decreased islet mass, and abnormal 
islet architecture, indicating that the appropriate gene dosage of PDX1 is crucial for normal
glucose homeostasis [117,119].
PDX1, a highly conserved protein of 283 amino acids, contains a transactivation domain at 
the N-terminus (amino acids 1-79), a homeodomain in the central region (amino acids 146-
208), and an evolutionarily conserved, C-terminal domain with poorly known function [120]
(Figure 9). 
Figure 9. Structure of PDX1 (Adapted from [120]). . Schematic representation of the domain 
structure of PDX1 showing the N-terminal transactivation domain (amino acids 1-79),
homeodomain which is called DNA binding domain (amino acids 146-208) and sequence C-
terminal following homeodomain with poorly known properties.
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The main activity of PDX1 is initiated through the transcriptional activation or repression of 
a plethora of target genes that encode f??? ???? ????????? ????????? ??? ?-cell function and 
survival. ???????????????????????????????????????????????????????????????????-cell function. 
PDX1 has been shown to directly bind to the promoter and enhance the expression of 
?????????-cell genes such as insulin, Glut2 and glucokinase [112,115], although the latter 
has been challenged [121]. PDX1 plays an ?????????????????????????????????????-cell survival 
and perhaps susceptibility to apoptosis [115,117,122,123,124]. Evidence to date suggests 
that PDX1 deficiency is contributing through impaired proliferation and enhanced apoptosis 
via transcriptional mechanisms in different models of type 2 diabetes such as Psammomys 
obesus and dbdb mouse [125,126]. Interestingly, overexpression of PDX????????????-cell 
mass and function, thereby preventing the onset of diabetes in IRS2 knockout mice 
showing the critical role ????????????-cell survival [123]. Reduced PDX1 expression in the 
?-cell cell occurs in cellular models of glucose toxicity and accompanies the development 
of diabetes in complex genetic and environmental animal models of the disease, where low 
PDX1 levels correlate with ?-cell failure [126,127].
PDX1 regulation is controlled by complicated signaling networks. Nucleo-cytoplasmic 
shuttling appears to play a major role in the regulation of PDX1 function 
[126,128,129,130,131]. Recent papers have characterized nuclear import and export 
signals (NLS/NES) in PDX1 and have suggested that this factor might be subjected to 
regulation at the level of cellular localization [128,132]. The post-translational modification 
of proteins is the most abundant form of cellular regulation, affecting many cellular signal 
pathways, including metabolism, growth, differentiation and apoptosis [133]. In respect to 
literature, at least three different post-translational modifications, including phosphorylation, 
sumoylation, and glycosylation, have been suggested to explain nuclear-cytoplasmic 
shuttling and/or other functions of PDX1 [130,131,134,135,136,137,138,139].
Phosphorylation is a common post-translational modification implicated in the regulation of 
numerous transcription factors but the precise role of PDX1 phosphorylation in the 
regulation of its subcellular localization remains unknown. In response to acute elevation of 
glucose and survival factors such as insulin, it becomes phosphorylated and translocated 
to the nucleus [134,135]. In contrast, several stimuli associated with diabetes cause 
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nuclear exclusion of PDX1 including oxidative stress [128], inflammatory mediators [126]
and palmitate [140]. In that regard, cytoplasmic accumulation may represent more a 
mechanism to reduce the nuclear action of PDX1 under pathologic conditions, rather than 
to promote a specific cytoplasmic function. We have recently demonstrated that the 
negative effect of chronically elevated glucose ???? ?????????? ??? ?-cell function/survival 
may be related to their eventual sequestration of PDX1 in the cytoplasm [141] (see result 
part 2), whereas it is firmly established that the positive effect of glucose on insulin 
expression is a result of its enhancement of PDX1 nuclear translocation [134,135]. If PDX1 
??? ???????? ??? ???? ????????????? ??? ?-cells during diabetes progression, these changes may 
????????-cell function at different levels. When not localized in the nucleus, PDX1-mediated 
??????????? ??? ???????????????????? ??? ?????? ???????? ????????? ???????? ???? ????????? ?-cell 
??????????????? ???????????????????????????? ????-cell death. In the short term, this stressful 
response may be well-tolerated. But under chronic conditions as in T2D, loss of normal 
function would ???? ??????????????-cell survival. 
Short term elevated glucose levels have been proposed to promote PDX1 phosphorylation 
and subsequent nuclear translocation through one or a combination of several pathways, 
including the stress-activated protein kinase (SAPK), extracellular signal-regulated kinase 
(ERK) 1/2 and phosphatidylinositol 3-kinase (PI3K)-AKT pathways [134,135,142]. By 
contrast, phosphorylation of specific residues within PDX1 negatively regulated its function. 
For example, phosphorylation of Ser61 and Ser66 of PDX1 via glycogen synthase kinase 3 
(GSK3) appears to mark PDX1 for proteosomal degradation under oxidative stress [136].
Moreove????-cell failure following DNA damage might be explained by phosphorylation of 
Thr11 of PDX1 by DNA-dependent protein kinases [137]. PDX1 protein is also regulated by 
the proteasome degradation system. Steady-state level of PDX1 is reduced in low glucose 
conditions in ?-cells, and this effect is largely attenuated by treatment of cells with GSK3 
inhibitor or overexpression of AKT2 [143]. Similarly, treatment of ?-cells with advanced 
glycation end-products (AGE) decreases levels of PDX1. This effect is inhibited by
lactacystin (a proteasome inhibitor) or overexpression of dominant-negative form of 
FOXO1, which suggests that proteasome mediated degradation of PDX1 depends on 
FOXO1 signaling [144].
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2.6. Mammalian Sterile-20-like kinase1 (MST1) 
2.6.1. MST1: An Introduction
Mammalian homologs of the budding yeast Ste20 (Sterile 20) serine/threonine kinases can 
be divided into two subfamilies: p21-activated protein kinases (PAKs) and germinal center 
kinases (GCKs). PAKs contain a kinase domain located in the COOH terminus and an N-
terminal p21 GTPase-binding domain that mediates binding to small GTPases such a 
Cdc42. PAKs are well-known regulators of cell migration, growth and apoptosis. GCKs 
contain an N-terminal catalytic domain and a C-terminal regulatory domain, but lack the 
p21-binding domain seen in PAKs [145,146,147]. The mammalian Sterile-20-like kinases 
(MST) belong to the Class II GCK family of kinases. The MST family of kinases consists of 
MST1, MST2, MST3, and MST4. Each of these proteins harbors an N-terminal kinase 
domain and a C-terminal regulatory domain [146,147,148]. MST1 (also known as Stk4 and 
Krs2) was initially cloned from a lymphoid cDNA library by PCR during a search for human 
relatives of Saccharomyces cerevisiae Ste20 [149,150]. Subsequently, this protein was
rediscovered by protein purification as kinase that responds to extreme cellular stress
[151]. The mRNA expression of MST1 kinase is generally ubiquitous in most tissues and in 
most cell lines examined. An approximately 7.0-kb MST1 transcript was detected in most
tissues with Northern blot analysis; a 3.5 kb alternatively spliced mRNA was detected in 
kidney, skeletal muscle, and placental tissues [150].
2.6.2. MST1: Structure
The MST1 protein is a ubiquitously expressed and involved in multiple cellular processes 
such as morphogenesis, proliferation, stress response and apoptosis [147,152,153,154]. It
is well-documented that MST1, when activated in the cellular response to cytotoxic stress, 
mediates cell death triggered by a variety of apoptotic stimuli such as oxidative stress, 
FasL treatment, tumor necrosis factor alpha (TNF-???? ??????? ??????? ?????rawal and 
genotoxic drugs [147,152,153,154,155,156,157]. MST1 contains a kinase catalytic domain 
in the N-terminal, followed by a non-catalytic tail that contains two caspase cleavage sites, 
two NES and dimerization domain at the C-terminal (Figure 10). MST1 can form 
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homodimers. The part of C-terminal domain (a. a. 431–487) is required for MST1 
dimerization, which may not be essential for kinase activity, since deletion of this domain 
does not affect kinase activity. Activated MST1 form dimers via the SARAH
(Salvador/Rassf/Hippo, aa 433-480) domain at the extreme C-terminal region of MST 1 are 
autophosphorylated on specific threonine residues in the activation loop
[147,148,158,159,160].
Figure 10. Structure of MST1. (Adapted from[148]). Schematic representation of the 
domain structure of MST1 showing the N-terminal transactivation domain, followed by a 
non-catalytic tail that contains two caspase cleavage sites, two NES and dimerization 
domain at the C-terminal. 
Several phosphorylation sites have now been identified in MST1, namely Thr175, Thr177, 
Thr183, Thr187, Ser327 and Thr387 [160,161]. Of these, Thr183 and Thr187 appear to be 
essential for kinase activity [161]. Threonine 183 in subdomain VIII of MST1 has been 
defined as a primary site for the phosphoactivation and the auto-phosphorylation of 
Threonine 183 within the MST1 kinase domain is essential for kinase activation [161,162].
Two caspase cleavage sites in MST1 (DEMD326?S, TMTD349?G) have been documented 
[158,160,163]. Importantly, cleavage sites in MST1 kinase are located between the 
catalytic and regulatory domains (Figure 10). Thus, in a familiar paradigm, caspase-
mediated cleavage results in removal of the regulatory domain and subsequent 
translocation of the constitutively active catalytic fragment to the nucleus [158,160,163].
Cell-free studies suggest that these sites may be selectively cleaved by caspases-3, -6, -7
and -9 at DEMD326S and caspases-6 and -7 at TMTD349G, to generate catalytically 
active enzymes of 36-38 and 40-42 kDa, respectively [153,158,160,164]. Subsequent 
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studies by several groups of investigators have reported that activation of MST1 is 
associated with the cleavage and release of the 36-38 kDa catalytic fragment
[153,164,165,166]. In this case, cleavage of the regulatory C-terminal domain liberates a 
fragment comprising the N-terminal kinase domain, which is nearly ten times more active 
than the full-length enzyme [152,153]. This cleavage also separates the N-terminal kinase 
domain from NES located in the C-terminal domain, thus allowing the translocation of the 
kinase domain from the cytosol to the nucleus and, presumably, offering it a different menu 
of substrates to phosphorylate (Figure 11) [167]. The mutation of these cleavage sites 
attenuates MST1 kinase activity, nuclear translocation and ability to induce apoptosis
[160,164]. Under resting conditions, MST1 has been reported to be exclusively located in 
the cytoplasm. Removing the two NES of MST1 by caspases or unmasking the nuclear 
localization sequence results in the translocation of MST1 into the nucleus, where it 
promotes chromatin condensation and nuclear fragmentation [167]. In addition to forming 
SARAH-domain-mediated homodimers, MST1 also heterodimerizes with other SARAH-
domain-containing proteins. For example, MST1 heterodimerizes with WW45 and with 
Nore1A/Nore1B, members of the RASSF family of linker proteins that bind activated Ras 
and Rap GTPases [147,152,162,168].
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Figure 11. Model for the role of MST1 translocation in apoptosis. (adapted from [167]). In 
nonapoptotic cells, MST1 is excluded from the nucleus by its NESs and predominantly distributed 
in the cytoplasm. In response to apoptotic stimuli, activated caspases cleave MST1 and release its 
C-terminal regulatory domain containing NESs, which results in nuclear translocation of the N-
terminal kinase domain. Nuclear translocation of cleaved MST1 enhances chromatin condensation.
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2.6.3. MST1: Cellular signaling
Protein kinase activities are altered during apoptosis in a variety of cell types, indicating 
that protein phosphorylation is involved in apoptotic regulation [169]. Among these, MST1 
serves as the key component in regulating apoptotic entry in several cell types under 
specific conditions through phosphorylation-dependent regulation of multiple substrates 
(Figure 12) [154].
Figure 12. Apoptotic signals lead to MST activation by phosphorylation and proteolytic cleavage
(Adapted from [154]).
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While the direct upstream regulators of MST1 are yet to be established, recent findings 
suggested that MST1 promotes cell death through regulation of multiple downstream 
targets such as tumor suppressor (LATS) 1/2, histone H2B, FOXO members family as well 
as induction of stress kinase c-Jun-N-terminal Kinase (JNK) and caspase-3 activation 
(Figure 13) [154]. Though a number of apoptotic or stress stimuli have been reported to 
activate MST1, proteolytic cleavage of MST1 by caspase-3 remains the only and best 
understood mechanism that regulate MST1 kinase activity to date [154]. The potential 
crosstalk between caspases and kinases becomes even more elaborate when one 
considers the possibility that kinases could phosphorylate the caspases (e.g. p38 MAPK).
In turn, kinases could potentially be activated by caspase-mediated cleavage of upstream 
components in their own regulatory pathways (for example, by the MAPKKKs or 
MAPKKKKs) [169]. MST1 is one of over 40 known caspase substrates and is cleaved 
specifically by caspase-3 [169]. The cleavage of MST1 is a common event in the death 
effector pathways of diverse apoptotic stimuli, including UV radiation, DNA-damaging 
drugs, cytokines, e.g. TNF-?, and anti-Fas antibody. MST1 is a target for caspases, which 
is then cleaved and activated by pro-apoptotic stimuli. It may also serve as activator of 
caspases to amplify the apoptotic signaling pathway [147,153,154,163,170].
The MST complex appears to contain many protein components and the association or 
dissociation of one component in response to an outside apoptotic stimulus may alter the 
activity of other components of this complex. A simplified scheme of MST1 signal 
transduction is shown in Figure 13 [154].
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Figure 13. Multiple apoptotic signaling pathways are mediated by MST1/2 targets (adapted from 
[154]).
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Allis's group has demonstrated that the mechanism of triggering chromatin condensation in 
vertebrate and yeast is mediated by phosphorylation of histone H2B. Deletion of ste20 
rendered yeast resistant to apoptosis and loss of H2B phosphorylation. The 
phosphorylation is catalyzed by the cleaved fragment of MST1 that translocates into the 
nucleus. Upon phosphorylation by MST1, the Ser14-phosphorylated form of H2B 
contributes to chromatin condensation and DNA fragmentation, and thus to the overall cell 
death program [171]. Interestingly, histone H2B phosphorylation also occurs in S. 
cerevisiae, through the phosphorylation on Ser10, a residue distinct from mammalian 
histone H2B Ser14 [172] .
Early studies showed that overexpression of MST1 activated p38 MAPK, JNK and their 
respective upstream kinases MAPK kinases 6 and 7, but did not activate ERK or its 
upstream kinase MAPK kinase 1 [150,153,163,173]. Although a role for p38 MAPK as a
downstream target of MST1 has not been supported in subsequent studies, several 
investigations have identified JNK as central mediator of the apoptotic effects of 
MST1[153,173]. Dominant-negative mutant of JNK inhibited both MST1-induced 
morphological changes and caspase activation. Glantschnig et al. [161] showed that
phosphorylation and activation of MST1 results in apoptosis via a pathway mediated by 
JNK and caspases. Activation of the JNK pathway has been shown to be essential and 
sufficient for induction of chromatin condensation by MST1 [174]. However, the concept of 
a linear pathway is challenged by a study which shows that JNK can act as upstream 
activator through phosphorylation of MST1 at Ser82 site [175]. Collectively, caspase-3 and 
JNK also act as the upstream activators of MST1 through cleavage- and phosphorylation-
dependent mechanisms, respectively suggesting that JNK and caspase-3 initiate a positive 
feedback loop with MST1 to regulate its pro-apoptotic action. MST1 is activated and 
cleaved by a broad range of stimuli in various cell types, which suggests that it is a 
common component in the diverse signaling pathways leading to apoptosis.
AKT is a main downstream effector of PI3K, whose pleiotropic functions include the
inhibition of apoptosis [176,177]. AKT phosphorylates MST1 at Thr-120 and Thr-387
leading to inhibition of its kinase activity, nuclear translocation, autophosphorylation and
ability to phosphorylate FOXO1. These results suggest that AKT phosphorylates MST1 and 
prevents its action from promoting apoptosis [170,178]. Furthermore, MST1 may be an
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important branch pathway of PI3K/AKT based on the observation that MST1 and AKT1 are 
localized to identical subcellular compartments in human prostate tumors. MST1 was 
identified as a component of an AKT1 multiprotein complex isolated from lipid raft-enriched 
fractions of human prostate cancer cells [179]. Both MST1 and its active cleavage form 
physically interact with AKT1 and function as direct inhibitors of AKT1. Depletion of MST1 
or MST2 with siRNA increased AKT activity, and depletion of both proteins further 
enhanced AKT activity [179].
The FOXO transcription factors represent a second class of MST1 substrates that is 
relevant to its pro-apoptotic effects [180]. MST1 phosphorylates FOXO3 and disrupts its 
interaction with 14-3-3 proteins, promotes FOXO3 nuclear translocation, and induces 
apoptosis in neuronal cells [155]. Furthermore, it has been shown that MST1-FOXO1 
signaling mediated neuronal death upon serum deprivation. MST1 specifically 
phosphorylates FOXO1 and this phosphorylation event facilitates FOXO1 translocation into 
the nucleus [181]. In such cells, MST1-FOXO1 signaling appears to be important in 
mediating neuronal death upon deprivation of serum and of neuronal activity [181].
MST1 has been identified as part of the Hippo signaling pathway, which controls organ size 
by regulating cell growth, proliferation, and apoptosis in Drosophila and mammals. The 
Hippo/MST kinase, when associated with scaffold protein Salvador (WW45 in mammals), 
phoshorylates and activates LATS/Warts kinase, which in turn phosphoryates the 
transcription coregulator Yorkie in Drosophila and YAP in mammals. Thus, the Hippo 
pathway inhibits cell proliferation and promotes apoptosis by phosphorylating and inhibiting 
Yorkie and YAP (Figure 14) [152,182,183,184,185].
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Figure 14. Models of the Hippo pathway in Drosophila and mammals (Adapted from [185]).
The AGC-family kinases Nuclear-Dbf2-related kinases 1/2 (NDR1/2) and LATS 1/2 are 
additional substrates of MST1 that contribute to apoptosis as well as cell cycle. Both Fas-
stimulated and okadaic-acid stimulated phosphorylation and activation of NDR1/2 are 
mediated by MST1 [186,187,188]. NDR1/2 can be phosphorylated by MST kinases and 
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mediate apoptotic signaling downstream of MST1. In this case, additional phosphorylation 
on the C-terminal hydrophobic motif of NDR1/2 by MST kinases is required for full NDR 
kinase activation [188]. WW45 (sav1) is required for MST1/2 binding to LATS1/2 and 
facilitates the phosphorylation of LATS1/2 by MST1/2. WW45 is phosphorylated by MST 
kinases at multiple sites, and these phosphorylations are required for the activation of 
WW45 and the induction of cell death by the MST pathway [154]. Notably, WW45 is 
required to potentiate MST1-mediated apoptosis and thus is a critical player in the MST1-
induced cell death-signaling pathway [168]. Very recently, it has been shown that protein 
tyrosine kinase c-Abl phosphorylates MST1 at Y433, which triggers the stabilization and 
activation of MST1 during oxidative stress-induced apoptosis [189].
2.7. Aim of thesis: Rationale and significance of the study to diabetes
The importance of apoptosis as a pathogenic mechanism with a causative or contributing 
role for diabetes has become increasingly evident [41,50,92]. Various imbalances in the 
apoptotic machinery can arise in ?-cells. Consequently, sensitivity towards apoptosis is 
progressively increased, which ultimately leads to ?-cell death and development of 
diabetes. Noticeably, ?-cells are more prone to apoptosis than other cell types. The 
apoptosis-prone phenotype of ?-cells is exploited by upregulation of one or more pro-
apoptotic pathways. The identification of the genes and gene products that regulate 
apoptosis, together with an increased knowledge about their mechanisms of action is the 
foundation for the discovery of new drugs towards targeting apoptosis. Indeed, the rational 
design of novel agents that can selectively block ?-cell apoptosis is urgently needed since 
current therapies for the treatment of diabetes are directed towards alleviating only the 
symptoms and not the cause of the disease. Based on the proposed function of MST1 in 
apoptosis, it might play a pro-apoptotic role in the human ?-cell in diabetes. So far, it is not 
known what the physiological role of MST1 in ?????-cell is and whether MST1 activation 
?????? ???????? ?-cell death and impaired insulin secretion. Since MST1 acts as common 
mediator in multiple apoptotic signaling pathways [152], I hypothesize that multiple 
apoptotic signals in the ?-cell are activated downstream of MST1. The aim of this thesis is
to investigate mechanisms of MST1-?????????-cell death and its down-stream signaling in 
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order to get new insights in the apoptosis biology of ?-cells. This integration of concepts 
might lead to the development of a new therapeutic approach perhaps best described as 
“Targeted apoptosis in diabetes”, which is in fact the subject of this thesis. By linking 
?????? ?? ??????? ???????? ??? ??????????? ??? ?-cell survival and function, this thesis provides
mechanistic insight into the enigmatically strong apoptosis inducing effect of MST1, and 
suggests that targeting the MST1 pathway may present therapeutic opportunities to 
?????????-cell apoptosis and treatment of diabetes.
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Abstract
Apoptotic cell death contributes to the loss of insulin producing ?-cells in all forms of 
diabetes mellitus 1-4. Current treatment strategies for both type 1 (T1D) and 2 diabetes 
(T2D) fail to halt the decline in functional ?-cell mass seen in either case. Strategies to 
prevent both ?-cell apoptosis and dysfunction are thus urgently needed to provide
effective new treatments. Here, we identify Mammalian Sterile 20-like kinase 1 (MST1) 
??????????????????????????????????????-cell death. We show that MST1 is strongly activated 
????-cells under diabetogenic conditions in vitro and in vivo. This correlated with ?-cell 
apoptosis, and was counter-?????????? ??? ???? ?-cell PI3K/AKT-prosurvival signaling.
MST1 specifically activates the mitochondrial-???????????????????????????????????-cells 
through up-regulation of the BH3-only protein Bim. Furthermore, MST1 directly 
phosphorylates the ?-cell transcription factor pancreatic duodenum homeobox-1 (PDX1) 
at Thr11. The resulting ubiquitination and degradation of PDX1 lowers target gene 
expression and impairs glucose-stimulated insulin secretion (GSIS). Importantly, MST1 
deficiency restores ?-cell function and survival in human and rodent ?-cells and in 
diabetic animal models. Thus, ablation of MST1 ??????????????? ??????-cell failure and 
the development of diabetes induced either by multiple low dose-streptozotocin (MLD-
STZ, T1D model) or high-fat diet (T2D model).  This protective action is due to an 
???????????????????????????????????????????????????????????????????????????-cell mass and 
normalize the ?- ??-cell ratio, and to improved GSIS. Strikingly, ?-cell-selective disruption 
of MST1 also prevented progressive hyperglycemia and improved glucose tolerance in 
MLD-STZ-treated mice indicating that ?-cell-specific activation of MST1 is a key event in 
???????????????? ?????????-cells in this model. Our findings identify MST1 as novel pro-
?????????????????????????????????????????????????????????????????????????????-cell which 
may serve as target for the development of novel therapies for both T1D and T2D.
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Pancreatic ?-cell death is the fundamental cause of type 1 diabetes (T1D) and 
contributes to reduced ?-cell mass in type 2 diabetes (T2D) 5,6. Whereas immune cell-
mediated events predominate in T1D 7, metabolic factors such as elevated levels of 
glucose and fatty acids, alongside proinflammatory cytokines, drive ?-cell loss and 
dysfunction in T2D 4.  In both cases t??????????????????-cell death are complex and as 
yet not fully defined. Thus, multiple triggering factors have been identified, which initiate
a variety of signaling cascades that affect the expression of apoptotic genes and the 
??????????? ?-cell failure 4,8. The identification of a ??????? ???? ?????????? ??? ?-cell 
apoptosis would thus offer a novel therapeutic target for the treatment of diabetes. MST1 
protein kinase plays an important role in the induction of apoptosis by a variety of 
cellular stressors 9-13. In the present study, we established MST1 as a novel regulator of ?-cell survival.
MST1 was highly up-regulated by a complex diabetic milieu in vitro in human (Fig. 1A) 
and mouse islets, and in the ?-cell line INS-1E (Suppl.Fig.1-2) in response to cytokines
(IL-???????), increasing glucose concentrations, free fatty acid (palmitic acid), oxidative 
stress (H2O2) and ER-stress (thapsigargin; Suppl Fig. 1-2). MST1 activation in ?-cells 
occurred by both caspase-mediated cleavage and through auto-phosphorylation
(pMST1-T183) in response to diabetic stimuli. These changes occurred in parallel with 
increased phosphorylation of histone H2B as well as induction of c-jun N-terminal kinase 
(JNK) signaling and thus represent major pathways in MST1-promoted apoptosis 11,12 in 
human islets and ?-cells (Fig.1A, Suppl.Fig.1A-C). Furthermore, MST1 activation in ?-
cells occurred in human diabetes and in diabetic animal models in vivo. Levels of P-
MST1 and its cleaved fragment were profoundly increased in diabetic islets from T2D 
patients (Fig.1B), obese diabetic Leprdb/db mice (db/db, Fig.1C) as well as hyperglycemic 
high fat/ high sucrose fed mice for 16 weeks (HFD; Surwit 14, Suppl.Fig.1D), which 
correlated with ?-cell apoptosis as described before 15. To confirm the ?-cell specific up-
regulation of MST1, double-staining for P-MST1 and insulin in pancreatic islets from
poorly controlled patients with T2D (Fig.1D) as well as db/db mice (Fig.1E) showed 
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expression of P-MST1 in ?-cells, while no signal was observed in non-diabetic patients 
and control mice.
Caspase-3 and JNK act not only as downstream targets, but also as upstream activators
of MST1 through cleavage- and phosphorylation-dependent mechanisms 16,17 and may 
initiate a vicious cycle and a pro-apoptotic signaling cascade in the ?-cell. Using JNK 
(SP600125) and caspase (z-DEVD-fmk) inhibitors and siRNA to caspase-3 (siCasp3),
we found that both JNK and caspase-3 were responsible for stress-induced MST1 
cleavage by diabetic stimuli in human islets and INS-1E cells (Suppl.Fig.2), suggesting
that MST1 induces a positive feedback loop with caspase-3 under diabetogenic 
conditions. Because phosphatidylinositol-3 kinase (PI3K)/AKT signaling is a key 
regulator of ?-cell survival and function 18,19 and since MST1 signaling is negatively 
regulated by this pathway in other cell types 20,21, we hypothesized that AKT is an 
important negative regulator of MST1. Maintaining AKT-activation through either 
exogenously added mitogens like glucagon-like peptide 1 (GLP1) or insulin or 
overexpression of constitutively active AKT1 (Myr-AKT1) inhibited glucose- and
cytokine-induced P-MST1, MST1-cleavage and apoptosis (Suppl.Fig.3A-E); these 
effects were abrogated by the PI3K inhibitor LY294002. Conversely, inhibition of 
PI3K/AKT pro-survival signaling itself induced MST1 activation (Suppl.Fig.4A-D) and 
potentiated cytokine-induced P-MST1 and ?-cell death (Suppl.Fig.4D), indicating that the 
loss of PI3K/AKT activity leads to a critical up-regulation of MST1 activity and induction 
of apoptosis. This is evidenced by the diminished insulin-induced AKT phosphorylation 
in the presence of MST1; and conversely by enhanced AKT phosphorylation in MST1-
depleted ?-cells (Suppl.Fig.4E,F). Also, knockdown of MST1 antagonized the apoptotic 
effect of AKT inactivation in INS1E cells, implicating endogenous MST1 in the apoptotic 
mechanism induced by PI3K/AKT inhibition (Suppl.Fig.4G,H). In summary, these results 
suggest that MST1 is activated in pro-diabetic conditions in vitro and in vivo, that is 
antagonized by PI3K/AKT signaling and depends on the JNK- and caspase-induced
apoptotic machinery.
MST1 over-expression was itself sufficient to induce apoptosis in human and rodent ?-
cells (Fig.1F-H, Suppl.Fig.5A-C). To investigate pathways that potentially contribute to 
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MST1-induced ?-cell apoptosis, we overexpressed MST1 in human islets and INS-1E
cells through an adenoviral system, which efficiently up-regulated MST1 and activated 
JNK, PARP- and caspase-3 cleavage (Fig.1F, Suppl.Fig.5C). Previous data proposed a 
role of the mitochondrial pathway in MST-dependent signaling 22,23. Profiling expression 
levels of established mitochondrial proteins in MST1-overexpressing islets showed 
cleavage of the initiator caspase-9, release of cytochrome c and induction of pro-
apoptotic Bax and a decline in anti-apoptotic Bcl-2 and Bcl-xL levels (Fig.1F,
Suppl.Fig.5C,E), which led to a drastic reduction of Bcl-2/Bax and Bcl-xL/Bax levels.
Notably, MST1-induced caspase-3 cleavage was reduced by treatment of human islets 
with the Bax-inhibitory peptide V5 (Fig.1G), which was shown to promote ?-cell survival
24 and emphasizes that MST1-induced apoptosis proceeds via the mitochondrial-
dependent pathway. We also analyzed the expression of BH3-only proteins as 
regulators of intrinsic cell death pathway 25. Of these, Bim was robustly induced,
whereas other BH3-only proteins levels were unchanged (Fig.1F, Suppl.Fig.5C,D). We 
next determined whether Bim is a major molecule to take over the pro-apoptotic action 
of MST1. Indeed, Bim depletion led to a significant reduction of MST1-induced apoptosis 
in human islets (Fig.1H,I). Notably, overexpression of MST1 further potentiated glucose-
induced apoptosis in ?-cells in a Bim-dependent manner (Suppl.Fig.5F). Bim is regulated 
by the JNK 26 and AKT 27 signaling pathways. This was confirmed in human islets:
MST1-induced increase in Bim and subsequent caspase-3 cleavage was prevented by 
JNK inhibition using two strategies; overexpression of dnJNK1 (Fig.1J) and 
pharmacological JNK inhibition (Suppl.Fig.6) suggesting that MST1 uses JNK signaling 
to mediate Bim upregulation and induction of apoptosis. The involvement of AKT in the 
regulation of MST1-induced apoptosis was confirmed by co-overexpression of MST1 
and Myr-AKT1, which remarkably reduced Bim induction and caspase-3 cleavage 
(Fig.1K) indicating that AKT negatively regulates the downstream target of MST1. These 
??????????????????????????????????????????????????-cell apoptosis through activation of the
Bim-dependent intrinsic pathway of cell death and is controlled by the AKT- and JNK 
signaling pathways.
We hypothesized that MST1 activation may elicit changes in ?-cell specific gene 
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transcription that initiate the process ????-cell failure. Overexpression of MST1 led to a 
complete loss of glucose-stimulated insulin secretion (GSIS; Fig.2A, Suppl.Fig.7A-C),
which could not be accounted solely by the induction of apoptosis. Previously, we noted 
????? ???? ????????? ?-cell transcription factor pancreatic duodenal homeobox-1 (PDX1),
which mediates glucose-induced insulin gene transcription in mature ?-cells 28, is 
mislocalized and reduced in diabetes 15. These changes are subsequently associated 
with impaired ?-cell function and hyperglycemia. Stress-induced kinases such as JNK 
and glycogen synthase kinase-3 (GSK3) phosphorylate and antagonize PDX1 activity 
29,30, leading to ?-cell failure. Thus, we hypothesized that the drastic reduction in insulin 
secretion following MST1 overexpression may be mediated by PDX1. This view was 
supported by a marked reduction in PDX1 levels in response to MST1 overexpression 
(Fig.2B, Suppl.Fig.7D). In contrast, MST1 overexpression did not affect PDX1 mRNA 
levels (Fig.2C, Suppl.Fig.7E), suggesting that MST1 may regulate PDX1 at the post-
transcriptional level. PDX1 binds to the promoters, and controls the expression of,
? ?????????-?????????????????????????????????-cell function. These include insulin, SLC2A2
(GLUT2) and glucokinase (GCK) 31,32. Real time PCR analysis of PDX1 target genes 
demonstrated that overexpression of MST1 significantly down-regulated Insulin (Ins1 or 
Ins2 for INS-1E), SLC2A2 and GCK in human islets and INS-1E (Fig.2C, Suppl.Fig.7E).
To clarify the mechanism by which MST1 regulates PDX1, we examined the effects of 
ectopic expression of MST1 and PDX1 in HEK293 cells. This revealed decreased PDX1 
level in cells co-overexpressing MST1, whereas a kinase-dead MST1 (K59R; dnMST19)
had no effect.  Thus, kinase activity is required for MST1-induced PDX1 degradation 
(Fig.2D). Overexpression of MST1 also attenuated the transcriptional activity of PDX1 on 
the rat insulin promoter, as shown by luciferase assays in HEK293-overexpressing 
PDX1 (Suppl.Fig.7F) and INS1E cells (Suppl.Fig.7G). To discriminate between a 
transcriptional/translational and a post-translational effect of MST1 on PDX1, we 
followed the stability of overexpressed-PDX1 upon treatment with cycloheximide (CHX), 
an inhibitor of protein translation. PDX1 protein levels rapidly decreased when co-
expressed with MST1 upon CHX exposure (Fig.2E), which suggests that MST1 reduced 
PDX1 protein stability. Consistent with these observations, MST1 overexpression also 
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decreased protein stability of endogenous PDX1 in human islets (Suppl.Fig.8). In 
contrast, inhibition of proteasomal degradation by treatment of PDX1 overexpressing 
HEK293 cells with the proteasome inhibitor MG-132 abolished the disappearance of 
PDX1 (Fig.2F), indicating that MST1-induced activation of the ubiquitin proteasome 
pathway. Proteasomal degradation of PDX1 has been described before and leads to 
impaired ?-cell function and survival 33. In vivo ubiquitination assays were next 
performed to determine whether MST1 induces PDX1 ubiquitination. PDX1 co-
transfected with MST1 but not with MST1-K59 was heavily ubiquitinated in HEK293 cells 
(Fig.2G). This was confirmed in human islets by showing that MST1 overexpression 
strongly promoted endogenous PDX1 ubiquitination (Fig.2H). Subsequently, a direct
interaction between PDX1 and MST1 proteins were verified. Reciprocal co-
immunoprecipitations showed the interaction between MST1 and PDX1 in HEK293 cells 
co-transfected with GFP-tagged PDX1 and myc-tagged MST1 (Fig.2I). We next 
examined whether a pro-diabetic milieu regulates the association between MST1 and 
PDX1. Strikingly, both cytokine- and gluco-toxicity increased the interaction between 
MST1 and PDX1 in INS-1E cells (Suppl.Fig.9). Since we observed that PDX1 
ubiqutination and degradation required MST1 kinase activity, we tested whether MST1 
directly phosphorylates PDX1. In vitro kinase assays showed that MST1 efficiently 
phosphorylated PDX1 shown by autoradiography using radiolabeled 32P (Suppl.Fig.10A)
and by non-radioactive kinase assays and western blotting using a phospho-specific 
PDX1 antibody (Fig.2J). The in vitro kinase assays were confirmed in HEK293 cells; co-
expression of MST1 and PDX1 led to PDX1 phosphorylation (Suppl.Fig.10B). Together, 
these results establish PDX1 as a substrate for MST1. The potential MST1-targeted 
phosphorylation sites of PDX1 were determined theoretically with the Netphos 2.0
program 34. This identified six candidate sites including T11, T126, T152, T155, T214 
and T231 within the PDX1 sequence based on a relative score (Suppl.Fig.11A). These 6 
sites were individually mutated to alanine to generate phospho-deficient constructs 35.
PDX1-GST fusion proteins with different PDX1 mutations were purified from bacteria 
and used as substrates for MST1 in the kinase assay. With the exception of T11A, 
PDX1-WT and other mutants were efficiently threonine phosphorylated (Suppl.Fig.11B).
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To confirm this, all PDX1 mutants were transfected into HEK293 cells,
immunoprecipitated with PDX1 and incubated with recombinant MST1 in a kinase 
assay. MST1 highly phosphorylated WT-PDX1 and other mutants, while phosphorylation 
in the PDX1-T11A was markedly decreased (data not shown), indicating that T11 is 
major site of phosphorylation by MST1. To further validate this, a phosphospecific 
antibody against T11 phosphorylation site in PDX1 (p-T11PDX1) recognized wild-type 
recombinant PDX1, which was incubated with MST1 in the kinase assay 
(Suppl.Fig.11C). Consistently, co-incubation of immunoprecipitated PDX1-WT or PDX1-
T11A with recombinant MST1 resulted in robust MST1-induced PDX1-WT 
phosphorylation at the T11 site (shown by p-T11 antibody) and in overall Thr-
phosphorylation (shown by pan-Threonine antibody); such phosphorylation was 
markedly reduced in the PDX1-T11A mutant protein (Fig.2K). This was further
corroborated with an in vivo kinase assay (Suppl.Fig.11D). Alignment of the amino acid 
sequences of PDX1 from different species revealed that T11 site is highly conserved 
among those species (Suppl.Fig.11E).
If T11 is the specific MST1-induced phosphorylation site of PDX1 and responsible for ?-
cell dysfunction, one would expect that mutated PDX1-T11A would reverse such 
deleterious effects of MST1. This hypothesis was supported by the observation that 
MST1 does not decrease PDX1 levels in PDX1-T11A-expressing HEK293 cells (Fig.3L). 
MST1-induced a rapid degradation of PDX1 in the presence of CHX, which did not occur 
in PDX1-T11A mutant transfected cells (Suppl.Fig.12A). Consistently, there was less 
PDX1 ubiquitination in the PDX1-T11A-transfected cells than in PDX1-WT 
(Suppl.Fig.12B). Since T11 is located within the transactivational domain of PDX1 and to 
evaluate the functional significance of the T11-dependent ubiquitination/degradation, we 
assessed transcriptional activity of PDX1. Reduction of PDX1 transcriptional activity 
occurred only in PDX1-WT but not in PDX1-T11A mutant transfected cells 
(Suppl.Fig.12C). Since mutation of PDX1 on T11 maintains PDX1 stability, we asked 
whether PDX1 stability is directly linked to improved ?-cell function. Indeed, PDX1-T11A 
mutant overexpression (Suppl.Fig.12D) normalized MST1-induced impairment in GSIS 
(Fig.2M, Suppl.Fig.12E) and restored MST1-induced down regulation of PDX1 target 
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genes (Fig.2N, Suppl.Fig.11F). These findings indicate that MST1-induced PDX1 
phosphorylation at T11 leads directly to PDX1 de-stabilization and impaired ?-cell 
function and suggest that PDX1 is a crucial target of MST1 in the regulation of ?-cell 
function.
Our further analyses established MST1 as a master regulator of apoptosis in ?-cells.
MST1 not only mediates ?-cell death and impaired function in vitro, but its down-
regulation can rescue from ?-cell failure (Fig.3, Suppl.Fig.13). Firstly, MST1 depletion 
protected ?-cells from cytokine-, H2O2-, gluco- and lipotoxicity; ?-cell apoptosis was 
inhibited (Fig.3A,B,D, Suppl.Fig.13A-D). Secondly, ?-cell function was greatly improved 
(Fig.3C,E,G) by MST1 gene silencing under diabetogenic conditions. Silencing of MST1 
also dramatically reduced Bim upregulation induced by diabetogenic conditions in
human islets (Fig.3B, Suppl.Fig.13A-B) as well as in INS1E cells which were stably 
transfected with shMST1 vector (Fig.3E). This further indicates that MST1 promotes 
apoptosis in pro-diabetic conditions through Bim induction. Cytochrome c release was 
markedly reduced in MST1-depleted ?-cells under diabetogenic conditions
(Suppl.Fig.13E,F). To confirm shMST1 data in INS1E cells, we show that inhibition of 
endogenous MST1 activity by overexpression of dnMST1 completely inhibited glucose-
induced caspase-3 and PARP cleavage in ?-cells (Suppl.Fig.13G). Notably, MST1 
deficiency prevented PDX1 depletion upon cytokine and high glucose treatment, 
implying that MST1 is indispensable for the PDX1 reduction induced by a diabetic milieu 
(Fig.3F). Also, the significant reduction in the mRNA level of PDX1 target genes, e.g. 
SLC2A2, GCK, Ins1 and Ins2 was prevented and GSIS significantly improved in MST1 
depleted ?-cells (Fig.3G,H; Suppl.Fig.13H). These data prove MST1 as determinant for 
?-cell apoptosis and defective insulin secretion under a diabetic milieu in ?-cells in vitro.
Since MST1 depletion protected from ?-cell apoptosis and restored ?-cell function in 
vitro, we hypothesized that MST1 deficiency may protect against diabetes in vivo by 
promoting ?-cell survival and preserving ?-cell mass. Neither body weight nor food 
intake differed between MST1-/- and their littermates (MST1+/+ WT) mice. MST1-/- mice 37
had no apparent metabolic phenotype under control conditions at the age of 2-6 months; 
glucose tolerance, insulin tolerance, insulin secretion as well as islet morphology and ?-
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cell mass were similar to MST1+/+ wild-type littermates (Suppl.Fig.14, 15A-C). To 
exclude a secondary effect of the MST1-depletion on the ?-???????-cell-specific MST1-/-
mice were generated by Cre-lox system (??????????????????????????-MST1-/- mice). These 
mice contained a null mutation for MST1, as confirmed by western blotting of lysates 
from isolated islets (Suppl.Fig.17A????-MST1-/- mice were viable, fertile and showed no 
difference in food intake and body weight (data not shown), glucose tolerance and 
insulin sensitivity compared to MST1fl/fl (Suppl.Fig.17B,C) or flox-negative littermates 
(RIP-Cre; data not shown). Diabetes was induced by multiple low-dose streptozotocin 
(MLD-STZ) in total MST1-/- and ?-MST1-/- mice and their wildtype controls. While
progressive hyperglycemia and severely impaired glucose tolerance was induced in WT
mice (MST1+/+, fl/fl, Rip-Cre) by MLD-STZ injections, blood glucose levels were 
significantly reduced in MST1-/- as well as ?-MST1-/- mice (Fig.4A,B,M,N); MST1-/- as 
well as ?-MST1-/- mice were completely protected from STZ-induced diabetes (Fig.4, 
Suppl.Fig.15). MLD-STZ treatment led to impaired insulin secretion and insulin to 
glucose ratio, which was significantly restored in MST1-/- and ?-MST1-/-mice (Fig.4C-E; 
N-P). Islet architecture in STZ-treated WT mice was disrupted and accompanied by 
reduced ?-cell mass, ?-cell fraction, islet density, mean islet size and increased ฀-cell to ?-cell ratio (Fig.4F-J, Suppl.Fig.15A-E), compared to that of non-MLD-STZ-treated mice. 
In contrast, islet architecture of MLD-STZ-treated MST1-/- mice had a normal 
morphology, comparable to that of non-MLD-STZ-treated mice (Fig.4I). TUNEL staining 
demonstrated that apoptosis was dramatically increased in MLD-STZ-treated MST1+/+
mice, compared to saline-treated MST1+/+ mice. MST1 deletion in MST1-/- as well as ?-
MST1-/- mice highly reduced apoptosis (Fig.4G,S;Suppl.Fig.15D). MLD-STZ substantially
???????????-cell proliferation in WT mice (MST1+/+, fl/fl, Rip-Cre), but in MST1-/- as well 
as ?-MST1-/- mice they proliferated at greater frequency, indicative of an improved 
compensatory capacity (Fig.4H,T; Suppl.Fig.15E). Importantly, no difference in the 
?????????? ??? ?????????????? ?-cells was observed between islets from MST1-/- mice and 
their WT littermates. ?????? ???????? ???????? ?????????? ????????? ???????????-cell mass 
and islet density predominantly as a result of ???????????-cell apoptosis and increased 
?-cell proliferation in response to diabetogenic stimulation. In line with our in vitro results 
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in ?-cells, where MST1 acts through changes in Bim, expression of the latter was clearly 
seen in ?-cells in diabetic STZ-mice, but not in MST1??? mice (Fig.4K). Also, ?-cell PDX1-
expression was normalized and the prominent nuclear localization important for its 
functionality re-established (Fig.4L). The PDX1 target gene SLC2A2 was largely 
?????????? ????-cell membranes in the MLD-STZ-treated MST1??? mice (supplementary 
Fig.15F). To directly assess the protective effect of MST1 depletion in STZ-induced ?-
cell apoptosis, we treated isolated mouse islets and INS-1E cells with STZ in vitro and 
found that STZ strongly induced P-MST1, Bim and ultimately apoptosis, and such 
apoptotic induction by STZ was attenuated by MST1 depletion (Suppl.Fig.15G-H),
consistent with the in vivo observations in MST1??? mice.
The protective effect of MST1 depletion against hyperglycemia and development of 
diabetes was further confirmed in a mouse model of T2D 38. The combination of high fat-
sucrose diet for 16 weeks and administration of a single dose of STZ (100 mg/kg) led to 
severe hyperglycemia 3 weeks after administration of STZ and impaired glucose 
tolerance in WT mice. Similar to the effects in the MLD-STZ model, MST1 deletion also 
resulted in improved glucose tolerance and insulin secretion, increased ?-cell mass and
restored ?-cell morphology as a result of improved ?-cell survival and proliferation 
(Suppl.Fig.16), compared to HFD/STZ-treated littermate MST1+/+ mice. Intraperitoneal 
insulin tolerance tests (ipITT) revealed that the glucose-lowering effects in the MST1-/-
mice can be accounted to the improved ?-cell mass and insulin secretion, since MST1-/-
mice and their WT littermates showed similar insulin sensitivity (Suppl.Fig.16B,C).
In summary, our work shows that MST1 acts as an essential apoptotic molecule in the 
presence of diabetic stimuli and is a common component in the diverse signaling 
pathways leading to impaired ?-cell survival. Importantly, our data also establish PDX1 
as novel and ?-cell specific substrate for MST1. Thus, we provide evidence that PDX1 
ubiquitination and subsequent degradation, resulting from inhibitory T11 
?????????????????????????????????-cell dysfunction after MST1 hyper-activation in diabetes
(Suppl.Fig.18). Together, these actions of MST1 are likely to explain how deletion of 
MST1 preserves ?-cell function and survival providing protection from diabetic insults.
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Current therapies for the treatment of all forms of diabetes mellitus are directed towards 
alleviating the symptoms of the disease, but there is an urgent medical need for 
therapies that slow or prevent the loss (rapid in T1D, progressive in T2D) of functional 
pancreatic ?-cell mass. ??????????????????????????????????????????-cell failure and initiation 
of “pro-diabetic milieu”-induced apoptotic signaling, therapeutic strategies designed to 
inhibit MST1 activity may both protect the ?-cell against the effects of autoimmune attack 
in T1D and preserve ?-cell mass and function in T2D.
Detailed methods are given in the supplementary material.
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Figure Legends
Figure 1. MST1 is activated in diabetogenic conditions in vitro and in vivo and 
causes ?-cell death
(A) Activated MST1 (cleaved and phosphorylated) in human islets exposed to 
diabetogenic conditions (33.3 mM glucose the cytokine mix 2 ng/ml IL-1?/1,000U/ml 
IFN ฀????/IF) together with caspase activation (cleaved caspase 3), JNK-phosphorylation 
and P-H2B as direct MST1 target shown by Western blotting. (B,C) Activated MST1 in 
diabetic islets. (B) Human isolated islets from non-diabetic controls and patients with 
T2D and (C) from 10-week old diabetic db/db and their heterozygous db/+ littermates 
were cultured for 24h after isolation and MST1 activity analyzed by western blotting. 
(D,E) Double immunostaining for p-MST1 in red and insulin in green in pancreatic tissue 
sections from a representative non-diabetic control and from patients with poorly 
controlled T2D, all with documented fasting plasma glucose >150 mg/dl (D) and from 
diabetic db/db mice (E, magnification x200). (F-K) Adenovirus-mediated MST1 or GFP 
(control) overexpression in human islets. (F) Efficient up-regulation of MST1 is achieved 
by adenoviral system. Profiling expression levels of proteins of the mitochondrial death 
pathway showed up-regulation of Bim, Bax and caspase-9 cleavage as well as down-
regulation of Bcl-2 and Bcl-xL together with JNK activation and caspase-3 cleavage 
upon MST1 overexpression. (G) Exposure of Ad-GFP- or Ad-MST1-infected human 
islets to Bax-inhibitory peptide V5 or negative control (NC) peptide for 36h. Caspase-3
cleavage was analyzed by western blotting (H,I) Human islets transfected with Bim 
siRNA or control siScr were infected with Ad-GFP or Ad-MST1 for 48h. (H) ?-cell 
apoptosis was analyzed by double staining of TUNEL and insulin.  An average number 
of 10378 insulin-positive ?-cells were counted in 3 independent experiments from 3 
different donors. (I) Bim, caspase-3 and PARP cleavage were analyzed by western 
blotting. (J) JNK inhibition diminished MST1-induced Bim induction and apoptosis. 
Human islets were transfected with GFP or dnJNK1 expression-plasmids and infected 
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with Ad-GFP or Ad-MST1 for 48h. P-C-Jun, Bim and caspase-3 cleavage were analyzed 
by western blotting. (K) AKT activation suppressed MST1-induced Bim up-regulation 
and apoptosis. Human islets were transfected with GFP or Myr-Akt1 expression-
plasmids and infected with Ad-GFP or Ad-MST1 for 48 h. Bim and caspase-3 cleavage 
were analyzed by western blotting. All western blots show representative results from at 
least 3 independent experiments from 3 different donors or mice. Tubulin/Actin was used 
as loading control. Results shown are means ±SE. *p<0.05 MST-OE compared to GFP 
control, **p<0.05 siBim-MST1 compared to siScr-MST1. (B-E) Representative analyses 
from 10 pancreases from patients with T2D and >10 controls and from 7 db/db and 7 
db/+ controls are shown. 
Figure 2. MST1 impairs ?-cell function through PDX1-T11 phosphorylation and 
degradation
(A-C) Adenoviruse-mediated GFP or MST1 overexpression in human islets for 96h. (A)
MST1 overexpression abolished glucose-induced insulin secretion. The insulin 
stimulatory index denotes the ratio of secreted insulin during 1h-incubation with 16.7 mM 
and 2.8 mM glucose, respectively. (B) MST1 and PDX1 immunoreactivity were analyzed 
by Western blotting. (C) PDX1 target genes including SLC2A2, GCK and Insulin were 
analyzed by RT-PCR. (D-F) HEK293 cells were transfected with plasmids encoding 
Myc-MST1 and GFP-PDX1. (D) A kinase-dead MST1 (dn-MST1: K59R) was co-
transfected with GFP-PDX1. (E) At 48 h after transfection, HEK293 cells were treated 
with 50 µg/ml cycloheximide (CHX) for 8h. (F) At 36h after transfection, HEK293 cells 
were treated with the proteasome inhibitor MG-132 (50 µM) for 6h. PDX1 and MST1 
were analyzed by western blotting. (G,H) In vivo ubiquitination assay in (G) HEK293 
cells and (H) human islets. (G) HEK293 cells were transfected with GFP-PDX1 and HA-
ubiquitin, alone or together with Myc-MST1 or MST1-K59 expression plasmids for 48h. 
(H) Human islets (2 different donors) were transfected with HA-ubiquitin and infected 
with Ad-GFP or Ad-MST1 for 48h. MG-132 was added during the last 6h of the 
experiment. HEK293 or islets lysates were immunoprecipitated with an anti-PDX1 
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antibody followed by immunoblotting with ubiquitin antibody to detect ubiquitinated 
PDX1. (I) HEK293 cells were transfected with GFP-PDX1 alone or together with Myc-
MST1 for 48h, reciprocal co-immunoprecipitations performed using anti-GFP and anti-
Myc antibodies and western blot analysis performed with precipitates and input fraction 
using anti-Myc and anti-GFP antibodies, respectively. (J) In vitro kinase assay was 
performed by incubating recombinant MST1 and PDX1 proteins and analyzed by 
NuPAGE followed by western blotting using pan-phospho-threonine specific, PDX1 and 
MST1 antibodies. (K) Lysates of HEK293 cells transfected with PDX1-WT or PDX1-
T11A expression-plasmids were immunoprecipitated with PDX1 antibody and subjected 
to an in vitro kinase assay using recombinant MST1. Phosphorylation reactions were 
analyzed by Western blotting using p-T11-PDX1 specific and pan-phospho threonine 
antibodies. (L) HEK293 cells were transfected with PDX1-WT or PDX1-T11A alone or 
together with MST1 expression-plasmids for 48h. MST1 and PDX1 were analyzed by 
western blotting (M,N) Human islets were transfected with PDX1-WT or PDX1-T11A
expression-plasmids and infected with Ad-GFP or Ad-MST1 for 72 h. (M) Insulin 
stimulatory index denotes the ratio of secreted insulin during 1h-incubation with 16.7 mM 
and 2.8 mM glucose, respectively. (N) PDX1 target genes in human islets analyzed by 
RT-PCR and levels normalized to tubulin and shown as change from PDX1-WT 
transfected islets. All western blots show representative results from at least 3 
independent experiments from 3 different donors (human islets). Tubulin/Actin was used 
as loading control. RT-PCR (C,N) and GSIS (A,M) show pooled results from 3 
independent experiments from 3 different donors. Results shown are means ±SE. 
*p<0.05 MST-OE compared to GFP (A,C,M,N) control, **p<0.05 compared to PDX-1WT-
MST1.
Figure 3. MST1 deficiency improves ?-cell survival and function
(A-C) Human islets transfected with MST1 siRNA (smart pool, mixture of 4 siRNA)  or 
control siScr and were treated with the cytokine mix IL/IF, 33.3 mM glucose or the 
mixture of 33.3 mM glucose and 0.5 mM palmitate (33.3Pal) for 72 hours.  (A) ?-cell 
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apoptosis was analyzed by double staining of TUNEL and insulin. An average number of 
11390 insulin-positive ?-cells were counted for each treatment condition in 3 
independent experiments from 3 different donors. (B) Western blotting confirmed 
successful (~80%) MST1 depletion in human islets.  MST1, p-MST1, Bim, caspase-9
and-3 cleavage and p-H2B all were analyzed by western blotting (C) Insulin stimulatory 
index denotes the ratio of secreted insulin during 1h-incubation with 16.7 mM and 1h-
incubation with 2.8 mM glucose. (D,E) Islets were isolated from MST1-/- mice and their 
WT littermates and exposed to the cytokine mix IL/IF or the mixture of 33.3 mM glucose 
and 0.5 mM palmitate (33.3Pal) for 72 hours. (D) ?-cell apoptosis was analyzed by 
double staining for TUNEL and insulin. An average number of 24180 insulin-positive ?-
cells were counted for each treatment condition in 3 independent experiments. (E)
Insulin stimulatory index denotes the ratio of secreted insulin during 1h-incubation with 
16.7 mM and 1h-incubation with 2.8 mM glucose. (F-H) Stable INS-1E clones were 
generated by transfection of vectors for shMST1 and shScr control and treated with the 
cytokine mix IL/IF or 33.3 mM glucose for 72 hours. (F) MST1, Bim, PDX1, caspase-3
and PARP cleavage were analyzed by western blotting (G) Insulin stimulatory index 
denotes the ratio of secreted insulin during 1h-incubation with 16.7 mM and 1h-
incubation with 2.8 mM glucose. (H) PDX1 target genes in shMST1 and shScr control 
INS-1E cells exposed to 5.5 or 33.3 mM glucose for 72h were analyzed by RT-PCR and 
levels normalized to tubulin and shown as change from shScr control INS1-E clones.
Western blots (B,F) show representative results from 3 independent experiments from 3 
different donors (human islets). Tubulin/Actin was used as loading control. TUNEL data 
(A,D), GSIS (C,E,G) or RT-PCR (H) show pooled results from 3 independent 
experiments. Results shown are means ±SE. *p<0.05 compared to siScr (A,C), WT 
(D,E) or shScr untreated controls at 5.5 mM glucose (G,H), **p<0.05 compared to siScr 
(A,C), WT (D,E) or shScr (G,H) at the same treatment conditions.
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Figure 4. MST1 deletion protects from diabetes in vivo
(A-K) MST1-/- mice (n=15) and their littermates (n=14) were injected with 40 mg/kg 
streptozotocin or citrate buffer for 5 consecutive days. (A) Random fed blood glucose 
measurements after last STZ injection (day 0) over 21 days. (B) Intraperitoneal glucose 
tolerance test (ipGTT) performed at day 17 after 12h fast with 1 g/kg BW glucose. (C,D)
Insulin secretion during an ipGTT measured before (0 min) and 30 min after glucose 
injection and data are expressed as (D) ratio of secreted insulin at 30 min/0 min 
(stimulatory index). (E) The ratio of secreted insulin and glucose is calculated at fed 
state. (F-L) Mice were sacrificed at day 22. (F) ?-cell mass per pancreas on fixed, 
paraffin embedded sections calculated as the product of the relative cross-sectional area 
????-cells (determined by quantification of the cross-????????????????????????????-cells 
divided by the cross-sectional area of total tissue multiplied with the weight of the 
pancreas). 10 sections per mouse spanning the width of the pancreas were included in 
the analysis. (G,H) Triple staining for (G) TUNEL or (H) Ki67, insulin and DAPI 
performed. Results are expressed as percentage of (G) TUNEL- or (H) Ki67-??????????-
cells ?????????????????????????-cells scored was 23121 for each treatment condition. 
(I,J) The pancreatic area of ?- (stained in red; J) and ?-cells (stained in green; J) are 
given as percentage of the whole pancreatic section from 10 sections spanning the 
width of the pancreas. (K,L) Representative double-staining for Bim (red, K) or PDX1 
(red, L) and insulin (green) is shown from STZ-treated MST-/- mice and controls. White 
arrows indicate areas of cytosolic PDX1 localization and its total absence in WT-STZ 
mice. (M-T) ?-MST-/- mice with specific deletion in the ?-cells using the Cre-Lox system 
(n=5) and their Rip-Cre (n=3) and fl/fl controls (n=3) were injected with 40 mg/kg 
streptozotocin for 5 consecutive days and (M) fed blood glucose, (N) glucose tolerance, 
(O,P) insulin secretion during ipGTT, (Q) the ratio of fed insulin and glucose, (R) ?-cell 
mass, (S) ?-cell apoptosis and (T) ?-cell proliferation analyzed as described above. Data 
show mean ? SE. *p<0.05 WT-STZ compared to WT saline injected mice, **p<0.05
MST-STZ compared to WT-STZ mice, +p<0.05 ?-MST-STZ compared to fl/fl-STZ or 
Cre-STZ mice.
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Methods
Cell culture, treatment and islet isolation
Human islets were isolated from twenty pancreases of healthy organ donors and from five with 
T2DM at the University of Illinois at Chicago or Lille University and cultured on extracellular 
matrix (ECM) coated dishes (Novamed, Jerusalem, Israel) as described previously 1. Islet purity 
was greater than 95% as judged by dithizone staining (if this degree of purity was not achieved 
by routine isolation, islets were handpicked). Islets from MST1-/- mice and their WT littermates 
were isolated as described previously 1. Pancreata were perifused with a Liberase TM 
(#05401119001, Roche, Mannheim, Germany) solution according to the manufacturer’s 
instructions and digested at 37°C, followed by washing and handpicking. The clonal rat beta-cell 
line INS-1E was kindly provided by Dr. Claes Wollheim, Geneva & Lund University. Human 
islets were cultured in complete CMRL-1066 (Invitrogen) medium at 5.5 mM glucose and mouse 
islets and INS-1E cells at complete RPMI-1640 medium at 11.1 mM glucose and HEK293 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM). All media included with 
glutamate, 1% penicillin–streptomycin and 10% fetal bovine serum (FBS, all PAA). INS-1E 
medium was supplemented with 10 mM HEPES, 1 mM sodium pyruvate ???? ??? ??? ?-
mercaptoethanol. Islets and INS-1E were exposed to complex diabetogenic conditions: 22.2-
33.3 mM glucose, 0.5 mM palmitic acid, the mixture of 2 ng/ml recombinant human IL-???(R&D 
Systems, Minneapolis, MN) +1,000 U/ml recombinant human IFN-?? ???????????? ???????? 100
????2O2 for 6h, 1 mM streptozotocin (STZ) for 8h or 1 mM thapsigargin for 6h (all Sigma). In 
some experiments, cells were additionally cultured with 10-25 µM JNK selective inhibitor 
SP600125, 25 µM selective PI-3 kinase inhibitor LY294002, 20 µM AKT inhibitor V, Triciribine, 
selective AKT1/2/3 inhibitor, 25 µM pan-caspase inhibitor Z-VAD (OMe)-fmk, 100 µM Bax-
inhibiting peptide V5 or Bax-inhibiting peptide, negative control, InSolutionTM MG-132,
proteasome inhibitor (all Calbiochem), 100 nM Glucagon like-peptide 1 (GLP1), 100 nM 
recombinant human insulin and cycloheximide (CHX) (all Sigma). Palmitic acid was dissolved 
as described previously 2. Ethical approval for the use of islets had been granted by the Ethics
Committee of the University of Bremen.
Animals
For MLD-STZ experiment, 8-10 week old MST1-/- mice on a 129/sv genetic background 3 and 
their MST1+/+ WT littermates were i.p. injected with streptozotocin (STZ; 40 mg/kg; Sigma) 
freshly dissolved in 50mM sodium citrate buffer (pH 4.5) or citrate buffer as control for 5
consecutive days (referred to as multiple low dose/MLD-STZ). For the high fat diet (HFD) 
2 
 
experiments, 8-10 week old MST1-/- mice and their MST1+/+ WT littermates were fed a normal 
diet (ND, Harlan Teklad Rodent Diet 8604, containing 12.2, 57.6 and 30.2% calories from fat, 
carbohydrate and protein, respectively) or a high fat/ high sucrose diet (HFD, “Surwit” Research 
Diets, New Brunswick, NJ, containing 58, 26 and 16% calories from fat, carbohydrate and 
protein, respectively 4). After 16 weeks of HFD feeding, a single dose of 100 mg/kg BW STZ
was i.p. injected to induce ?-cell failure and insulin deficiency. Three weeks after STZ injection, 
wild-type HFD/STZ-treated mice displayed hyperglycemia, insulin resistance and glucose 
intolerance. For both models, random blood was obtained from the tail vein of non-fasted mice 
and glucose was measured using a Glucometer (Freestyle; TheraSense Inc., Alameda, CA).
Mice were killed at the end of experiment, pancreas was isolated. Throughout the whole study, 
food consumption and body weight were measured weekly. To create ?-cell-specific MST1-/-
mice, mice harboring exon 4 of the MST1 gene flanked by loxP sites (MST1fl/fl) 3) were crossed 
with mice expressing cre under the rat insulin-2 promoter (B6;D2-Tg(Ins-cre)23Herr: RIP-Cre
5, kindly provided by Pedro Herrera, University of Geneva and Ahmed Mansouri, Max Planck 
Institute for Biophysical Chemistry). RIP-Cre-MST1fl/- mice were intercrossed to generate RIP-
Cre-MST1fl/fl. Mice were MLD-STZ injected as described above.
All animals were housed in a temperature-controlled room with a 12-hour light/dark cycle and 
were allowed free access to food and water in agreement to NIH animal care guidelines of the 
§8 German animal protection law and approved by the Bremen Senate.
Intraperitoneal glucose and insulin tolerance tests and measurement of insulin release
For intraperitoneal glucose tolerance tests (ipGTTs), mice were fasted 12h overnight and 
injected i.p. with glucose (40%; B.Braun, Melsungen, Germany) at a dose of 1 g/kg body weight.
Blood samples were obtained at time points 0, 15, 30, 60, 90, and 120 min for glucose 
measurements using a Glucometer and at time points 0 and 30 min for measurement of serum 
insulin levels. For i.p. insulin tolerance tests, mice were injected with 0.75 U/kg body weight 
recombinant human insulin (Novolin, Novo Nordisk) after 5-h fasting, and glucose concentration 
was determined with the Glucometer. Insulin secretion was measured before (0min) and after 
(30min) i.p. injection of glucose (2 g/kg) and measured using ultrasensitive mouse Elisa kit 
(ALPCO Diagnostics, Salem, NH).
Plasmids
pCMV-myc-MST1 and kinase-dead (MST1-K59; dnMST1) was kindly provided by Dr. Junichi 
Sadoshima and Dr. Yasuhiro Maejima (UMDNJ, New Jersey Medical School) 6. Mouse 
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pB.RSV.PDX1-GFP plasmid was kindly provided by Dr. Ingo Leibiger (Karolinska University, 
Stockholm). pcDNA3 Myr-HA Akt1, HA-Ubiquitin and pCDNA3 Jnk1a1 (apf)(dn-JNK) plasmids 
were obtained from Addgene (Cambridge, MA). Mouse PDX1 mutants (T11, T126, T152, T155, 
T214 and T231) in pCGIG5 vector were generated by site-directed mutagenesis as described 
previously 7. All mutations were verified by sequencing. To make bacterial expression plasmids 
for PDX1 mutants, the complete mouse PDX1 CDS (wild type and mutants) has been amplified 
by PCR using a specific set of primers from pCGIG5 plasmids and cloned into a pGEX-6P-1
bacterial expression vector (kindly provided by Dr. Reinhard Walther, University of Greifswald).
The rat insulin driven luciferase vector (RIP-Luc) was constructed by subcloning a 700bp 
fragment containing -660bp of the rat 2 insulin promoter (kindly provided by Dr. Rolf 
Zinkernagel, University of Zurich) into a pMCS-Green-Renilla-Luc vector (Thermo Scientific).
pCMV-Red firefly Luc vector was obtained from Thermo Scientific.
Transfections
To knockdown MST1 in human islets, SMARTpool technology from Dharmacon was used. A
mix of ON-TARGETplus siRNAs directed against the following sequences in human MST1:
UAAAGAGACCGGCCAGAUU, GAUGGGCACUGUCCGAGUA, GCCCUCAUGUAGUCAAAUA, 
CCAGAGCUAUGGUCAGAUA (100 nM, Dharmacon) was transiently transfected into human 
islets and efficiently reduced MST1 levels. An ON-TARGETplus non-targeting siRNA pool from 
Dharmacon served as a control. To knock down Bim and caspase-3 in human islets, siRNA 
targeting human Bim (SignalSilence Bim SiRNA I, Cell Signaling) and caspase-3 (NEB) was 
used. GFP, MST1, dn-MST1 (K59), dn-JNK1 and Myr-Akt1 plasmids were used to overexpress 
these proteins in human islets and INS1E cells. 
An adapted improved protocol 8 to achieve silencing and overexpression in human islets was 
developed. Islets were partially dispersed with accutase (PAA) to break islets into smaller cell 
aggregates to increase transfection efficiency and cultured on ECM dishes for at least 2 days.
Isolated islets and INS1E cells were exposed to transfection Ca2+-KRH medium (KCl 4.74 mM, 
KH2PO4 1.19 mM, MgCl26H2O 1.19 mM, NaCl 119 mM, CaCl2 2.54 mM, NaHCO3 25 mM, 
HEPES 10 mM). After 1h incubation, lipoplexes (Lipofectamine2000, Invitrogen)/-siRNA ratio 
1:20 pmol or -DNA ratio 2.5:1) were added to transfect the islets and INS1 cells. After additional
6h incubation, CMRL-1066 or RPMI-1640 medium containing 20% FCS and L-Glutamine were 
added to the transfected islets or INS1 cells. Efficient transfection was evaluated based on 
Fluorescein-labeled siRNA (NEB) or eGFP positive cells analyzed by fluorescent or confocal 
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microscopy. HEK293 were transiently transfected using Optimem medium and Lipofectamine 
(Invitrogen) according to the manufacturer’s instructions.
Glucose stimulated insulin secretion
For acute insulin release in response to glucose, primary human and mouse islets and INS1 
cells were washed and pre-incubated (30 min) in Krebs-Ringer bicarbonate buffer (KRB) 
containing 2.8 mM glucose and 0.5% BSA. KRB was then replaced by KRB 2.8 mM glucose for 
1 h (basal), followed by an additional 1 h in KRB 16.7 mM glucose. Insulin content was
extracted with 0.18N HCl in 70% ethanol. Insulin was determined using human and mouse 
insulin ELISA (ALPCO Diagnostics, Salem, NH). Secreted insulin was normalized to insulin 
content.
Immunohistochemistry
Pancreatic tissues were processed as previously described 9. In brief, mouse pancreases were 
dissected and fixed in 4% formaldehyde at 4°C for 12h before embedding in paraffin. Human 
and mouse 4-µm sections were deparaffinized, rehydrated and incubated overnight at 4ºC with 
anti-insulin (Dako), anti-P-MST1 (Cell Signaling), anti-Bim (Cell Signaling), anti-PDX-1 (abcam), 
anti-glucagon (Dako), anti-glut2 (Chemicon) and anti-mouse anti-Ki67 (BD Pharmingen)
antibodies followed by fluorescein isothiocyanate (FITC)- or Cy3-conjugated secondary 
antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA). Slides were mounted 
with Vectashield with 4’6-diamidino-2-phenylindole (DAPI) (Vector Labs). ?-cell apoptosis for
mouse sections or primary islets cultured on ECM dishes was analyzed by the terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) technique according to 
the manufacturer’s instructions (In Situ Cell Death Detection Kit, TMR red; Roche) and double 
stained for insulin. Fluorescence was analyzed using a Nikon MEA53200 (Nikon GmbH, 
Dusseldorf, Germany) microscope and images were acquired using NIS-Elements software 
(Nikon).
Morphometric analysis
For morphometric data, ten sections (spanning the width of the pancreas) per mouse were 
analyzed. Pancreatic tissue area and insulin-positive area were determined by computer-
assisted measurements using a Nikon MEA53200 (Nikon GmbH, Dusseldorf, Germany) 
microscope and images were acquired using NIS-Elements software (Nikon). The number of 
islets (defined as insulin-positive aggregates at least 25 µm in diameter) was scored and used 
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to calculate islet density (number of islets per square centimeter of tissue), mean islet size (the
ratio of the total insulin-positive area to the total islet number on the sections). Mean percent ?-
cell fraction per pancreas was calculated as the ratio of insulin-positive and whole pancreatic
tissue area. ?-cell mass was obtained by multiplying the ?-cell fraction by the weight of the 
pancreas. Morphometric ?-cell and islet characterizations are results from analyses of at least 
100 islets per mouse.
Western Blot analysis
At the end of the incubation periods, islets and INS1E cells were washed in ice-cold PBS and 
lysed in lysis buffer containing 20 mM Tris acetate, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 
50mM NaF, 1% Triton X-????? ?????????????????????????? ???? ???????-glycerophosphate. 
Prior to use, the lysis buffer was supplemented with Protease- and Phosphatase-inhibitors 
(Pierce, Rockford, IL, USA). Protein concentrations were determined with the BCA protein
assay (Pierce). Equivalent amounts of protein from each treatment group were run on a
NuPAGE 4-12% Bis-Tris gel (Invitrogen) and electrically transferred onto PVDF membranes. 
After 1h blocking at room temperature using 5% milk (Cell Signaling), membranes were 
incubated overnight at 4°C with rabbit anti-MST1, rabbit anti-P-MST1, rabbit anti-Bim, rabbit 
anti-P-AKT (Ser437), rabbit anti-Bax, rabbit anti-Bcl-2, rabbit anti-Bcl-xL, rabbit anti-Bad, rabbit 
anti-phospho Bad, rabbit anti-PUMA, rabbit anti-Bak, rabbit anti-Mcl1, rabbit anti-pan-phopsho 
threonine, mouse monoclonal anti-pan-phospho threonine, rabbit anti-phospho GSK-3, rabbit 
anti-phospho FOXO1, mouse anti-Myc, rabbit anti-cleaved caspase-3, rabbit anti-cleaved 
caspase-9, rabbit anti-cytochrome c, rabbit anti-cytochrom oxidase (COX), rabbit anti-phospho 
JNK (Thr183/Tyr185) , rabbit anti-phospho c-Jun (Ser63), rabbit anti-PARP, rabbit anti-tubulin, 
rabbit anti-GAPDH and rabbit anti-?-actin (all Cell Signaling Technology), rabbit anti-P-MST1,
rabbit anti-GFP, mouse anti-NOXA and rabbit anti-PDX1 (Abcam), rabbit anti-P-H2B (Millipore)
and rabbit anti-P-PDX1 (Thr11) (Abgent) antibodies, followed by horseradish-peroxidase-linked 
anti-rabbit or mouse IgG (Jackson). Membrane was developed using a chemiluminescence 
assay system (Pierce) and analyzed using DocIT®LS image acquisition 6.6a (UVP BioImaging 
Systems, Upland, CA, USA).
Immunoprecipitation
For immunoprecipitation, cells were washed with PBS and lysed in cold buffer containing 20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 
1% NP-40?? ?????????????????????????????????????-glycerophosphate supplemented with 
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proteinase/phosphatase inhibitors for 30 min on ice. Lysates were centrifuged at 12,000 g for 15 
min at 4oC prior to immunoprecipitation. Immunoprecipitations were carried out with incubating 
0.5-1 mg of total lysate with rabbit anti-PDX1 (1:500), rabbit anti-MST1 (1:50), mouse anti-Myc 
(1:1000) and rabbit anti-GFP (1:1000) antibodies on a rotator at 4oC overnight. 
Immunocomplexes were then captured with Protein A Agarose Fast Flow (Millipore) by rotation 
at 4oC for 4 h. After five washes with cold lysis buffer, the immunoprecipitates were used for 
kinase assays or resuspended in sample buffer and separated by NuPAGE 4-12% Bis-Tris gels 
(Invitrogen). 
In vitro kinase assay 
Purified human active MST1 (Upstate Biotechnology) was incubated with 32P-ATP (2 µCi, Perkin 
Elmer Life Sciences), ATP (100 µM) and 1 mM dithiothreitol (DTT) in a kinase buffer containing 
40 mM HEPES (pH 7.4), 20 mM MgCl2, 1mM EDTA and 1 µg of purified recombinant human 
PDX-1 (Abcam) or bacterially purified GST-PDX1 (WT and mutants) as substrates. After 
incubation at 30oC for 30 min, the reaction was stopped by adding loading buffer and proteins
were separated on NuPAGE gels and phosphorylation levels visualized either by 
autoradiography or specific antibody for phospho-PDX1. The total PDX1 was detected with anti-
PDX1 antibody.
In vivo kinase assay
In vivo phosphorylation was performed in two different ways:
1) In vivo 32P Metabolic Labeling: HEK293 cells were transiently transfected with PDX1 and 
MST1 expression plasmids. At 48h after transfection, cells were cultured in labeling medium 
(phosphate-free/serum free DMEM for 4h containing 0.5 mCi/ml 32P-ATP. Cells were then lysed 
in lysis buffer and were immunoprecipitated using anti-PDX1 antibody and subjected to western 
blot analysis and visualized by autoradiography.
2) In vivo phosphorylation detection using pan phospho-Thr/Ser antibodies: HEK293 cells 
were transiently transfected with PDX1 and MST1 expression plasmids. Then, cell lysates were 
subjected to immunoprecipitation with anti-PDX1 antibody. The immunoprecipitates were 
separated by NuPAGE Bis-Tris gels and transferred to PVDF membranes and subsequently 
subjected to analyses of phosphorylation levels by pan phospho-threonine antibody, which 
binds to threonine-phosphorylated sites in a manner largely independent of the surrounding 
amino-acid sequence or pan phospho-serine antibody which is recognizes serine-
phosphorylated proteins.
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In vivo ubiquitination
HEK293 cells were cultured in 10-cm cell culture dishes and transfected with HA-ubiquitin,
PDX1 and MST1 expression plasmids for 48h. For ubiquitination in human islets, 5000 islets per 
condition were transfected with ubiquitin plasmid. After 24h, islets were infected with Ad-GFP or
Ad-MST1 for 6h and kept for another 48h. HEK293 cells and islets were exposed to ????????-
132 for the last 6h of the experiment. Lysates were immunoprecipitated with PDX1-specific 
antibody overnight at 4oC. Immunocomplexes were then captured with Protein A Agarose by 
rotation at 4oC for 4h. After extensive washing, immunoprecipitates were boiled in sample buffer
and proteins subjected to western blotting with ubiquitin-specific antibody.
Protein degradation analysis
HEK293 cells were transfected with PDX1 alone, or together with MST1 expressing-plasmids.
Human islets were infected with Ad-GFP (control) or Ad-MST1. At 48h after post-transfection/
infection, cells were treated with 50 µg/ml translation initiation inhibitor cycloheximde (CHX) to 
the medium at the times indicated and the lysates were subjected to western blotting.
RNA extraction and RT-PCR analysis
Total RNA was isolated from cultured human islets and INS1 cells using TRIzol (Invitrogen), and 
RT-PCR performed as described previously 8. For analysis, we used the Applied Biosystems 
StepOne Real-Time PCR system (Applied Biosystems, CA, USA) with TaqMan(R) Fast 
Universal PCR Master Mix for TaqMan assays (Applied Biosystems). TaqMan(R) Gene 
Expression Assays were used for pdx1 (Hs00426216_m1), SLC2A2 (Hs01096905_m1), GCK
(Hs01564555_m1), insulin (Hs02741908_m1), PPIA (Hs99999904_m1) and tubulin
(Hs00362387_m1) for human and PDX1 (Rn00755591_m1), SLC2A2 (Rn00563565_m1), GCK
(Rn00688285_m1), INS1 (Rn02121433_g1), INS2 (Rn01774648_g1), BCL2L11 
(Hs01083836_m1), PPIA (Rn00690933_m1) and tuba1a (Rn01532518_g1) for rat.
Luciferase reporter assay
The transcriptional activity of the PDX1 at promoter level was evaluated using rat Ins2-Luc
renilla reporter gene. HEK293 cells were transfected with Ins2-Luc renilla, pCMV-firefly, PDX1-
WT or PDX1-T11A, alone or together with Myc-MST1 expressing plasmids for 48h. INS-1E cells 
transfected with Ins2-Luc renilla and pCMV-firefly plasmids and were infected with Ad-GFP or 
Ad-MST1 for 48h. Luciferase activity determined using the Renilla-Firefly Luciferase Dual Assay 
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Kit according to the manufacturer’s instructions (Pierce). pCMV-firefly was used as transfection 
control.
Adenovirus Infection
Isolated human islets and INS1E cells were infected with adenovirus carrying e-GFP as a 
control (kindly provided by Dr. Allan E. Karlsen, Novo Nordisk A/S, Denmark) or MST1 (AdX-
MST1, kindly provided by Dr. Sadoshima) at a multiplicity of infection (MOI) of 20 (for INS1E) or 
100 (for human islets) for 4h. Adenovirus was subsequently washed off with PBS and replaced 
by fresh medium with 10% FBS and GSIS or RNA and protein isolation performed after 48 or 72 
h post-infection.
Purification of GST-PDX1 recombinant proteins
Expression and induction of recombinant GST proteins were performed as described previously
10. Escherichia coli BL21 cells with various GST-fusion expression plasmids were cultured at 
37°C and expression of recombinant proteins was induced by 0.1mM final concentration of 
Isopropyl-?-D-thio-galactoside (IPTG; sigma) for 2.5h. Cells were lysed using B-PER bacterial 
protein extraction reagent (Pierce) and purified using Glutathione Spin Columns (Pierce). 
Cytochrome c release
Cytochrome c release was performed by digitonin-based subcellular fractionation technique 11.
Briefly, INS1 cells were digitonin-permeabilized for 5min on ice after resuspension of the cell 
pellet in 200 µl of cytosolic extraction buffer (CEB: 250 mM sucrose, 70 mM KCl, 137 mM NaCl, 
4.3 mM Na2HPO4, 1.4 mM KH2PO4 (pH 7.2), with 300 µg/ml digitonin (Sigma). Cells were then 
centrifuged at 1000g for 5min at 4°C. Supernatants (cytosolic fractions) were collected and 
pellets solubilized in the same volume of mitochondrial lysis buffer (MLB: 50 mM Tris, pH 7.4, 
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton X-100, 0.3% NP-40), followed by 
centrifugation at 10,000g for 10 min at 4 C. After centrifugation, supernatants, which are the
heavy membrane fractions enriched for mitochondria as well as cytosolic fractions were 
subjected to western blot analysis.
Generation of stably expressed shRNAmir-MST1 INS1 cell line
To knock down MST1 expression in INS1E cells, lentiviral shRNAmir targeting MST1 or control 
shRNAmir vectors (pGIPZ collection, Open Biosystems, Huntsville, AL) were transfected into 
INS-1E cells and stable clones were generated by selection with puromycin (1 to 2.????? ?).
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Positive clonal cell lines were identified by immunoblotting using antibody directed against 
MST1. After selection, INS1E lines were maintained in culture medium containing 1??? ??? ??
puromycin.
Statistical analysis. Samples were evaluated in a randomized manner by three investigators 
(A.A., V.K., S.K.) who were blinded to the treatment conditions. Data are presented as means 
+/- SE. Mean differences were tested by Student’s t- tests. To account for multiplicity in the 
treated cells in vitro and mice in vivo, a Bonferroni correction used. 
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The transcription factor PDX1 plays a critical role during
b-cell development and in glucose-induced insulin gene tran-
scription in adultb-cells. Acute glucose exposure leads to trans-
localization of PDX1 to the nucleoplasm, whereas under condi-
tions of oxidative stress, PDX1 shuttles from the nucleus to the
cytosol. Here we show that cytosolic PDX1 expression corre-
lated with b-cell failure in diabetes. In isolated islets from
patients with type 2 diabetes and from diabetic mice, we found
opposite regulation of insulin and PDX1 mRNA; insulin was
decreased in diabetes, but PDX1 was increased. This suggests
that elevated PDX1mRNA levelsmay be insufficient to regulate
insulin. In diabetic islets, PDX1 protein was localized in the
cytosol, whereas in non-diabetic controls, PDX1 was in the
nucleus. In contrast, overexpression of either IL-1 receptor
antagonist or shuttling-deficient PDX1 restored b-cell survival
and function and PDX1 nuclear localization. Our results show
that nuclear localization of PDX1 is essential for a functional
b-cell andprovides a novelmechanismof the protective effect of
IL-1 receptor antagonist on b-cell survival and function.
New therapies for diabetes that lead to protection of the insu-
lin-producing b-cell are urgently needed. Only when the b-cell
compensates for the higher insulin demand during insulin
resistance can normoglycemia be maintained. Recent studies
suggest that the low grade inflammation in type 2 diabetesmel-
litus (T2DM)3 contributes tob-cell failure (1). Especially, inter-
leukin-1b (IL-1b), whose secretion has been postulated from
intraislet macrophages (2) and from b-cells themselves when
exposed to double-stranded RNA (3), to elevated glucose con-
centrations (4–6), or to free fatty acids (7), initiates b-cell
destruction.
The receptor for IL-1b, IL-1R1, is highly expressed in the
b-cell, and more than 10-fold higher expression of IL-1R1
mRNA was observed in isolated islets than in total pancreas,
which is attributed to the expression in b-cells (7). This may
explain the high sensitivity of theb-cell to IL-1b. A recent study
shows that glucose-induced IL-1b secretion involves caspase 1
activationmediated by the NALP3 inflammasome. The inflam-
masome is activated by bacterial toxins or endogenous stress
signals (e.g.ATP and b-amyloid (8–10)) through the formation
of reactive oxygen species (6, 11). Glucose-induced IL-1b secre-
tion by the b-cell is prevented in NALP32/2 mice, indicating
that IL-1b is generated through glucose-induced reactive oxy-
gen species production and oxidative stress (6). The thiore-
doxin-interacting protein, which has been linked to insulin
resistance (12), functions as an activator of NALP3. In line with
these data, another recent study shows that thioredoxin-inter-
acting protein is highly increased by elevated glucose in b-cells
and that thioredoxin-interacting protein-deficient islets are
protected against glucose toxicity (13). Although glucose-in-
duced IL-1b production in the b-cell was not observed in all
studies (14), IL-1b expression in islets from patients with
T2DM has been confirmed (5, 15), supporting the concept of
blocking IL-1b signals as a target for diabetes treatment.
Indeed, daily injection of IL-1Ra in mice fed a high fat diet
(HFD) improves glycemia, glucose-stimulated insulin secre-
tion, and survival (16); reduces hyperglycemia; and reverses the
islet inflammatory phenotype in the GK rat (17). Treatment
with an IL-1b antibody also improves glycemic control in diet-
induced obesity inmice (18, 19). Results from a clinical study in
patients with T2DM showed that IL-1Ra improves glycemic
control and b-cell function (20–22). Blocking IL-1b signals
reduces expression of inflammatory marker in fat tissue and in
islets (16). None of the studies have studied the mechanisms of
the protective effect of IL-1Ra at the level of b-cell gene regu-
lation. IL-1b affects expression of the transcription factor
PDX1 (pancreatic duodenal homeobox-1, previously called
IPF1, IDX1, STF1, or IUF1) (23), a key factor in pancreas devel-
opment and function. Reduced PDX1 expression levels nega-
tively regulates insulin expression and secretion and predispose
islets to apoptosis (24–26). Its homozygous mutations result in
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pancreas agenesis associated with neonatal diabetes (27, 28).
PDX1 directly binds to the promoter and controls expression of
important b-cell genes, which are vital for b-cell function, such
as insulin, Glut2, and glucokinase (27). PDX1 deficiency con-
tributes to impaired proliferation and enhanced apoptosis via
transcriptional mechanisms in models of type 2 diabetes,
such as Psammomys obesus and the leptin receptor-deficient
(Leprdb/db) db/db mice (29). Overexpression of PDX1 restores
b-cell mass and function, thereby preventing the onset of dia-
betes in IRS2 knock-outmice, showing the critical role of PDX1
in b-cell survival (30).
Complicated signaling networks control PDX1 regulation,
and nucleo-cytoplasmic shuttling plays a major role in the reg-
ulation of PDX1 function (31, 32). Well characterized PDX1
nuclear import signal and nuclear export signal (NES) suggest
that PDX1might be regulated at the level of cellular localization
(31, 33). Post-translational modification of proteins is the most
abundant form of cellular regulation, affecting many cellular
signal pathways, includingmetabolism, growth, differentiation,
and apoptosis. In response to acute elevation of glucose and
survival factors, such as insulin, PDX1 is phosphorylated and
translocates to the nucleus (34, 35). By contrast, stimuli associ-
ated with diabetes, such as oxidative stress (31) and free fatty
acids (36), cause nuclear exclusion of PDX1 (36). This suggests
that cytoplasmic accumulation may represent a mechanism to
reduce the nuclear action of PDX1 under pathologic conditions
rather than to promote a specific cytoplasmic function.
We have shown previously that a diet enriched with fat and
sucrose (“Surwit”; HFD) induces impaired glucose tolerance
after 4 weeks of feeding, impaired fasting glucose after 8 weeks,
and hyperglycemia after 12 weeks in C57Bl/6J mice (16, 19, 37).
These changes in glycemia were accompanied by fluctuations
in b-cell mass. Despite the reduction in b-cell proliferation and
the increase in b-cell apoptosis, islets showed a compensatory
increase in b-cell mass up to 12 weeks of diet. After 16 weeks,
apoptosis was increased, and b-cell mass was reduced in the
HFD-treated mice. IL-1b antagonism by anti-IL-1b antibody
treatment, IL-1Ra injections, or overexpression restored nor-
moglycemia and b-cell function and survival (16, 19, 37), but
also changes in the inflammatory state of the fat tissue were
involved in the protective effects of IL-1b antagonism. There-
fore, we asked how IL-1b signals regulate gene transcription in
the b-cell. We tested the effect of IL-1Ra on regulating glucose
homeostasis in another animal model, the obese diabetic leptin
receptor-deficient Leprdb/db mice (db/db). Commonly, we
detected that IL-1Ra was able to maintain the cellular localiza-
tion of PDX1. A diabetic milieu in vitro as well as T2DM in vivo
induced a switch of PDX1 from the nucleus to the cytosol,
which was accompanied by a loss in b-cell mass and function.
Whether PDX1 is altered in its localization in b-cells during
the progression to diabetes and whether these changes may
affect b-cell function in different levels was previously un-
known. Because PDX1 regulates insulin and specific b-cell
genes, altered localization may contribute to b-cell death and
loss of function. In the short term, this stressful response may
be tolerated, but under chronic situations in T2DM, prolonged
stress conditions ultimately affect b-cell survival.
EXPERIMENTAL PROCEDURES
Animals—Transgenic mice overexpressing IL-1Ra (IL-1Ra-
OE) were kindly provided by Dr. Emmet Hirsch (Northwestern
University, Evanston, IL) (38). Beginning at 5 weeks of age and
continuing for 12weeks, transgenic animals as well as their wild
type littermateswere fed a normal diet (WTNDand IL-1Ra-OE
ND) or a high fat/high sucrose diet (WT HFD and IL-1Ra-OE
HFD, Surwit (Research Diets, New Brunswick, NJ), containing
58, 26, and 16% calories from fat, carbohydrate, and protein,
respectively (39)) or were treated daily with IL-1Ra from the
starting day of the diets (ND1IL-1Ra and HFD1IL-1Ra;
Kinerett, Amgen (Thousand Oaks, CA), intraperitoneal injec-
tion of 10 mg/kg body weight) as described previously (16).
Four independent experiments with a total of 16 mice (4 mice/
cage) in each group were performed, respectively.
Heterozygous leptin receptor deficient mice on the
C57BLKS/J background (Leprdb/1, db/1) were purchased from
Jackson Laboratory. By cross-breeding these mice to C57BL/
6J-IL-1Ra-overexpressing mice (OE), we obtained diabetic
Leprdb/db (db/db) as well as non-diabetic Lepr1/1 (WT) with
endogenous overexpression of IL-1Ra (OE-db/db and OE) as
well as littermates without IL-1Ra as appropriate negative con-
trols (db/db and WT) with the same mixed background. In all
experiments, littermates from the F2 breeding were used. All
animals were housed in a temperature-controlled room with a
12-h light/dark cycle and were allowed free access to food and
water in agreement with National Institutes of Health animal
care guidelines and Section 8 of the German animal protection
law.
Intraperitoneal Glucose and Insulin Tolerance Tests—After
4, 8, and 12 weeks of diet (HFD) or at the age of 6 and 10 weeks
(db/db), all animals underwent in vivo studies (intraperitoneal
glucose and insulin tolerance tests) as described before (16).
Islet Isolation and Culture—Islets from all groups were iso-
lated as described previously (40). Human islets were isolated
from eight pancreases of healthy organ donors and from eight
with T2DM at the University of Illinois (Chicago, IL), Lille Uni-
versity, or Pisa University as described previously (41) and cul-
tured inCMRL-1066mediumas described previously (42). Islet
purity was greater than 95% as judged by dithizone staining (if
this degree of puritywas not achieved by routine isolation, islets
were hand-picked). Islets were exposed to 5.5, 11.1, 22.2, or 33.3
mM glucose or 5.5 mM plus 2 ng/ml recombinant human IL-1b
(R&D Systems, Minneapolis, MN), with or without 500 ng/ml
recombinant human IL-1Ra (R&D Systems) or 10 mM JNKi
(kindly provided byXigen S.A., Lausanne, Switzerland) for 72 h.
Transfections—At 2 days postisolation and culture on extra-
cellular matrix-coated dishes, isolated islets were exposed to
transfection Ca21-KRH medium (4.74 mM KCl, 1.19 mM
KH2PO4, 1.19 mM MgCl26H2O, 119 mM NaCl, 2.54 mM CaCl2,
25 mM NaHCO3, 10 mM HEPES). After 1 h of incubation, lip-
oplexes (Lipofectamine2000 (Invitrogen)/DNA ratio 2.5:1, 5mg
of DNA/100 islets) were added to transfect the islets. After an
additional 6 h of incubation, CMRL 1066 medium containing
20% FCS and L-glutamine was added to the transfected islets.
Efficient transfection was evaluated based on enhanced GFP-
positive cells, which resulted in 60% transfection efficiency in
PDX1 Localization in Diabetes
MAY 13, 2011 •VOLUME 286•NUMBER 19 JOURNAL OF BIOLOGICAL CHEMISTRY 17145
 at UNIVERSITÄT BREM
EN, on January 30, 2013
www.jbc.org
Downloaded from
 
b-cells through the whole islets, analyzed by fluorescence and
confocal microscopy.
Glucose-stimulated Insulin Secretion and Insulin Content—
Islets used to perform glucose-stimulated insulin secretion
experiments were kept in culture medium on matrix-coated
plates derived from bovine corneal endothelial cells (Novamed
Ltd., Jerusalem, Israel) for 4 days, allowing the cells to attach to
the dishes and spread (43). These experimental conditions
allowed direct comparison with our previous studies in human
and mouse islets pretreated with IL-1Ra in vitro (4, 16). There-
after, islets were washed with PBS and extracted with HCl (0.18
N) in 70% ethanol for 24 h at 4 °C. The acid-ethanol extracts
were collected for determination of insulin content. Insulin was
determined using a human insulin ELISA kit (Alpco).
b-Cell Mass and Histochemical Analyses—Pancreatic sec-
tions from seven healthy controls and from seven patients with
T2DM were obtained from the National Disease Research
Interchange (NDRI) and from Kangnam St. Mary’s Hospital
(Seoul, Korea) as described (44); approval for the studies was
granted by the Kangnam St. Mary’s Hospital and by the Ethical
Commission of Bremen University.
Mouse pancreases and sections from isolated islets were
obtained as described (16). To determine b-cell mass, 10 sec-
tions (spanning the width of the pancreas) were analyzed as
described (16). For detection of b-cell apoptosis, insulin and
TUNEL staining were performed (In Situ Cell Death Detection
Kit, TMRRed; RocheApplied Science) (16). For PDX1 localiza-
tion studies, after dehydration, sections were incubated in
blocking buffer containing 0.2% Tween 20, 3% IgG-free bovine
serum albumin (BSA), 2% Triton X-100 for 1 h at room tem-
perature and overnight at 4 °C with rabbit anti-PDX1 (kindly
provided by Christopher Wright, Vanderbilt University Medi-
cal Center, Nashville, TN) in antibody buffer containing 0.2%
Tween 20, 3% IgG-free BSA, and 0.5% Triton X-100. Subse-
quently, all sections were double-stained for insulin and
detected by donkey anti-guinea pig FITC-conjugated antibody
(Dako). Fluorescent slides were analyzed using a Nikon
MEA53200 microscope (Nikon GmbH Dusseldorf, Germany),
and images were acquired using NIS-Elements software
(Nikon).
RNA Extraction and RT-PCR Analysis—Total RNA of
isolated islets was extracted after overnight culture, and RT-
PCR was performed as described previously (4). Primers
used were as follows: 59-ttcttctacacaccca-39/59-ctagttgcagt-
agttct-39 (human and mouse insulin); 59-gaggacccgtactgcct-
aca-39/59-cggggtcccgctactacgtt-39 (mouse PDX1), 59-ctgga-
ttggcgttgtttgtg-39/59-tcccaaggtggagtgctgtag-39 (human PDX1),
59-gtccatgccatcactgccac-39/59-cagcaccagtggatgcaggg-39 (mouse
GAPDH); 59-gttggccaggctggtgtccag-3/5-ctgtgatgagctgctcaggg-
tgg-3 (human and mouse tubulin), 59-ccaaccgcgagaagatga-39/59-
ccagaggcgtacagggatag-39 (human actin), and 59-tacgggtcctggcatc-
ttgt-39/59-ccatttgtgttgggtccagc-39 (human cyclophilin).
Nuclear Fractionation—Nuclear and cytoplasmic extrac-
tions of human islets were performed according to the instruc-
tions for the NE-PER nuclear and cytoplasmic extraction
reagents (Pierce). The purity of fractions was analyzed by incu-
bation of the membranes with anti-tubulin and anti-GAPDH
for cytosolic and anti-PARP or anti-histone H3 for nuclear
extracts.
Western Blot Analysis—At the end of the incubation periods,
islets were washed in ice-cold PBS and lysed as described (42).
Membranes were incubated with rabbit anti-phospho-JNK
(Thr183/Tyr185), rabbit anti-histone H3, rabbit anti-PARP,
rabbit anti-tubulin, rabbit anti-GAPDH, and rabbit anti-b-
actin (Cell Signaling Technology) antibodies, followed by
horseradish peroxidase-linked anti-rabbit IgG. Density of
the bands was analyzed using DocITtLS image acquisition
6.6a (UVP BioImaging Systems, Upland, CA).
Statistical Analysis—Samples were evaluated in a random-
ized manner by a single investigator, who was blinded to the
treatment conditions. Data are presented as means 6 S.E. and
were analyzed by paired, Student’s t test or by analysis of
variance with a Bonferroni correction for multiple group
comparisons.
RESULTS
High Fat Diet Induces PDX1 Translocalization to the Cytosol
and Is Prevented by IL-1Ra—Looking into detailedmechanisms
of the loss of adaption in C57Bl/6Jmice fed a diet enriched with
fat and sucrose (HFD; Surwit), we isolated RNA from islets
from mice after 12 weeks of diet and IL-1Ra treatment and
performed RT-PCR for insulin and its transcription factor
PDX1.Whereas insulin mRNA in islets fromHFD animals was
decreased to 27% of control islets (Fig. 1A), PDX1 levels were
2.8-fold increased (Fig. 1C). Also, insulin content from isolated
islets was significantly decreased in the HFD-fed mice (Fig. 1B,
p , 0.05). Such changes did not occur in IL-1Ra-treated ani-
mals. Because it has been reported that PDX1 activity is primar-
ily regulated by its subcellular localization (45, 46), we stained
pancreatic tissue sections for PDX1 and insulin. Sections from
both normal diet groups showed PDX1 immunoreactivity pre-
dominantly (95 and 94%) in the nucleus of b-cells (Fig. 1D, b
and d). In contrast, the majority (67%) of the b-cells under the
high fat diet expressed PDX1 in the cytoplasm (Fig. 1C, f).
IL-1Ra treatment inhibited this translocalization to the cyto-
plasm (30% cytosolic PDX1), and the islets showedmore prom-
inent staining in the nucleus (54% nuclear PDX1; Fig. 1D, h).
Western blot analysis from nuclear and cytosolic fractions
from isolated islets from WT and IL-1Ra-OE mice fed for 12
weeks with normal chow or HFD confirmed the decrease in
nuclear together with the increase in cytosolic PDX1 in islets
under theHFDcondition, whichwas prevented by IL-1Ra over-
expression (Fig. 1E).
PDX1 Translocalization to the Cytosol in db/db Mice
Is Prevented by IL-1Ra Overexpression—To investigate
whether PDX1 shuttling also occurs in another mouse model,
we examined the effects of IL-1Ra in Leprdb/db mice (db/db).
By cross-breeding mice, which endogenously overexpress
IL-1Ra (OE) to C57BLKS-Leprdb, we used four groups of
mice in the experiments: IL-1Ra-OE-Leprdb/db (db/dbIL-
1Ra) and heterozygous Leprdb/1-IL-1Ra-OE (db/1IL-1Ra) as
well as their littermates without IL-1Ra-overexpression,
Leprdb/db (db/db) and Leprdb/1 (db/1).
Heterozygous db/1 and db/1IL-1Ra mice showed clear
nuclear PDX1 localization independent of their age (84 and 87%
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nuclear PDX1; Fig. 2A,a–f). In contrast, 6-week-old db/dbmice
showed a clear switch of PDX1 from the nucleus into the cyto-
sol (Fig. 2A, g–i). Littermates, which overexpressed IL-1Ra,
were clearly protected from such localization change (Fig. 2A,
j–l). The switch in localization was predominant in the 6-week-
oldmice.With the progression of diabetes in 10-week-oldmice,
loss of PDX1 expression was observed (only 15% PDX1 1
b-cells; Fig. 2A, m–o). IL-1Ra-OE mice partly restored overall
PDX1 expression and its nuclear localization (51% b-cells had
nuclear and 12% cytosolic PDX1; Fig. 2A, p–r). The localization
switchwas again confirmed byWestern blot analysis in 6-week-
old mice. Although heterozygous db/1 and db/1IL-1Ra as well
as db/dbIL-1Ramice showedmajor nuclear PDX1 localization,
we found PDX1 predominantly in the cytosol in the db/dbmice
(Fig. 2B).
The switch in the PDX1 localization to the cytosol was
accompanied by impaired glucose tolerance. Although
db/1IL-1Ra and db/1 mice showed normal glucose toler-
ance, db/db mice revealed increased fasting glucose levels
and impaired glucose tolerance. IL-1Ra overexpression in
the db/1IL-1Ra mice could partially but significantly restore
glucose tolerance at all time points during the intraperito-
neal glucose tolerance test and decrease fasting glucose levels
(supplemental Fig. 1A). Glucose-stimulated insulin secretion
was completely abolished in the db/db mice but was signifi-
cantly restored in the db/dbIL-1Ra mice with the significant
increase in stimulated insulin secretion and a restoration of the
stimulatory index (supplemental Fig. 1, B and C). b-Cell failure
seen by the impaired GSIS was also confirmed when we ana-
lyzed b-cell mass and survival. b-Cell apoptosis was 4.5-fold
FIGURE 1. High fat diet induces PDX1 translocalization to the cytosol. C57Bl/6J mice treated daily with vehicle or 10 mg/kg IL-1Ra were fed a diet enriched
with fat and sucrose (HFD) or a normal chow diet (ND) for 12 weeks. A–C, RT-PCR analysis of insulin (A) and PDX1 (C) expression relative to control normal diet
conditions and insulin content (B) of mouse islets isolated from the four treatment groups. In the LightCycler System, mRNA levels were normalized to GAPDH
and tubulin with the same result. Islets were isolated from four mice per treatment group. D, double immunostaining for insulin (green; a, c, e, and g) and PDX1
(red; b, d, f, and h) in mouse pancreatic tissue sections from all four treatment groups; staining was performed on four different pancreases per treatment group
(magnification, 3250; inset magnification, 32000). The percentage of nuclear and cytosolic PDX1 was calculated by counting 2000 insulin-positive b-cells from
four mice in each condition. E, Western blot analysis of PDX1 from nuclear and cytosolic fractions from isolated islets from C57Bl/6J WT- or IL-1Ra-overexpress-
ing mice fed an ND or HFD for 12 weeks. Histone H3 and tubulin were used as loading controls, and purity of fractions for the nuclear and cytosolic extracts from
the same protein lysates was assessed. One representative blot of three experiments is shown. Densitometry analysis of bands normalized to histone H3 or
tubulin shows the ratio of nuclear and cytosolic PDX1 expression. Data are shown as mean 6 S.E. *, p , 0.05 HFD compared to ND WT mice, **, p , 0.05 IL-1Ra
treated HFD compared to nontreated HFD mice.
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increased, and b-cell mass was 2.1-fold reduced in the db/db
mice. In contrast,b-cell apoptosis was reduced, andb-cellmass
was partially restored in the db/db IL-1Ra mice (supplemental
Fig. 1, D and E).
PDX1 Is Localized in the Cytosol in T2DM—To investigate
whether our results in the two diabetic mouse models can be
translated into human diabetes, we analyzed PDX1 localiza-
tion and expression in human T2DM (Fig. 3, A–D) and the
effect of IL-1Ra on PDX1 localization in human isolated
islets (Fig. 3F) and in the rat b-cell line INS-1E (Fig. 3, G and
H). In most b-cells of the control patients investigated in
pancreatic sections (Fig. 3, A (a and b) and B) or in sections
from isolated islets (Fig. 3, A (e and f) and C), PDX1 was
clearly nuclear (Fig. 3A, b and f). In contrast, PDX1 expres-
sion was much weaker in islets from patients with T2DM,
and no nuclear PDX1 was observed in (Fig. 3, A (d and h), B,
and C). Similar opposite effects in insulin and PDX1 mRNA
expression as observed in the HFD mouse model could be
observed in human diabetes. Whereas insulin mRNA in
islets from patients with T2DM was reduced to 40% of the
expression in islets isolated from non-diabetic control
patients, PDX1 was 2.8-fold increased (Fig. 3D). This is in
FIGURE 2. PDX1 translocalization to the cytosol in db/db mice is prevented by IL-1Ra overexpression. A, insulin staining in green (a, d, g, j, m, and p) and
PDX1 in red (b, e, h, k, n, and q) of control heterozygous db/1 (a– c) and db/1IL-1Ra (d–f) mice and db/db (g–i and m– o) and db/dbIL-1Ra (j–l and p–r) littermates
at the age of 6 (g–l) and 10 weeks (m–r). Staining was performed on three different pancreases per treatment group from three independent experiments,
respectively (magnification, 3250; inset magnification, 32000). Percentage of nuclear and cytosolic PDX1 was calculated by counting 2000 insulin-positive
b-cells from three mice in each condition. B, Western blot analysis of islet lysates from 6-week-old heterozygous db/1, db/1IL-1Ra, db/db, and db/dbIL-1Ra
mice. Histone H3 and tubulin were used as loading controls, and purity of fractions in the same membrane after stripping was assessed. One representative blot
of three experiments is shown. Densitometry analysis of bands normalized to histone H3 or tubulin shows the ratio of nuclear and cytosolic PDX1 expression.
Data are shown as mean 6 S.E. *, p , 0.05 db/db compared to db/1, **, p , 0.05 OE-db/db compared to db/db.
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line with previous data from Del Guerra et al. (47). Insulin
content from diabetic islets was decreased when compared
with islets from control patients (Fig. 3E, p , 0.01).
Isolated human islets were treated with increasing glucose
concentrations (5.5, 11.1, and 33.3 mM glucose) or 5.5 mM glu-
cose plus 2 ng/ml IL-1b for 72 h. As reported before and in our
previous studies (4, 48), under conditions of elevated glucose
levels or IL-1b treatment, b-cells failed to adequately increase
insulin secretion in response to a glucose challenge. As shown
in Fig. 3F (b), PDX1 is localized in the nucleus in insulin-posi-
tive b-cells at control conditions at 5.5 mM glucose. Co-expo-
sure of islets to IL-1Ra did not change PDX1 localization (Fig.
FIGURE 3. PDX1 is localized in the cytosol in T2DM. A, representative double immunostaining for insulin (green; a, c, e, and g) and PDX1 (red; b, d, f, and h)
performed in human pancreatic (a– d) and human isolated islet (e– h) sections from seven (c and d) or three (g and h) poorly controlled patients with T2DM and
seven (a and b) or three (e and f) healthy controls (magnification, 3250; inset magnification, 32000). The percentage of nuclear and cytosolic PDX1 was
calculated by counting 2000 insulin-positive b-cells from seven pancreatic sections (B) and three islet sections (C) in each condition. D, quantitative RT-PCR
analysis of insulin and PDX1 expression from mRNA; E, insulin content from HCl-ethanol extracts from human islets isolated from control patients and patients
with T2DM. In the LightCycler system, mRNA levels was normalized to cyclophilin and tubulin with the same result. Data are shown as mean 6 S.E. (error bars)
from six (mRNA) or three (content) islet isolations from six (three) control patients and six (three) patients with T2DM. *, p , 0.05 T2DM compared with controls.
F, human isolated islets were treated for 72 h with 5.5 mM glucose (control), 33.3 mM glucose, or 2 ng/ml IL-1b with or without 500 ng/ml recombinant human
IL-1Ra. Fixed and paraffin-embedded islets sections were double-stained for insulin (green; a, c, e, g, i, and k) and PDX1 (red; b, d, f, h, j, and l) and analyzed under
the confocal microscope. (magnification, 31000; inset magnification, 34000). Islets were isolated from three different donors, and 3 independent experiments
were performed. The percentage of nuclear and cytosolic PDX1 was calculated by counting 2000 insulin-positive b-cells from three experiments in each
condition. G and H, Western blot analysis of PDX1 of glucose-treated (3 days; 11.1–33.3; G) and IL-1b-treated (2–3 days; 2 ng/ml; H) nuclear and cytosolic cell
lysates of the b-cell line INS-1E. GAPDH was used as loading control, and purity of fractions for the cytosolic extracts and full-length PARP for the nuclear extracts
in the same membrane after stripping was assessed. One representative blot of three experiments is shown. Densitometry analysis of bands normalized to
PARP or GAPDH shows the ratio of nuclear and cytosolic PDX1 expression. Because there were no changes, the 2-day results were not analyzed in H.
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3F (h)). Increasing glucose concentrations to 11.1 (not shown)
and 33.3 mM (Fig. 3F (d)) or the addition of IL-1b (Fig. 3F (f))
shifted the PDX1 signal to the cytoplasm, resulting in co-local-
ization of PDX1 with insulin (yellow merged color), whereas
co-incubation with IL-1Ra protected from such PDX1 shift;
PDX1 remained in the nucleus in the IL-1Ra-treated islets (Fig.
3F, j and l). In order to show a b-cell-specific mechanism, such
changes were confirmed by Western blot analysis of glucose-
and IL-1b-treated cell lysates of the b-cell line INS-1E. Glucose
induced a dose-dependent decline in nuclear PDX1 together
with an increase in cytosolic PDX1 expression after 72 h (Fig.
3G). 2 ng/ml IL-1b reduced nuclear and induced cytosolic
PDX1 expression after 3 days of exposure but not after 2 days,
showing a time-dependent IL-1b effect (Fig. 3H).
IL-1Ra Prevents Prolonged Glucose- and IL-1b-induced JNK
Activation—PDX1nuclear export is induced by oxidative stress
through a signaling pathway that involves JNK activity (31, 49,
50). Therefore, we investigated whether JNK alsomediates glu-
cose- and IL-1b-induced effects on PDX1 localization by first
evaluating whether IL-1Ra regulates JNK activation.
In isolated mouse islets, JNK remained in its activated state
over a 3-day period in the presence of elevated glucose concen-
trations (Fig. 4A, left). In islets from mice that endogenously
overexpress IL-1Ra (IL-1Ra-OE), glucose induced transient
JNK phosphorylation after 1 day of culture, whereas after 3
days, JNK activation decreased (Fig. 4A, right). We confirmed
these findings in isolated human islets. Phosphorylated JNK
levels were increased by a 3-day culture in 33.3mM glucose or in
the presence of 2 ng/ml IL-1b (Fig. 4B) compared with control
cultures at 5.5 mM glucose. In both cases, this increase was
ameliorated when IL-1Ra was added to the culture medium.
Because we postulated that glucose-induced JNK activation
leads to PDX1 export, JNK inhibition should prevent shuttling
despite the presence of elevated glucose or IL-1b. To test this
hypothesis, we treated human islets with 22.2 mM glucose or 2
ng/ml IL-1b, with or without the addition of 10 mM JNKi, a
small peptide that inhibits JNK activity, as described before (51,
52). We again observed glucose- and cytokine-mediated PDX1
translocalization (Fig. 4C, top, a–c). We not only found cells
that co-express insulin and PDX1 in the cytoplasm but found
that some cells displayed PDX1 in the nuclear periphery, which
has been observed previously in cell lines kept at low glucose
concentrations (34). JNK inhibition prevented glucose- and
IL-1b-induced PDX1 translocalization and kept the transcrip-
tion factor in the nucleus in most cells, indicating that the JNK
pathway is involved in regulating PDX1 localization (Fig. 4C,
bottom, d–f).
b-Cell apoptosis and function were analyzed in the same
experiments. The switch of nuclear to cytosolic PDX1 was
accompanied by increasedb-cell apoptosis. 3-day incubation of
human islets with elevated glucose (22.2 mM) or 2 ng/ml IL-1b
resulted in a 1.8- and 2.1-fold increase in b-cell apoptosis, and
glucose-stimulated insulin secretion was impaired by 75 and
52%, respectively. In contrast, 1 h of pre-exposure and pro-
longed culture of the islets with 10 mM JNKi or 250 ng/ml
IL-1Ra restored b-cell survival (Fig. 4D) and function (Fig. 4, E
and F).
Mutation of the PDX1 Nuclear Export Signal Restores b-Cell
Survival and Function—Because we have observed PDX1
nuclear exclusion in a prodiabetic milieu, we tested whether
maintaining PDX1 localization in the nucleus may restore
b-cell function and survival.
PDX1 WT plasmid and a mutant PDX1, in which the NES-
like sequence was disrupted by substituting alanine for leucine
at positions 91 and 93 and linked to GFP as described before
(33, 49), were expressed in human islets by transient plasmid
Lipofectamine-mediated transfection. Plasmids were kindly
provided by Dr. Ingo Leibiger. Transfection efficiency was ana-
lyzed imunocytochemically by GFP plasmid overexpression,
which showed a ;60% transfection efficiency (supplemental
Fig. S2). We also evaluated transfection efficiency by Western
blot analysis. Linking PDX1 to GFP resulted in an additional
band at 70 kDa, which gave an intensive band in the transfected
but not in the GFP-transfected islets (Fig. 5D). Under these
conditions, we analyzed b-cell apoptosis and function. Overex-
pression of WT or NES mutant PDX1 did not result in signifi-
cant changes of b-cell apoptosis or function at 5.5 mM glucose.
3-day exposure to 22.2mM glucose or 2 ng/ml IL-1b resulted in
a 1.9- and 2.3-fold increase in b-cell apoptosis and to a 56 and
68% decrease in glucose-stimulated insulin secretion, respec-
tively (Fig. 5, A–C, p . 0.05), compared with GFP-transfected
control. AlthoughWTPDX1 andNESmutant PDX1 improved
b-cell survival significantly, glucose-stimulated insulin secre-
tion was only improved by the NES mutant PDX1 and not by
WT PDX1 overexpression, indicating 1) that PDX1 overex-
pression improved b-cell survival and 2) the necessity of
nuclear PDX1 for restoration of b-cell function. When
PDX1-WT was overexpressed in human islets, IL-1b and
glucose induced shuttling of transfected PDX1 to the cytosol
(Fig. 5D), which resulted in a clear decrease in the nuclear/
cytosolic PDX1 expression ratio (Fig. 5E). In contrast, PDX1-
NES overexpression inhibited such PDX1 shuttling in IL-1b-
and glucose-treated islets, and the ratio of nuclear/cytosolic
PDX1 expression was significantly increased, compared with
PDX1-WT (Fig. 5, D and E).
Immunostaining of PDX1-NES and PDX1-WT confirmed
Western blot results (Fig. 5F). PDX1 was localized in the
nucleus in insulin-positive b-cells in both WT- and PDX1-
NES-transfected islets (Fig. 5F, a, b, g, and h). Although
PDX1-WT expression was shifted to the cytosol in response to
IL-1b and glucose treatment (Fig. 5F, c–f), shuttling-deficient
PDX1-NES remained in the nucleus (Fig. 5F, i–l).
DISCUSSION
Human mutations of PDX1 as well as changes in its transac-
tivation are strongly associated with diabetes (53, 54). In the
present study, we show that localization of PDX1 correlates
with T2DM, b-cell function, and survival. PDX1 shuttling is
one of themechanisms thatmay explain the dual role of glucose
on b-cell function and survival. Although acute elevated glu-
cose induces b-cell proliferation and insulin secretion, chroni-
cally elevated glucose concentrations impair b-cell function,
induce apoptosis (40), and thus may accelerate diabetes. Upon
acute exposure of b-cells to glucose, PDX1 translocates to the
nucleus, leading to insulin gene transcription (34). In contrast,
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oxidative stress induces PDX1 shuttling to the cytosol (49) and
impairs insulin secretion (55). We show here that in diabetic
islets or under conditions of chronic hyperglycemia or IL-1b
exposure for 3 days in vitro, conditions of impaired b-cell sur-
vival and function shifted PDX1 expression to the cytoplasm.
These data show the impact of PDX1 localization in regulating
b-cell turnover and function.
Whenever it was shifted to the cytosol, PDX1 showed a
weaker staining and signal intensity, which suggests the possi-
bility of PDX1 degradation after translocalization. This is also
supported by the observation that overexpression of PDX1-
NES, which remains in the nucleus, prevents PDX1 shuttling
together with degradation at conditions of chronically elevated
glucose. Although transfection could not be achieved in all islet
cells, nuclear PDX1 overexpression prevented the deleterious
effects of glucose and IL-1b on b-cell survival and function.
Previously, we have observed such quantitative decrease in
PDX1 induced by elevated glucose concentrations in human
and rat islets. At this time, whole islet lysates were used for the
analysis, and we did not investigate PDX1 localization. PDX1
decrease was dose-dependent on glucose concentrations (5.5–
33.3 mM) (56). In the same previous study, we also show an
age-dependent PDX1 decrease in human and rat islets,
which was confirmed in pancreatic biopsy samples (57).
Such PDX1 decrease correlated with the increased suscepti-
bility to glucose-induced apoptosis and with a decline in
FIGURE 4. IL-1Ra prevents prolonged glucose- and IL-1b-induced JNK-activation. A, isolated islets from mice overexpressing IL-1Ra (IL-1Ra-OE) and wild
type littermates were treated for 24 –72 h with 11.1 mM glucose (control) or 33.3 mM glucose. Shown is immunoblotting for phosphorylated JNK and b-actin
(loading control). The antibodies were blotted on the same membrane. One representative experiment of three is shown. Shown is densitometry analysis of
phospho-JNK bands normalized to b-actin. B–D, isolated human islets were cultured in suspension for 24 –72 h in 5.5 mM glucose (control), 22.2 or 33.3 mM
glucose, or 2 ng/ml IL-1b with or without the addition of 500 ng/ml recombinant human IL-1Ra (B) or 10 mM JNKi (C). B, immunoblotting of phosphorylated JNK
and b-actin (loading control). The antibodies were blotted on the same membrane. One representative blot of three experiments from three donors is shown.
Shown is densitometry analysis of phospho-JNK bands normalized to b-actin. C, after 72 h of treatment, fixed and paraffin-embedded islet sections were
double-stained for insulin in green and PDX1 in red and analyzed under the microscope (magnification, 3250; inset magnification, 32000). Islets were isolated
from three different donors, and 3 independent experiments were performed. D and E, for the analysis of b-cell survival and glucose-stimulated insulin
secretion, islets were cultured on extracellular matrix-coated dishes and treated for 72 h. D, b-cell apoptosis expressed as a percentage of TUNEL-positive
b-cells 6 S.E. The mean number of b-cells scored was 2945 6 218 for each treatment condition in three independent experiments from three different donors.
E and F, glucose-stimulated insulin secretion of islets. Stimulatory index (E) denotes the ratio between stimulated (16.7 mM glucose) and basal (2.8 mM glucose)
values normalized to insulin content (F) of insulin secretion during successive 1-h incubations. Results are means 6 S.E. (error bars) from three independent
experiments from three donors. *, p , 0.05 compared with control at 5.5 mM glucose. **, p , 0.05, IL-1Ra- or JNKi-treated islets compared with untreated islets
under the same conditions.
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b-cell proliferation at an older age. Neither Reers et al. (57)
nor we were able to show nuclear PDX1 localization. It was
suggested that the human pancreas embedding method pre-
vented detection of nuclear PDX1. Here we improved tissue
permeabilization and clearly detected nuclear PDX1 even in
sections from human autopsy and biopsy, with strong PDX1
signals in the nucleus in non-diabetic control pancreases and
a shift of PDX1 to the cytosol in diabetic conditions, a signal
that appeared much weaker in sections from patients with
T2DM. Together, the data support PDX1 shuttling in
response to chronic glucose to the cytosol and its subsequent
degradation as one deleterious factor contributing to b-cell
failure.
Strategies to block these deleterious effects on the b-cell are
needed for a successful diabetes therapy. Blocking IL-1b signals
has been suggested as a novel treatment for diabetes. The anti-
inflammatory cytokine IL-1Ra prevents glucose-induced apo-
ptosis by blocking proapoptotic IL-1b signaling in vitro (4) and
FIGURE 5. Mutation of the PDX1 nuclear export signal restores b-cell survival and function. Human isolated islets were cultured on extracellular matrix-
coated dishes and transfected with a GFP control plasmid, with WT PDX1, or with an NES mutant PDX1 (PDX1-NES), in which the NES-like sequence was
disrupted. 24 h after transfection, islets were exposed to elevated glucose or IL-1b for 72 h. A, b-cell apoptosis expressed as a percentage of TUNEL-positive
b-cells 6 S.E. The mean number of b-cells scored was 1545 6 112 for each treatment condition in three independent experiments from three different donors.
B and C, glucose-stimulated insulin secretion of islets. Stimulatory index (B) denotes the ratio between stimulated (16.7 mM glucose) and basal (2.8 mM glucose)
values normalized to insulin content (C) of insulin secretion during successive 1-h incubations. Results are means 6 S.E. from three independent experiments
from three donors. **, p , 0.05 compared with control at 5.5 mM glucose. *, p , 0.05, PDX1-WT- or PDX1-NES-treated islets compared with untreated islets
under the same conditions. D, Western blot analysis for transfected PDX1 fused to GFP was performed with nuclear and cytosolic fractions of islet lysates. PARP
and GAPDH were used as loading control for nuclear (left) and cytosolic (right) extracts. One representative blot of three experiments is shown. E, densitometry
analysis of bands normalized to PARP or GAPDH shows the ratio of nuclear and cytosolic transfected PDX1 expression. *, p , 0.05 compared with control at 5.5
mM glucose. Islets were isolated from three different donors, and 3 independent experiments were performed. F, fixed and paraffin-embedded islet sections
were double-stained for PDX1 (green; a, c, and e and g, i, and k) and insulin (red; b, d, and f and h, j, and l) and analyzed under the fluorescent microscope
(magnification, 3800).
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improves glycemia and b-cell function and survival in vivo (16,
17, 20).
In this study, we provide further mechanisms of the protec-
tive effect of IL-1Ra directly on the b-cell transcriptional regu-
lation inC57BL/6Jmice fed a high fat/high sucrose diet (Surwit)
and in db/db mice, serving as two animal models of T2DM and
inhuman islets exposed to a diabeticmilieu. 12weeks of high fat
feeding induced impaired glucose tolerance, which was inhib-
ited in the IL-1Ra-OE mice. Unexpectedly, insulin and PDX1
mRNA levels were oppositely regulated in the HFD-treated
mice; insulin was reduced, and PDX1 was significantly
increased in islets after 12 weeks of high fat/high sucrose diet.
IL-1Ra prevented such changes. Many previous studies have
observed no changes or increases in insulin mRNA in response
to a high fat diet without increase in sucrose (“Western diet”) in
rat or mouse models (e.g. see Refs. 58 and 59). The addition of
sucrose to the diet (Surwit) causes b-cell failure together with
reduced insulin mRNA in the b-cell (60).
Although our results are in contrast to previous data showing
PDX1 down-regulation in response to hyperglycemia in b-cells
in culture aswell as in type 2 diabetic animalmodels (e.g. in ZDF
rats (61), in P. obesus (29), and in partially pancreatectomized
rats (62)), studies in isolated human islets from patients with
T2DMshow a similar opposite regulation, with reduced insulin
mRNA and increased PDX1mRNA levels compared with islets
isolated from non-diabetic controls (47).
PDX1 expression seems to be important for the b-cell
response to a higher insulin demand (e.g. in insulin resistance
and b-cell compensation may occur through increased PDX1
mRNA). But suppression of PDX1 expression inMIN6 cells did
not lead to a decrease of insulin or glucokinase mRNA (63). To
activate insulin transcription, PDX1 translocates into the
nucleus, where it binds to the insulin gene (46, 64). Therefore,
post-translational changes, which define PDX1 localization,
rather than mRNA expression levels may play a more impor-
tant role under diabetic conditions. For instance, oxidative
stress induces PDX1 shuttling from the nucleus to the cytosol
and thus causes a severe reduction of PDX1 activity (49). Also,
24-h exposure of rat islets to palmitic acid at elevated glucose
concentrations causes PDX1 localization to the cytosol
together with a decrease in MafA expression and inhibition of
insulin expression (36). In line with these previous observa-
tions, we detected PDX1 predominantly expressed in the cyto-
sol in HFD-treated and in hyperglycemic db/db mice. In con-
trast, in IL-1Ra-treated as well as the normal diet groups, PDX1
was localized in the nucleus. Because IL-1Ra protected from the
prodiabetic effect of the diet, we propose that this is a result of
maintaining PDX1 functionally in the nucleus.
Homozygous Leprdb/db mice (db/db) on the C57BLKS/J
background with this depletion in the leptin receptor become
obese, hyperglycemic, and hyperinsulinemic within the first
month of age. In these mice, IL-1b-mediated innate immunity
is augmented, which results from a diabetes-associated loss of
IL-1b counterregulation (65). To test the hypothesis that
IL-1Ra would prevent diabetes progression in this model of
T2DM, we injected db/db mice daily with IL-1Ra or with vehi-
cle from 4 weeks of age on. db/db mice that received IL-1Ra
showed improved glucose tolerance during intraperitoneal glu-
cose tolerance test experiments after 2 weeks of treatment as
compared with their vehicle-treated littermates (p , 0.05 at
time points 30 and 60 min; data not shown). From 3 weeks of
treatment on, we did not observe any differences in glucose
levels between the two groups anymore. Considering the short
half-life of IL-1Ra (6–8 h) and the 10–100-fold excess that is
needed to block IL-1b-mediated effects (66), we tested whether
constitutive endogenous overexpression of IL-1Ra would
improve the outcome of elevated IL-1Ra levels in db/db mice.
We could confirm in the db/dbmouse model that IL-1Ra over-
expression was protective against the development of diabetes
and b-cell failure, although the effects of IL-1Ra in db/db mice
were quitemodest. However, considering the db/dbmouse as a
model of severe diabetes with rapid development of hypergly-
cemia, any significant rescue in the model and a combined
effect on glucose tolerance, insulin secretion, b-cell mass, and
apoptosis confirms a protective effect on the b-cell. This was
paralleled by IL-1Ra-induced PDX1 stabilization in the nucleus
in the db/db mice. Already at 6 weeks of age, PDX1 was pre-
dominantly expressed in the cytosol in the db/dbmice, whereas
at the age of 10 weeks, PDX1 was strongly decreased. IL-1Ra
restored nuclear PDX1 in 6-week-old mice, and also in
10-week-oldmice, nuclear PDX1 expression could be detected.
Previous cytochemistry analyses of db/db mouse pancreases
show a nuclear loss of MafA rather than of PDX1 (67). To
exclude differences in the background, we also analyzed PDX1
in male BKSdb/db mice and could confirm the switch of PDX1
localization to the nucleus already after 6 weeks of age.
Activation of JNK is a hallmark in glucose and IL-1b effect on
the b-cell and is involved in PDX1 regulation (68, 69). We used
such well known results to confirm our study design and could
identify JNK as cellular component also involved in glucose-
and IL-1b-regulated PDX1 localization. In wild type islets, JNK
was phosphorylated after short term (30 min (data not shown)
and 1 day) as well as long term (3 days) incubations with ele-
vated glucose. Therefore, it seems that acute JNK activation
does not necessarily cause impairment in b-cell function and
survival, whereas chronic activation correlates with glucotox-
icity. IL-1Ra protected islets from prolonged JNK activation.
JNK activity has previously been linked to PDX1 shuttling
under conditions of oxidative stress (49) and in prostaglandin
E2-induced b-cell dysfunction (32), together with Foxo1 as a
key player (31). Foxo1 cellular localization determines PDX1
localization, and both are reversely expressed. Foxo1 itself is
regulated by JNK and AKT activity; JNK induces Foxo1 nuclear
import, which leads to PDX1 export, whereas AKT-mediated
Foxo1 phosphorylation results in Foxo1 cytoplasmic and PDX1
nuclear localization. Our findings suggest the JNK-PDX1 path-
way as a critical signaling network that transduces short term as
well as long term glucose stimulation and therefore might
partly mediate the dual effect of glucose on b-cell function and
survival.
The fact that IL-1Ra potentially prevented hyperglycemia
and improved b-cell function favors the critical role of IL-1b
signaling in the b-cell not only in a type 1 but also in a type 2
diabetic environment. Our data provide new insights into
mechanisms of the protective effect of IL-1Ra on b-cell func-
tion and turnover, establish the important role of nuclear PDX1
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localization, and support IL-1Ra as a potential therapy for
diabetes.
Acknowledgments—We thank Dr. Ingo Leibiger for the PDX1 plas-
mids, Dr. Chris Wright for the PDX1 antibody, Jennifer Bergemann
andAnkeMeyer for excellent assistance,MadhuraPanse for the anal-
ysis of PDX1 in isolated islets, Silvia Del Guerra for the islet RNA
preparation, and the National Disease Research Interchange for pro-
viding human pancreatic sections. Human islets were provided
through the Islet Cell Resource Consortium (administered by the
Administrative and Bioinformatics Coordination Center (ABCC)
and supported by the National Center for Research Resources
(NCRR); NIDDK, National Institutes of Health; and the Juvenile Dia-
betes Research Foundation) and through the European Consortium
for Islet Transplantation Islets for Research Distribution Program.
REFERENCES
1. Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Per-
ren, A., and Ehses, J. A. (2008) Diabetes Care 31, Suppl. 2, S161–S164
2. Ehses, J. A., Bo¨ni-Schnetzler, M., Faulenbach, M., and Donath, M. Y.
(2008) Biochem. Soc. Trans. 36, 340–342
3. Heitmeier, M. R., Arnush, M., Scarim, A. L., and Corbett, J. A. (2001)
J. Biol. Chem. 276, 11151–11158
4. Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas,
G. A., Kaiser, N., Halban, P. A., and Donath, M. Y. (2002) J. Clin. Invest.
110, 851–860
5. Bo¨ni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A.,
Kerr-Conte, J., Pattou, F., Halban, P. A., Weir, G. C., and Donath, M. Y.
(2008) J. Clin. Endocrinol. Metab. 93, 4065–4074
6. Zhou, R., Tardivel, A., Thorens, B., Choi, I., and Tschopp, J. (2010) Nat.
Immunol. 11, 136–140
7. Bo¨ni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D. T.,
Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J. A., Schuit, F. C., andDonath,
M. Y. (2009) Endocrinology 150, 5218–5229
8. Donath, M. Y., and Bo¨ni-Schnetzler, M. (2010) Cell Metab. 12,
427–428
9. Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M.,
Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., Mullooly, N.,
Mielke, L. A., Harris, J., Coll, R. C.,Mills, K. H.,Mok, K. H., Newsholme, P.,
Nun˜ez, G., Yodoi, J., Kahn, S. E., Lavelle, E. C., and O’Neill, L. A. (2010)
Nat. Immunol. 11, 897–904
10. Mandrup-Poulsen, T. (2010) Nat. Immunol. 11, 881–883
11. Schroder, K., Zhou, R., and Tschopp, J. (2010) Science 327, 296–300
12. Parikh, H., Carlsson, E., Chutkow, W. A., Johansson, L. E., Storgaard, H.,
Poulsen, P., Saxena, R., Ladd, C., Schulze, P. C., Mazzini, M. J., Jensen,
C. B., Krook, A., Bjo¨rnholm, M., Tornqvist, H., Zierath, J. R., Ridderstråle,
M., Altshuler, D., Lee, R. T., Vaag, A., Groop, L. C., and Mootha, V. K.
(2007) PLoS Med. 4, e158
13. Chen, J., Fontes, G., Saxena, G., Poitout, V., and Shalev, A. (2010)Diabetes
59, 440–447
14. Cnop, M., Welsh, N., Jonas, J. C., Jo¨rns, A., Lenzen, S., and Eizirik, D. L.
(2005) Diabetes 54, Suppl. 2, S97–S107
15. Igoillo-Esteve,M.,Marselli, L., Cunha, D. A., Ladrie`re, L., Ortis, F., Grieco,
F. A., Dotta, F., Weir, G. C., Marchetti, P., Eizirik, D. L., and Cnop, M.
(2010) Diabetologia 53, 1395–1405
16. Sauter, N. S., Schulthess, F. T., Galasso, R., Castellani, L. W., andMaedler,
K. (2008) Endocrinology 149, 2208–2218
17. Ehses, J. A., Lacraz, G., Giroix,M. H., Schmidlin, F., Coulaud, J., Kassis, N.,
Irminger, J. C., Kergoat, M., Portha, B., Homo-Delarche, F., and Donath,
M. Y. (2009) Proc. Natl. Acad. Sci. U.S.A. 106, 13998–14003
18. Osborn, O., Brownell, S. E., Sanchez-Alavez, M., Salomon, D., Gram, H.,
and Bartfai, T. (2008) Cytokine 44, 141–148
19. Owyang, A. M., Maedler, K., Gross, L., Yin, J., Esposito, L., Shu, L., Jadhav,
J., Domsgen, E., Bergemann, J., Lee, S., andKantak, S. (2010)Endocrinology
151, 2515–2527
20. Larsen, C.M., Faulenbach,M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B.,
Mandrup-Poulsen, T., and Donath, M. Y. (2007) N. Engl. J. Med. 356,
1517–1526
21. Donath, M. Y., Bo¨ni-Schnetzler, M., Ellingsgaard, H., Halban, P. A., and
Ehses, J. A. (2010) Trends Endocrinol. Metab. 21, 261–267
22. Maedler, K., Dharmadhikari, G., Schumann, D. M., and Storling, J. (2009)
Exp. Opin. Biol. Ther. 9, 1177–1188
23. Eizirik, D. L., and Mandrup-Poulsen, T. (2001) Diabetologia 44,
2115–2133
24. Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. (1998)Genes
Dev. 12, 1763–1768
25. Brissova, M., Shiota, M., Nicholson, W. E., Gannon, M., Knobel, S. M.,
Piston, D. W., Wright, C. V., and Powers, A. C. (2002) J. Biol. Chem. 277,
11225–11232
26. Johnson, J. D., Ahmed, N. T., Luciani, D. S., Han, Z., Tran, H., Fujita, J.,
Misler, S., Edlund, H., and Polonsky, K. S. (2003) J. Clin. Invest. 111,
1147–1160
27. McKinnon, C. M., and Docherty, K. (2001) Diabetologia 44, 1203–1214
28. Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Clarke, W. L., and Habener,
J. F. (1997) Nat. Genet. 15, 106–110
29. Leibowitz, G., Ferber, S., Apelqvist, A., Edlund, H., Gross, D. J., Cerasi, E.,
Melloul, D., and Kaiser, N. (2001) Diabetes 50, 1799–1806
30. Kushner, J. A., Ye, J., Schubert, M., Burks, D. J., Dow, M. A., Flint, C. L.,
Dutta, S., Wright, C. V., Montminy, M. R., andWhite, M. F. (2002) J. Clin.
Invest. 109, 1193–1201
31. Kawamori, D., Kaneto, H., Nakatani, Y., Matsuoka, T. A., Matsuhisa, M.,
Hori, M., and Yamasaki, Y. (2006) J. Biol. Chem. 281, 1091–1098
32. Meng, Z., Lv, J., Luo, Y., Lin, Y., Zhu, Y., Nie, J., Yang, T., Sun, Y., and Han,
X. (2009) Endocrinology 150, 5284–5293
33. Moede, T., Leibiger, B., Pour, H. G., Berggren, P., and Leibiger, I. B. (1999)
FEBS Lett. 461, 229–234
34. Elrick, L. J., and Docherty, K. (2001) Diabetes 50, 2244–2252
35. Macfarlane, W. M., Shepherd, R. M., Cosgrove, K. E., James, R. F., Dunne,
M. J., and Docherty, K. (2000) Diabetes 49, 418–423
36. Hagman, D. K., Hays, L. B., Parazzoli, S. D., and Poitout, V. (2005) J. Biol.
Chem. 280, 32413–32418
37. Glas, R., Sauter, N. S., Schulthess, F. T., Shu, L., Oberholzer, J., and
Maedler, K. (2009) Diabetologia 52, 1579–1588
38. Hirsch, E., Irikura, V.M., Paul, S.M., andHirsh, D. (1996)Proc. Natl. Acad.
Sci. U.S.A. 93, 11008–11013
39. Surwit, R. S., Kuhn, C. M., Cochrane, C., McCubbin, J. A., and Feinglos,
M. N. (1988) Diabetes 37, 1163–1167
40. Maedler, K., Spinas, G. A., Lehmann, R., Sergeev, P., Weber, M., Fontana,
A., Kaiser, N., and Donath, M. Y. (2001) Diabetes 50, 1683–1690
41. Oberholzer, J., Triponez, F., Mage, R., Andereggen, E., Bu¨hler, L., Cre´tin,
N., Fournier, B., Goumaz, C., Lou, J., Philippe, J., and Morel, P. (2000)
Transplantation 69, 1115–1123
42. Schulthess, F. T., Paroni, F., Sauter, N. S., Shu, L., Ribaux, P., Haataja, L.,
Strieter, R. M., Oberholzer, J., King, C. C., and Maedler, K. (2009) Cell
Metab. 9, 125–139
43. Kaiser, N., Corcos, A. P., Sarel, I., and Cerasi, E. (1991) Endocrinology 129,
2067–2076
44. Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo,
S. J., Kang, M. I., Cha, B. Y., Lee, K. W., Son, H. Y., Kang, S. K., Kim, H. S.,
Lee, I. K., and Bonner-Weir, S. (2003) J. Clin. Endocrinol. Metab. 88,
2300–2308
45. Guillemain,G., Da SilvaXavier, G., Rafiq, I., Leturque, A., andRutter, G.A.
(2004) Biochem. J. 378, 219–227
46. Macfarlane, W. M., McKinnon, C. M., Felton-Edkins, Z. A., Cragg, H.,
James, R. F., and Docherty, K. (1999) J. Biol. Chem. 274, 1011–1016
47. Del Guerra, S., Lupi, R., Marselli, L., Masini, M., Bugliani, M., Sbrana, S.,
Torri, S., Pollera, M., Boggi, U., Mosca, F., Del Prato, S., and Marchetti, P.
(2005) Diabetes 54, 727–735
48. Mandrup-Poulsen, T., Bendtzen, K., Nielsen, J. H., Bendixen, G., and Ne-
rup, J. (1985) Allergy 40, 424–429
49. Kawamori, D., Kajimoto, Y., Kaneto, H., Umayahara, Y., Fujitani, Y., Mi-
yatsuka, T., Watada, H., Leibiger, I. B., Yamasaki, Y., and Hori, M. (2003)
Diabetes 52, 2896–2904
PDX1 Localization in Diabetes
17154 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 19•MAY 13, 2011
 at UNIVERSITÄT BREM
EN, on January 30, 2013
www.jbc.org
Downloaded from
 
50. Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W. H., 3rd, Wright,
C. V., White, M. F., Arden, K. C., and Accili, D. (2002) J. Clin. Invest. 110,
1839–1847
51. Maedler, K., Schulthess, F. T., Bielman, C., Berney, T., Bonny, C., Prentki,
M., Donath, M. Y., and Roduit, R. (2008) FASEB J. 22, 1905–1913
52. Bonny, C., Oberson, A., Negri, S., Sauser, C., and Schorderet, D. F. (2001)
Diabetes 50, 77–82
53. Liu, A., Oliver-Krasinski, J., and Stoffers, D. A. (2006) FEBS Lett. 580,
6701–6706
54. Stoffers, D. A., Stanojevic, V., and Habener, J. F. (1998) J. Clin. Invest. 102,
232–241
55. Robertson, R. P. (2006) Curr. Opin. Pharmacol. 6, 615–619
56. Maedler, K., Schumann, D. M., Schulthess, F., Oberholzer, J., Bosco, D.,
Berney, T., and Donath, M. Y. (2006) Diabetes 55, 2455–2462
57. Reers, C., Erbel, S., Esposito, I., Schmied, B., Bu¨chler, M. W., Nawroth,
P. P., and Ritzel, R. A. (2009) Eur. J. Endocrinol. 160, 185–191
58. Briaud, I., Kelpe, C. L., Johnson, L. M., Tran, P. O., and Poitout, V. (2002)
Diabetes 51, 662–668
59. Hansotia, T., Maida, A., Flock, G., Yamada, Y., Tsukiyama, K., Seino, Y.,
and Drucker, D. J. (2007) J. Clin. Invest. 117, 143–152
60. Mulder, H., Mårtensson, H., Sundler, F., and Ahre´n, B. (2000)Metabolism
49, 1518–1522
61. Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y., and Takahashi, H.
(2003) Diabetes 52, 581–587
62. Zangen, D. H., Bonner-Weir, S., Lee, C. H., Latimer, J. B., Miller, C. P.,
Habener, J. F., and Weir, G. C. (1997) Diabetes 46, 258–264
63. Kajimoto, Y.,Watada, H.,Matsuoka, T., Kaneto, H., Fujitani, Y., Miyazaki,
J., and Yamasaki, Y. (1997) J. Clin. Invest. 100, 1840–1846
64. Rafiq, I., Kennedy, H. J., and Rutter, G. A. (1998) J. Biol. Chem. 273,
23241–23247
65. O’Connor, J. C., Satpathy, A., Hartman, M. E., Horvath, E. M., Kelley,
K. W., Dantzer, R., Johnson, R. W., and Freund, G. G. (2005) J. Immunol.
174, 4991–4997
66. Eizirik, D. L., Tracey, D. E., Bendtzen, K., and Sandler, S. (1991) Diabeto-
logia 34, 445–448
67. Harmon, J. S., Bogdani, M., Parazzoli, S. D., Mak, S. S., Oseid, E. A.,
Berghmans, M., Leboeuf, R. C., and Robertson, R. P. (2009) Endocrinology
150, 4855–4862
68. Størling, J., Zaitsev, S. V., Kapelioukh, I. L., Karlsen, A. E., Billestrup, N.,
Berggren, P. O., and Mandrup-Poulsen, T. (2005) Endocrinology 146,
3026–3036
69. Kaneto, H., Matsuoka, T. A., Nakatani, Y., Kawamori, D., Matsuhisa, M.,
and Yamasaki, Y. (2005) Curr. Diabetes Rev. 1, 65–72
PDX1 Localization in Diabetes
MAY 13, 2011 •VOLUME 286•NUMBER 19 JOURNAL OF BIOLOGICAL CHEMISTRY 17155
 at UNIVERSITÄT BREM
EN, on January 30, 2013
www.jbc.org
Downloaded from
 
0 
1 
2 
3 
0 
0.5 
1 
1.5 
0 min 
30 min 
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0 
100 
200 
300 
400 
500 
600 
0 15 30 60 90 120 
gl
uc
os
e 
m
g/
dl
 
db/+WT 
db/+OE 
db/db WT 
db/db OE 
0 
1 
2 
3 
4 
Suppl. Figure 1 
β-
ce
ll 
m
as
s 
(m
g)
 
%
 T
U
N
E
L+
 β
-c
el
ls
 
st
im
ul
at
or
y 
in
de
x 
             db/+        db/+         db/db      db/db 
IL-1Ra   WT          OE           WT         OE             
             db/+     db/+     db/db    db/db 
IL-1Ra   WT      OE        WT        OE             
             db/+      db/+      db/db    db/db 
IL-1Ra   WT       OE         WT        OE             
             db/+      db/+      db/db    db/db 
IL-1Ra   WT       OE         WT        OE             
B C 
D 
E 
A 
** 
* 
** 
* ** 
* 
** 
* 
** 
* 
in
su
lin
 (µ
g/
l) 
time (min) 
Fig.S1: PDX1 translocalization in db/db mice is paralleled by impaired glycemia and insulin secretion 
(A,B) Blood glucose (A) and insulin (B) levels following i.p. injection of 1 (A) or 2 (B) g/kg body weight glucose in 7-
week-old control heterozygous db/+, db/+IL-1Ra, db/db and db/dbIL-1Ra littermate mice. (C) Stimulatory index 
calculated from stimulated divided by basal insulin secretion (B) shows significant decrease in the db/db mice, which 
was prevented in the db/dbIL-1Ra mice. (D) β-cell apoptosis expressed as percentage of TUNEL-positive β-cells ± SE. 
The mean number of β-cells scored was 2620 ± 256 for each treatment condition in four independent experiments. (E) 
The β-cell mass per pancreas was estimated as the product of the relative cross-sectional area of β-cells (determined 
by quantification of the cross-sectional area occupied by β-cells divided by the cross-sectional area of total tissue) and 
the weight of the pancreas. Pancreases were analyzed from 8-week-old mice. **p<0.05 db/db compared to db/+, 
*p<0.05 db/dbIL-1Ra compared to db/db mice. 
Data were collected from 4 animals per group in each of three independent experiments. 
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Suppl. Figure 2 
Fig.S2: Transfection efficiency in human islets plated on extracellular matrix coated dishes 
Human islets were plated on ECM dishes and transfected with GFP control plasmid (see material and methods). 48 h 
later, transfection efficiency was determined by fluorescence microscopy (a). (b) shows brightfield picture of all plated 
cells. 
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changes of PDX1 gene expression can lead to
the development of b-cell failure.121
PDX1 nuclear import and export
signals (NLS/NES) suggest that this factor is
subjected to regulation at the level of cellular
localization122,123 and that PDX1 nucleo-
cytoplasmic shuttling regulates its func-
tion.117,118,122,124 We have recently shown that
the negative effect of IL-1b on b-cell function/
survival is modulated by the shuttling of
PDX1 to the cytoplasm, whereas IL-1b neutral-
izing by IL-1Ra results in enhancement of
PDX1 nuclear translocation rescuing human
islets in vitro and b-cells in diabetic mouse
models from apoptosis and impaired func-
tion.124 To establish whether IL-1b mediates b-
cell death and impaired function via nuclear
exclusion of PDX1. Overexpression of shuttling
deficient-mutant PDX1-NES, which remains in
the nucleus, reduced human islet apoptosis
and improved islet function under IL-1b treat-
ment. IL-1b-induced nuclear exclusion of
PDX1 and its translocation to the cytoplasm
was also JNK dependent and prevented by
JNK inhibition further supporting JNK
signaling as downstream of the IL-1 receptor.
Nucleocytoplasmic shuttling of PDX1 under
diabetogenic conditions (IL-1b, chronically
elevated glucose124 or free fatty acids)125 is
a feature of diabetes. Our recent data124 demon-
strated that in all islets from patients with T2DM
as well as in animal models, PDX1 protein was
localized in the cytoplasm, whereas in the non-
diabetic controls, PDX1 was in the nucleus.
IL-1b antagonism by IL-1Ra overexpression or
injections restored normoglycemia and b-cell
function and survival in db/db and HFD-fed
mice through redistribution of PDX1 into the
nucleus. IL-1b-induced PDX1 cytoplasmic accu-
mulation and its subsequent degradation may
affect b-cell function in different levels. Cytosolic
PDX1 may be inactive and regulation of gene
expression is lost. As PDX1 regulates insulin
and specific b-cell genes, altered localization
may contribute to b-cell death and impaired
function and provides another explanation for
the toxic effects of IL-1b on b-cells.
IL-1b AND GENETIC
PREDISPOSITION
Genetic variation in the IL-1 gene family is
associated with hyperglycemia and insulin
resistance provides another proof for the
involvement of IL-1b in the pathogenesis of dia-
betes.126 Results from recent genome-wide asso-
ciation studies (GWAS) show that TCF7L2
(transcription factor 7-like 2, previously known
as TCF-4) is a strong risk factor for type 2 dia-
betes.127 This association of TCF7L2 variants
with type 2 diabetes has been replicated in
numerous study populations worldwide.128
Since polymorphisms were found in the non-
coding region of the gene, effects on the b-cell
and whether there is a link between TCF7L2
and b-cell survival was previously unknown.
TCF7L2 is an important component of the
WNT signaling cascade; the WNT/b-catenin
signaling pathway is involved in many physio-
logical and pathophysiological activities such as
embryonic development, cell differentiation and
tumorigenesis.WNTsignal regulates lipidmetab-
olism and glucose homeostasis as well, and regu-
lates b-cell proliferation and function.129
Mutations in LRP5 may lead to the development
of diabetes and obesity.130 The single nucleotide
polymorphism locus in the Wnt5b gene confers
susceptibility to type 2 diabetes in a Japanese
population.131 The Wnt antagonist sFRP inhibits
b-cell proliferation and insulin secretion.132
TCF7L2 plays a role in glucose homeostasis
through the regulation of pro-glucagon gene
expression, which encodes incretin hormone
GLP-1 (glucagon-like peptide-1) in intestinal
cells.133 TCF7L2 expression in the b-cells is
correlated with b-cell function and survival.
Reducing TCF7L2 gene expression by siRNA
leads to increased b-cell apoptosis and
impaired function.134e137 A diabetic milieu,
IL-1b AND GENETIC PREDISPOSITION 241
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4. Discussion
4.1. MST1 is activated in diabetes
Glucose homeostasis is largely maintained by the pancreatic ?-cells, which secrete 
insulin in response to elevated ATP levels as a result of glucose metabolism [1]. ?-cell 
dysfunction leads to diabetes [2,3] . However, the underlying mechanisms involved in ?-
cell failure remain to be fully understood. Considering that ?-cell death might underlie 
both types of diabetes [4,5,6,7,8,9,10,11], elucidation of the molecular processes 
associated with ?-cell apoptosis and maintenance of ?-cell mass are critical to develop 
new therapeutic strategies to prevent and/or delay these pathological events since 
current treatment strategies do not include the preservation of endogenous ?-cell mass
[12,13]. Upregulated apoptotic pathways play an important role in the initiation and
progression of ?-cell failure in diabetes [7,8,9,10]. Inhibiting pro-apoptotic or potentiating 
anti-apoptotic molecules can serve as an excellent treatment strategy for diabetes.
???????? ???? ??????sis mediated-signal transduction pathways and the intricate 
molecular interactions will help to guide us in developing potent drugs for patients with 
diabetes [8]. Despite much evidence to support the essential role of ?-cell apoptosis 
???????????????????????????????-cells and diabetes, the specific pro-apoptotic signaling has
not been comprehensively studied so far. In this study, we demonstrated that MST1 is 
critical for ?-cell apoptosis triggered by multiple diabetogenic conditions in vitro and in 
vivo. MST1 overexpression itself leads to impaired ?-cell survival and function. This 
suggests that MST1 overexpression is sufficient to cause ?-cell apoptosis.  In contrast, 
loss of MST1 in ?-cells leads to protection from apoptosis and improves insulin secretion 
in primary islets and INS-1E cells under pro-diabetic conditions. In this case, multiple 
techniques for MST1 downregulation were applied to islets and the ?-cell line; siRNAs to 
MST1, which resulted in ~70% depletion, a dominant negative MST1 (kinase-dead 
MST1-K59) and INS1 cells stably transfected with a vector for shMST1. Our data also 
suggests a direct regulation of the critical ?-cell transcription factor PDX1 by MST1 in 
which physical and functional interactions between MST1 and PDX1 directly influence ?-
cell function. We introduce PDX1 as a novel ?-cell specific substrate for MST1 and 
provide evidence that PDX1 ubiquitination and subsequent degradation, resulting from 
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inhibitory T11 phosphorylation is crucial for ?-cell dysfunction in the setting of MST1 
hyper-activation. MST1-deficient primary human and mouse islets and INS-1E cells 
showed decreased apoptosis after diabetogenic assaults. Further in vivo experiments 
proved that MST1 deletion in the MLD-STZ and HFD/STZ models protected mice from
loss of ?-cell mass and diabetes. To our surprise, loss of MST1 specifically in ?-cells 
protects mice from ?-cell failure and diabetes development in the MLD-STZ model. 
Taken together, we demonstrate that MST1 functions as an essential apoptotic molecule 
in the presence of diabetic stimuli, and loss of MST1 in ?-cells leads to protection from 
diabetes.
Accumulating evidence suggests that MST1 plays a central role in the initiation of cell 
death [14,15,16,17,18,19,20,21,22,23,24,25,26,27]. The broad nature of the diabetic
stimuli and the range of the cell systems in our study, in which MST1 is activated,
suggest that this enzyme may be a common component in the diverse signaling 
pathways leading to ?-cell apoptosis. From regulatory and therapeutic perspectives, it is 
very important to determine if increased MST1 activity is a general mechanism in various 
diabetic conditions since next generation of T1/2D medicines aiming for the preservation 
???????????????-cell mass, must target more than one single apoptotic pathway. Using a
complex diabetic milieu in vitro including proinflammatory cytokines, gluco- and lipo-
toxicity and oxidative stress, we demonstrated that MST1 is activated in response to a 
broad range of stimuli in human and mouse primary islets as well as in the insulin-
producing ?-cell line INS-1E. To further confirm this, we showed that MST1 activity is 
markedly increased in islets of T2D patients and two distinct mouse models of T2D.
While the endogenous molecule(s) that trigger MST1 activation remain largely unknown,
our data show that MST1 is highly active in response to various diabetic stimuli. This is
consistent with the multi-?????????? ??????? ??? ?-cell failure in diabetes on one hand and
multiple regulatory features and cell type-specific mechanisms of MST1 on the other 
hand and may be required to integrate inputs from diverse signaling pathways to an
apoptotic end.
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4.2. Molecular mechanisms of MST1-induced apoptosis
Understanding of the pathways by which the complex “diabetic milieu” triggers ?-cell 
apoptosis, will shed new light on mechanisms of ?-cell loss in diabetes and may 
therefore improve therapeutic intervention. Proinflammatory c??????????????????????-cells, 
especially the pathway leading to nitric oxide (NO) generation and NF-฀B activation,
which causes ?-cell death, has been studied for many years [11,28,29,30,31,32]. Also, 
prolonged exposure to elevated glucose or free fatty acid concentrations exerts toxic 
???????? ??? ?-cell survival and function, a concept termed glucotoxicity [33,34] and
lipotoxicity [35,36,37] . High glucose or free-fatty acid-?????????-cell oxidative stress, ER 
stress, proinflammatory cytokines production and other mechanisms have been 
identified ??????????? ????????????????????????????? ?????-cells [34,38,39,40]. Interestingly, 
more recent studies have begun to characterize the intrinsic pathway of cell death as the 
main road of complex “diabetic milieu” ????????????-cell apoptosis. In this case, multiple 
pro-diabetic stressors such as proinflammatory cytokines, gluco- and lipotoxicity induce 
apoptosis through activation of the intrinsic pathway of cell death, leading to 
mitochondrial-dependent caspase-9 cleavage (initiator caspase of intrinsic pathway) and
downstream caspase-3 activation [41,42,43,44,45,46,47,48,49]. Additionally, the 
extrinsic apoptotic pathway is important for ?-cell death in both types of diabetes shown 
in in vivo mouse models and in vitro [7,10,50,51,52,53,54,55]. However, the molecular 
links between these areas have remained unclear, and the precise identity of the key 
players at each level is poorly understood. As a model, Scaffidi et al [56] have 
introduced two cell types. In type I cells, death receptor (such as Fas) triggering leads to 
strong caspase-8 activation, which bypasses mitochondria, leading directly to activation 
of caspase-3 followed by apoptosis. In type II cells, death receptor-induced caspase-8
activation (initiator caspase of extrinsic pathway) requires mitochondrial pathway-
mediated amplification of the caspase cascade. Pancreatic ?-cells are classified as type 
II cells suggesting that amplification of apoptosis signaling through the mitochondrial 
pathway is completely essential for pancreatic ?-cell apoptosis [57]. Our data clearly 
show that MST1 activated the mitochondrial pathway in ?-cells through regulating Bcl-2
family proteins. Basically, the observation that loss of Bax protects islet cells from the 
deleterious effects of MST1 overexpression demonstrated that the mitochondrial 
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pathway of apoptosis is involved. This indicates that cell death is initiated by members of 
the BH3-only subgroup of the Bcl-2 family. We found that MST1-induced apoptosis 
requires the BH3-only proteins Bim and the multi-BH domain protein Bax.
Mechanistically, our data show that MST1 targeting Bim evokes Bax/Bcl-2 alteration, 
leading to cytochrome c release and subsequent caspase-9 and -3 activation and 
mitochondrial-mediated apoptosis in ?-cells. Very interestingly, in isolated human islets, 
treatment with multiple diabetic milieu including IL/IF, HG/Pal and H2O2 induced Bim 
upregulation. Consistently, Bim has been shown to be induced by glucotoxicity, 
proinflammatory cytokines [41,47] and also by double strand-RNA [58] and human islet 
amyloid polypeptide (hIAPP) [59] underscoring its importance in mediating apoptosis in 
response to other types of stress in the islet. In our study, we have identified Bim as an 
important target for ?-cell apoptosis mediated by MST1. Ectopic expression of MST1 
caused up-regulation of Bim, and this was required for MST1-induced caspase-3
cleavage and cell death. In consistency with our data, MST1 promotes neuronal cell 
death through induction of Bim [60]. In primary mammalian neurons, H2O2-induced 
MST1 phosphorylates the transcription factor FOXO, which could translocate into the 
nucleus and upregulate the transcriptional expression of Bim [60]. Although it has been 
reported that BH3-only protein NOXA is a target of MST1 [27], it is unlikely that NOXA is 
responsive to MST1 in ?????-cells since MST1 overexpression did not alter the level of 
NOXA.
We also examined the mechanism of MST1-induced apoptotic signaling by initially 
?????????? ???? ?????????????????????????? ?????????? ????-cell responses, including entry 
into apoptosis [61,62,63,64,65]?????????????????????????? ????????-cells with SP600125, 
a JNK-specific inhibitor, indicate that JNK mediates MST1-induced caspase-3 activation 
???? ?????????? ??? ?-cells and may initiate a vicious cycle and pro-apoptotic signaling 
cascade in the ?-cells. This would explain why ?-cell death, once initiated, rapidly 
progresses. Interestingly, several lines of evidence suggest that chromatin condensation 
and DNA fragmentation, the most prominent morphological characteristics of early and 
late apoptosis, respectively, are, at least in part, mediated by MST1 and JNK activation 
[18,26]. In response to cellular stress, JNK phosphorylates histone H2AX, thus 
promoting DNA fragmentation by caspase-activated DNase (CAD) [66]. On the other 
hand, it has also been shown that DNA condensation during early apoptosis is triggered 
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by phosphorylation of histone H2B by caspase-activated MST1 [26,67]. JNK is also 
required, at least in part for Bim induction and subsequent cell death upon MST1 
overexpression. It has been demonstrated that MST1-induced apoptosis can be 
suppressed by expression of dnJNK1 or by knockdown of either mitogen-activated
protein kinase kinase 4 (MKK4) or MKK7, the two direct activators of JNK [26,68].
Previous studies suggested that transactivation of c-Jun through JNK-dependent 
phosphorylation is essential for Bim-induced apoptosis in cerebellar granule neurons
(CGNs) [69]. ChIP assay using primers designed to amplify the unique AP-1 site in the 
regulatory sequence of the Bim gene indicated strong c-Jun binding under stress 
conditions [70]. This confirms physical interaction of c-Jun with the Bim promoter, and 
suggests that c-Jun positively regulates Bim expression. In additions, recent studies 
suggest that JNK induces apoptosis by directly phosphorylating Bim [71]. Notably, 
cytokine- and hIAP-induced Bim induction ????-cells is JNK-dependent [59,72]. Of note, 
although Bim is a critical regulator of the mitochondrial pathways of cell death that 
senses intracellular stresses, it is also downstream of extracellular-responsive factors 
like AKT [73]. Our data showed that AKT activation efficiently diminished Bim induction 
and apoptosis through suppression of Bim. Of these potential mechanisms, we highlight 
the JNK- and AKT-?????????????????????????? ?????-cells, consistent with earlier studies 
in other cell types [59,71,72,73]. Our findings are essential, because the MST1-triggered 
Bim activation integrates signals from pro-apoptotic diabetogenic stimuli to caspase 
machinery to run efficient apoptosis. This implicates that pro-diabetic milieu induces Bim 
in islet cells predominantly by triggering MST1 activation.
Importantly, caspase-mediated cleavage of kinases can terminate pro-survival signaling 
or generate pro-apoptotic peptide fragments that help to execute the death program and 
facilitate packaging of the dying cells [74]. Caspase-3-mediated cleavage of MST1 
elevates its activity, alters its substrate specificity and its cellular localization providing 
the opportunity for positive feedback in the pathway to amplify caspase-3 activation and 
bolster transmission of the apoptotic signal. Interestingly, full-length MST1 is found 
mostly in the cytoplasm, whereas the cleaved MST1 fragment translocates to the 
nucleus due to loss of a C-terminal NES [75]. This nuclear translocation may account, at 
least in part, for the H2B-promoted chromatin condensation and targeting of nuclear 
PDX1.
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There is emerging evidence that oxidative stress appears to be one of the most 
important processes ???????????????????????????????? ? ????????? ??? ?-cell destruction 
and pathophysiology of both types of diabetes [34,76,77,78,79,80]. The molecular 
mechanisms which enforce the vulnerability of ?-cells to oxidative challenge have been
elucidated. ?-cells have relatively low levels of free radical detoxifying and redox-
regulating enzymes, such as SOD, CAT, glutathione peroxidase, and thioredoxin
[81,82]. This low antioxidant defense capacity of ?-cells and the resultant enhanced 
sensitivity towards oxidative stress have been considered to be an important aspect of 
oxygen free radical-???????? ??????? ???????? ??? ?-cell death during the progression of 
diabetes. In our study, H2O2 efficiently activates MST1 and results in oxidative stress-
induced apoptosis in ?-cells. In the line with our data, treatment of HL-60 cells with H2O2
leads to apoptosis which was associated with the cleavage of MST1 [83]. Importantly, a 
role for endogenous oxidant-mediated activation of MST1 was supported by the finding 
that neutralizing H2O2 with antioxidants like N-acetylcysteine and GSH prevented stress-
induced MST1 activation [83]. How does H2O2 activate MST1? The precise molecular 
mechanism by which oxidative stress induces the activation of MST1 remains unclear. 
Very recently, Chae et al showed that antioxidant protein, thioredoxin-1 prevented the 
homodimerization and autophosphorylation of MST1 through direct protein-protein 
interaction. However, this inhibitory interaction was abolished in the presence of H2O2 or 
TNF-?????????? promoting MST1 activation [84].
4.3. The bidirectional crosstalk of MST1 and AKT
?????????????????????????????????????????????????????????????-cell survival. AKT kinase is 
one of the most promising downstream molecules of this pathway, which could be 
targeted to induce proliferation and survival of ?-cells. AKT-mediated phosphorylation of 
multiple substrates positively regulates insulin transcription, insulin secretion, and ?-cell 
growth and survival [3,85,86,87,88,89,90]. Recent studies suggest potential crosstalk 
between MST1 and AKT [19,91]. MST1 activity is negatively regulated by AKT-mediated 
phosphorylation at its Thr120 and Thr387 residues and results in inhibition of its
cleavage, autophosphorylation, kinase activity and nuclear translocation [91,92,93]. On 
the other hand, MST1 and its cleaved form have been shown to interact with AKT1 and 
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act as direct AKT1 inhibitors [19]. Recently, it has been reported that MST1 can interact 
with phosphatase PHLPP, thus potentiating the ability of PHLPP to dephosphorylate and 
inhibit AKT [94]. Our data demonstrate that activation of the PI3K-AKT pathway through 
exogenously added insulin or GLP1 or a constitutively active form of AKT1 abrogated 
glucose- and cytokine-???????? ????? ??????????? ???? ?-cell apoptosis, whereas 
suppression of PI3-K/AKT signaling (by LY294002, AKTi or siRNA to AKT1-3), induced 
????? ????????? ???? ?-cell apoptosis. AKT and MST1 are components of two parallel 
stress-triggered signaling pathways, which functionally antagonize each other. Activated 
AKT itself down-?????????? ????? ????????? ??? ???? ?-cells, indicating the existence of a 
potential bidirectional crosstalk between these two pathways. Our results suggest that
MST1 and AKT negatively regulate each other and constitute a stress-sensitive survival 
pathway. Under acute stress conditions, AKT promoted cell survival by inhibiting MST1, 
but prolonged stress decreased AKT, which allowed pro-apoptotic MST1 signaling. This 
antagonism between MST1 and AKT suggests that the outcome of simultaneous 
stimulation of both pathways is determined by the extent and duration of the respective 
apoptotic stimulus. In this context, MST1 may shift the balance towards the 
predominance of stress-triggered JNK activation, resulting in Bim-dependent 
mitochondrial apoptotic pathway, whereas AKT-mediated survival signals are 
suppressed. This model is consistent with our observation that activation of AKT can 
overcome MST1-mediated apoptosis.
4.4. ??????????????????????-cell survival and function
PDX1 plays a crucial role in both pancreatic development and main???????? ??? ?-cell 
function?? ????????? ??????????? ??? ????? ??? ?-cell leads to diabetes, and reducing its 
expression affects insulin expression and secretion [95,96]. We have recently shown 
that the negative effect of pro-diabetic milieu (glucotoxicity and IL-???? ??? ?-cell 
function/survival is modulated by the shuttling of PDX1 to the cytoplasm, whereas 
neutralizing IL-??? ??? ??-1Ra results in enhancement of PDX1 nuclear translocation 
rescuing human islets in vitro and ?-cells in diabetic mouse models from apoptosis and 
impaired function [97]. To establish whether IL-?????????????????????????????-cell death 
and impaired function via nuclear exclusion of PDX1, a shuttling deficient-mutant PDX1-
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NES, which remains in the nucleus, was overexpressed in human islets. The PDX-1-
NES mutant reduced human islet apoptosis and improved islet function under IL-?? or 
high glucose treatment. Interestingly, high glucose- and IL-??-induced nuclear exclusion 
of PDX1 and its translocation to the cytoplasm was also JNK dependent and prevented 
by JNK inhibition [97]. Nucleo-cytoplasmic shuttling of PDX1 under diabetogenic 
conditions (IL-???? ????????????????????????????? [97] or free fatty acids [98] or oxidative 
stress [99] is a feature of diabetes. Interestingly, PDX1 phosphorylation at serine 269 by 
HIPK2 kinase affects PDX1 subcellular localization [100]. Our data demonstrate that in 
all islets from patients with T2DM as well as in animal models, PDX1 protein level was
reduced and dominantly localized in the cytoplasm, whereas in non-diabetic controls, 
PDX-1 was in the nucleus. IL-??? ??????????? ??? ??-1Ra overexpression or injections 
????????? ?????????????? ???? ?-cell function and survival in db/db and HFD-fed mice 
through redistribution of PDX1 into the nucleus. Pro-diabetic-induced PDX1 cytoplasmic 
????????????? ???? ???? ??????????? ???????????? ???? ??????? ?-cell function in different 
levels. Cytosolic PDX1 may be inactive and subsequently, regulation of gene expression 
??? ?????? ??? ????? ?????????? ???????? ???? ????????? ?-cell genes, altered localization may 
???????????????-cell death and impaired function and provides another explanation for the 
toxic effects of IL-?? or high glucose ????-cells.
4.5. MST1-PDX1 connection: T11 as the site for MST1-induced PDX1 
phosphorylation
MST1 may affect signal pathways of diabetic stimuli through modulation of transcription
factors and gene expression profiles that initiate the process ??? ?-cell destruction by 
apoptosis. MST1/2 has been shown to directly phosphorylate several transcription 
factors such as FOXO1, FOXO3 and thyroid transcription factor 1 (TTF1), a 
homeodomain-containing transcription factor [60,101,102,103] providing evidence for an 
important role of MST1/2 in the regulation of transcription. For instance, it has been 
shown that MST1-FOXO1 signaling mediated neuronal death upon serum deprivation. 
MST1 specifically phosphorylates FOXO1 and this phosphorylation event facilitates 
FOXO1 translocation into the nucleus [60]. Although we elucidated MST1 signaling 
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pathways, much remains to be done to gain a full understanding of the role of MST1 in 
the regulation of cell death; in particular, of the cell type-specific substrate that mediates
an action of MST1 within the cells. Since MST1 is a kinase and the kinase activity is 
essential for its pro-apoptotic and other functions, identification of the kinase substrates 
of MST1 is crucial to elucidate the biological and biochemical functions of MST1. In this 
study, we have shown for the first time that MST1 can physically interact with and 
phosphorylate PDX1 in vitro and in vivo. We also show here that MST1-induced PDX1
degradation was prevented in response to treatment with the proteasome inhibitor MG-
132, which suggests that PDX1 is also degraded by the proteasomal pathway. We have 
identified threonine 11 (T11) residue of PDX1 as the phosphorylation site used by 
MST1. This modified threonine is found in the highly conserved region of PDX1 at the 
transcription activation domain. Thus, it is possible that phosphorylation of T11 may be 
????????????????????????????????????????????????????????????????????-cell with the switch
from normal to stressed conditions, although this remains to be validated. We provided 
convincing evidence that T11-phosphorylation of PDX1 by MST1 marked PDX1 for 
degradation by the proteasome machinery, which would prohibit it to function as a 
transcription factor in the nucleus. In that regard, overexpression of MST1 caused 
reduction of PDX1 target genes and ?-cell functional impairment, as assessed by GSIS,
whereas mutation of the T11 site allowed PDX1 to be more stabilized and resistant to a 
MST1-induced degradation to restore PDX1-induced gene expression and improvement 
of ?-cell function. Therefore, MST1 is a PDX1 kinase and phosphorylation of PDX1 plays 
a very important role in regulating its function. PDX1 degradation requires the T11-
dependent phosphorylation by MST1. Such a kinase-dependent function would be 
consistent with a comparably low level of PDX1 and high levels of active MST1 in 
stressed ?-cells and pancreases of diabetic mice in our study. PDX1 levels were
restored by MST1 knockdown in ?-cells and by deletion of MST1 in knockout mice under 
diabetic conditions. Interestingly, the same site (Thr11) was previously shown to be 
targeted by DNA-dependent protein kinase. Consistent with our data, phosphorylation of 
PDX1 by this kinase results in enhancement of protein degradation [104]. It has also
been shown previously that PDX1 phosphorylation at Ser61 and Ser66 positions by 
GSK-3 increases the rate of PDX1 degradation and decreases the half-life of PDX1 
protein [105]. However, our preliminary mutation study revealed that at least ser61 was 
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not targeted by MST1 (data not shown). Previous studies suggested that PDX1 protein 
loss by chronic exposure to oxidative stress or AGE is mediated at the level of protein 
stability [105,106]. Ubiquitination regulates protein stability and involves the sequential 
modification of the targeted proteins by the action of an E1 ubiquitin-activating enzyme, 
an E2 ubiquitin-conjugating enzyme and E3 ubiquitin-protein ligase [107].
Phosphorylation is a molecular signature that often leads to recruitment of the E3 ligase 
complex to a target protein [108]. For example, GSK3-mediated phosphorylation of 
PDX1 causes its proteosomal degradation and impairs its transcriptional activity
[105,109]. Recently, Claiborn et al [110] have shown that PDX1 C-terminus-interacting 
factor 1 (Pcif1) targets PDX1 for ubiquitination and proteasomal degradation by the E3 
ubiquitin ligase Culin3. Also here, PDX1 ubiquitination regulates PDX1 activity since 
Pcif1 deficiency normalizes PDX1 protein levels and improves glucose homeostasis and
?-cell function in PDX1+/– mice. Interestingly, accumulation of polyubiquinated proteins 
was increased in ?-cells of individuals with T2D [111] highlighting that increased 
expression of polyubiquinated proteins may contribute to ?-cell dysfunction under 
diabetic conditions.
Despite its implication in ?-cell function, PDX1 is also associated with ?-cell survival 
[112,113]. Downregulation of PDX in islets from PDX1+/– mice or in vitro in ?-cells 
causes apoptotic cell death, indicating the requirement of PDX1 for ?-cell survival [112].
PDX1 deficiency is characterized by a lack of cell survival and seems to trigger a
mitochondrial-dependent pathway. Interestingly, PDX1 deficiency might associate with
up-regulation and repression of mitochondrial genes with crucial roles in survival such as 
Bcl-2, Bcl-xL and Bim. Islets of PDX1+/– mice have reduced levels of the anti-apoptotic 
proteins Bcl-2 and Bcl-xL [112]. Furthermore, knockdown of PDX1 in MIN6 insulinoma 
cells induces expression of the pro-apoptotic gene like Nix-3 like protein X (Nix) and Bim
[114]. In line with this, suppression of Nix expression in PDX1+/– mice normalized ?-cell 
survival and glucose tolerance [114]. Therefore, MST1 impairs ?-cell function and exerts 
apoptosis-inducing effects at least through two mechanisms: (i) MST1 specifically 
activates the intrinsic pathway of cell death through up-regulation of Bim, which leads to 
apoptosis of ?-cells. (ii) MST1 directly phosphorylates PDX1 on Thr 11, resulting in 
ubiquitination and degradation of PDX1, which leads to functional ?-cell impairment. 
The consequence is increased apoptosis and ?-cell dysfunction.  Interestingly, PDX1 
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and Bim are reciprocally inhibitory [114]. Thus, MST1 may induce ?-cell apoptosis and 
impairment by indirect activation of Bim via targeting PDX1. Further studies are required 
to disclose this possibility.
4.6. MST1 protects from diabetes in vivo
In mammals, the absolute number of ?-cells reflects a dynamic balance between ?-cell 
growth and death. An inadequate expansion of ?-cell mass to compensate for the 
increased insulin demand, followed by the eventual loss of ?-cells due to apoptosis, is a 
hallmark of diabetes [115,116]. This is most apparent in T1D when ongoing 
autoimmunity causes destruction and consequent loss of ?-cells. Through deletion of the 
MST1-mediated death signal, we have uncovered an important deleterious action of 
MST1 to induce apoptosis in response to diabetic injuries in the mice.
Two mouse models of ?-cell destruction were investigated; (1) the immune-??????????-
cell destruction in the MLD-???? ??????? ?? ?????? ??? ?-cell demise that occurs in the 
absence of insulin resistance and (2) insulin resistance in mice fed a high fat/high 
sucrose diet in conjunction wi????-cell failure induced by the STZ treatment [117]. MLD-
STZ is a well-established experimental tool for the induction of autoimmune T1D, which 
is mediated by hyperglycemia and hypoinsulinemia due to its selective cytotoxicity 
towards insulin-??????????????????????-cells [118,119]. As a result there is a decrease in 
the number of functional ?-cells ???????????? ????????????????????????-cells (first peak of 
???????????-???????????????????????????????????????????????????????-cells by infiltrated 
lymphocytes (second peak of apoptosis) [120] . Cytokine and chemokine expression by 
inflammatory cells, T cells, and macrophages and ROS is proposed to be the major 
??????????? ?????????? ???????? ??? ?????????? ???? ?-cell apoptosis and reduced insulin 
secretion [120,121,122]. STZ induces selective ?-cell killing [123,124,125], it is taken up 
by GLUT-??????-?????????????????-cells by inducing DNA damage, which causes activation 
of poly ADP-ribosylation that leads to depletion of cellular NAD+ and ATP [126].
Additionally, STZ treatment induces ATP dephosphorylation, which is then further 
degraded to nucleosides to eventually yield the base hypoxanthine, the substrate for 
xanthine oxidase, resulting in the formation of superoxide radicals [126,127].
Surprisingly, MST1 deletion did not only prevent MLD-STZ- and HFD/STZ-induced ?-cell 
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death, but also improved ???? ????????? ??? ?????-cell to produce insulin in both models. 
MST1 ????????? ?????????? ?-cell mass ???? ? ??????? ?-cell function, monitored by 
glucose homeostasis and GSIS. In the context of MLD-STZ, MST1 deletion prevented 
MLD-STZ-induced islets deterioration, as shown by the maintenance of the islet 
structure, density, size and mass. Indeed, while MLD-STZ treatment induced reduction 
in islets size, density and ?-cell number in WT mice, the morphology of the islets, the 
abundance and distribution of insulin-, as well as glucagon-, expressing cells in the 
MST1-/- mice treated with MLD-STZ, remained comparable to islets derived from control 
mice. The observed ability to preserve the islets appearance was associated with a 
protective role of MST1 deficiency on MLD-STZ-induced ?-cell death and enhancing ?-
cell proliferation, as shown by both TUNEL analysis and Ki67 staining. The MLD-STZ-
induced ?-cell death observed within the islet was almost completely prevented by 
MST1 deletion. ?????? ???? ????? ???????? ?-cell death, which results from both (1) an 
initial, direct cytotoxic effect (generation of free radicals and DNA strand breaks) and 
from (2) ?-cell death caused by the subsequent immune ???????????????????????????????-
cell, are diminished in MST1-/- mice.
In addition to the apparent functional abnormality of ?-cells that result in inappropriate 
glucagon secretion, there are multiple reports of ?-cell hyperplasia in diabetic animals 
and human subjects with type 2 diabetes [128,129,130,131,132] which may contribute to
increased glucagon levels. We observed ?-cell expansion including increased ?-cell 
number accompanied by ?-cell reduction in response to MLD-STZ injections in MST1+/+
mice, but these changes were suppressed by MST1 deletion. Therefore, MST1 may 
contribute to both ?-cell protection and regulation of ?-cell number in MLD-STZ mice. 
Although ?-cell expansion is commonly observed after ?-cell loss, the mechanisms 
regulating ?-cell number under physiological and diabetic conditions are not well 
defined. However, MST1 deletion itself has no effect on ?-cell number in normal 
conditions suggesting that ?-cell proliferation is not influenced by MST1 ablation.
Therefore it is possible that ?-cell restoration and a potential paracrine insulin effect in 
islets caused by MST1 deletion stop pancreatic ?-cell expansion in MLD-STZ-treated 
mice. Interestingly, Thorel et al showed that ?-cells can be converted into ?-cells under 
conditions of extreme damage to ?-cells [133]. Also, ?-cell proliferation and elevated 
glucagon levels may aid in the formation of new ?-cells, since pancreatic glucagon is 
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required for ?-cell formation and differentiation [134]. Further studies are needed to 
explore the exact MST1 role in this aspect.
Preservation of PDX1 levels ????????????????? ????????? ??? ???????????????????-cells by 
MST1 deletion. This conclusion is strongly supported by our in vitro and in vivo data. 
Immunostaining of pancreatic sections also showed that Glut?? ????????????? ??? ?-cell 
membranes after STZ injections were highly preserved in the MST1-/- mice as compared 
with the control mice. These data may partly explain why MST1-/- mice showed normal 
blood glucose levels and higher circulating insulin levels, since PDX1 and Glut2 is 
involved in glucose sensing and glucose-stimulated insulin secretion. Since STZ enters 
????????-cells via Glut2, it is unlikely that resistance of MST1-/- mice to STZ-?????????-cell 
damage was due to changes in membrane Glut?????????????????-cells, because MST1
deletion did not reduc??????????????????????????????? ??? ?-cells in mice without STZ 
treatments.
Since the pro-?????????? ??????? ??? ????? ??? ?-cells is Bim-dependent and MST1 is a 
????????? ?????????? ??? ?????? ??? ??? ????? ??????? ????? ???? ?????????? ?-cell apoptosis and 
enhanced resistance to stress-induced diabetes in MST1-/- mice are due to decreased
Bim expression and/or PDX1 preservation. Consistent with this, we found that MLD STZ 
induced Bim upregulation, while the expression of Bim was blunted in MST1-/- mice.
Thes??????????????????? ????? ?????????? ????? ???????????????????????-cell death, thereby 
??????????? ??????????? ?-cell mass under conditions of MLD-STZ-induced diabetes. A
remarkable resistance of MST1-/- mice islets to MLD-STZ-induced cell death in vivo was 
consistent with our in vitro data obtained in INS-1E cells and primary islets where MST1 
??????????? ????????? ????????? ?-cells from STZ-, lipo- and gluco-lipotoxicity through Bim 
suppression and PDX1 restoration. Interestingly and in line with our data, MST1 ablation 
in vivo resulted in resistance to TNF-?- [135] Fas ligand- [136] and IFN-?- [137] induced 
apoptosis. In cardiomyocytes, MST1 is activated by pathological stimuli, such as 
hypoxia/reoxygenation in vitro and ischaemia/reperfusion in vivo [138]. Cardiac-specific 
overexpression of MST1 has been shown to cause dilated cardiomyopathy in mice 
[138]. Remarkably, suppression of endogenous MST1 by cardiac-specific 
overexpression of the dominant-negative form of MST1 prevented myocyte death 
induced by ischemia/ reperfusion [139] supporting that the patho-physiological 
significance of MST1 in apoptosis.
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It has been demonstrated that the combination of high-fat diet, which induces a stress to ?-cells in form of insulin resistance, and a single dose STZ, which then destroys the ?-
cells, stands as a model for the metabolic progression to human T2D. With time- ?-cell 
function impairs and is thus unable to compensate for insulin resistance [117]. MST1
deletion in the MST-/- mice also prevented hyperglycemia and improved glucose 
tolerance in HFD-STZ-treated mice as a result of decreased apoptosis, increased 
proliferation and restoration of ?-cell mass. The important outcome of the observed 
protective effects of MST1 ablation in this model of improved ?-cell survival and function 
is the preservation of pancreatic metabolic activity. The significant increase in serum 
insulin levels were particularly impressive, and in the context of reduced ?-cell 
apoptosis, this finding underlines the importance and the extent of functional ?-cell 
preservation achieved by MST1 deletion. On the other hand, in HFD/STZ mice, MST1 
deletion had no effect on insulin resistance, and this indicates that the overall improved 
glucose homeostasis in this model is due to ?-cell protection and insulin secretion.
4.7. MST1 primarily protects the ?-cell in vivo
The high rate of apoptosis in the MST1-deficient thymocytes further illustrates the cell 
type-specific variation in the outputs of MST1 signaling. While in thymocytes and T-cells,
deletion of MST1 increases the apoptosis rate [140,141,142] possibly through high 
levels of ROS; MST1-deficient hepatocytes and microglia exhibit a marked resistance to 
stress-induced apoptosis [136,137] . Thus, the consequences of MST1 deficiency needs
to be established in each cell type and tissue. In that regard, tissue-specific gene-
targeting approach was used in the current study to provide insights into the biological 
?????????????????-cells in vivo.
It is known that both T-cell and macrophage activation and migration play an important 
role in islet destruction leading to hyperglycemia in the MLD-STZ model [121].
Furthermore, infiltrating macrophages and T-cells are a major source of the pro-
inflammatory cytokines IL-???? ???-?? ???? ???-?? ????? ???????? ?????? ???????????? ??? ?????
model. Thus, the depletion of peripheral T-cells in MST1-/- mice as reported by different 
groups [140,141] might be a reason for their protection from MLD-STZ-induced
hyperglycemia. We cannot exclude such T-cell depletion in our model, but if it occurs, it 
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only plays a minor role, because ?-cell-specific deletion of MST1 completely protected
from hyperglycemia and islet destruction. This shows ???????????????????????-cells and 
not in other tissues is a major reason for the protection from MLD-STZ induced diabetes.
In the current study, we have used a cell type-specific knockout strategy to demonstrate 
for the first time that MST1 plays an important autonomous role in the negative 
regulation of pancreas mass and ?-cell ?????????? ? ?-cell-specific MST1 deficiency 
protected against diabetes induced by MLD-STZ injections. This is highly appreciated 
since it is well-??????????????????-cells have low antioxidant protection capability and are 
highly prone to apoptosis induced by oxidative stress and inflammation [81,82].
???????????????????-???????????????????????????????????????????????????????????????????-cell 
???????????????????????? ???????????????????? ????????????? ??????-???????????????? ?????-cell 
survival. Consistently, it should be noted that isolated MST1-/- islets were protected from 
STZ- and cytokine-induced apoptosis in vitro, further proving that protection of MST1-/-
mice from islet destruction in the MLD-STZ model is due to intrinsic resistance of MST1-/-
?-cells to stress-induced cytotoxicity. 
In addition to the well-characterized pro-apoptotic role of MST1, it has a potential tumor 
suppressor role. However, the MST1 knockout mouse has a surprisingly mild phenotype 
and does not appear, on its own, to have tumor suppressor function most likely because 
of functional redundancy between MST1 and its closest paralog MST2 [135,136] . For 
example, liver [136] and pancreas [143] specific double-knockout of MST1/2 in mice has 
been associated with cellular hyper-proliferation, while MST1 deletion alone has no 
effect on proliferation. MST1 deletion prevented ?-cell apoptosis, while the maintained 
MST2 function should serve to suppress hyper-proliferation with its tumor suppressor 
mechanisms. The role of MST1 deficiency on ?-cell proliferation is context-dependent in 
our study. MST1 deletion had no impact on ?-cell proliferation in non-stressed 
conditions, but it significantly induced proliferation under conditions of extreme damage 
to ?-cells induced by MLD-STZ or HFD/STZ. Consistently, silencing of MST1 did not 
alter cell proliferation in human islets as compared with matched controls in normal 
conditions (data not shown).
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4.8. Outlook: the Hippo pathway
Mammalian MST1 is the core kinase of the Hippo pathway, which was initially identified 
in the fly to control organ size. Its core components are evolutionally conserved in 
mammals. Hippo, Sav, Wts and Mats in the Drosophila are homologous to mammalian 
MST1/2, WW45, LATS1/2, and Mob1, respectively [16,144,145] . The pathway regulates
transcriptional co-activator Yorkie in Drosophila and YAP in mammals to coordinate cell 
proliferation and apoptosis [145]. MST1 and its associated proteins in the Hippo 
pathway, such as Mob1, WW45 or LATS1/2, have been implicated in apoptosis 
induction. For instance, overexpression of LATS2, the direct down-stream substrate of 
MST1, was reported to induce apoptosis, which was associated with a decline in the 
level of anti-apoptotic Bcl-2 and Bcl-xL [146]. In addition, WW45 (MST1 adaptor)
overexpression potentiated MST1-induced apoptosis [147]. It has also previously shown 
that RASSF1 and NORE1, two other MST1-ascoiated proteins, are highly up-regulated
in the pancreas of MLD-STZ-treated mice [148]. Of interest, it has been demonstrated 
that RASSF1 mediate the pro-apoptotic effects of MST1 [149], raising the possibility
whether two proteins might be able to mediate MST1 action to induce ?-cell death. It is 
also possible that the components of the canonical Hippo pathway may be involved in 
the mechanism of the MST1-mediated ?-cell apoptosis but such possibility needs to be 
mechanistically clarified in further studies.
4.9. Blocking MST1 as a future diabetes treatment
Our findings raise the possibility that MST1 hyperactivity may be associated with ?-cell 
failure and development of diabetes. Unfortunately, there is currently no selective MST1 
inhibitor on the market and our search for novel drugs specifically targeting MST1 was 
not successful so far. Hopefully, specific inhibitors will be synthesized in the future and 
some of them could block ???? ?????????? ????? ???????????-cell mass in both T1D and 
T2D. Given that MST1 has been implicated to play a pivotal role in the development of 
certain number of pathological cases such as cardiovascular and neurodegenerative 
diseases [20,137,138], such pharmacological tools may also be of value in a variety of
diseases.
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Conclusion
In the present study, we have used a multi-model approach to uncover the role of MST1 
????-cell apoptosis and impaired function. We combined mechanistic molecular studies 
in vitro using primary islets and a ?-cell line, and in vivo studies using two different 
mouse models of T1/T2D. Based on the results from this study, we have proposed a 
model depicting how MST1 triggers apoptosis and impairs function in ?-cells 
(Suppl.Fig.18). Diabetic stimuli lead to activation of MST1. Active MST1 triggers 
cytochrome c release and mitochondrial-dependent apoptosis by modulating 
Bim/Bax/Bcl2&Bcl-xL signaling through JNK and AKT signaling pathways. Active 
caspase-9 then triggers the activation of caspase-3, resulting in caspase-3-dependent 
cleavage of MST1 to its constitutively active fragment which leads to further MST1 
activation. Active MST1 triggers the processing of caspase-3 by a positive feedback 
mechanism and acceleration of ?-cell death may occur. Cleaved MST1 also translocated 
to the nucleus and directly phosphorylated PDX1 (we do not exclude the possibility that 
MST1 might target PDX1 also in cytoplasm) and histone H2B. PDX1 then shuttles to the 
cytosol, where it marks for ubiquitination and subsequent degradation by the 
proteasome machinery and ?-cell function is impaired. Histone H2B phosphorylation by 
MST1 also induces chromatin condensation, one of the characteristic features of 
apoptosis.
In summary, MST1 overexpression induces ?-cell apoptosis and impaired function and 
is essential for pro-diabetic milieu-induced ?-cell death, whereas lack of MST1 promotes 
endogenous ?-cell survival and prevents type 1 and type 2 diabetes.  Together, these 
data clearly demonstrate that the MST1 pathway plays a critical role in promoting ?-cell
death in response to multiple stress stimuli both in vitro, with various cellular models,
and in vivo.  Therefore, disruption of the MST1 pro-apoptotic network by targeting MST1 
in ?-cells may have important therapeutic implications. The most immediate application 
of this work is the potential to target MST1 in ways that could be beneficial for cell-based 
therapies in which the extent of cell apoptosis could have potential benefit. So, blocking 
MST1 expression may also be beneficial in the setting of islet transplantation. We 
propose that islets in which MST1 is inactivated could provide an advantage upon 
transplantation and would remarkably improve islet survival.
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Abstract 
Context. Inhibition of Dipeptidyl peptidase-4 (DPP-4) is a potent strategy to increase GIP 
and GLP-1 induced insulin secretion in diabetes. It is important to know if new drugs 
approved for the treatment of type 2 diabetes have direct effects on the β-cell. 
Objective. Herein, we investigated the effect of linagliptin, a novel DPP-4 inhibitor, on β-
cell function and survival. 
Design. Human islets were exposed to a diabetic milieu (11.1-33.3 mM glucose, 0.5 mM 
palmitic acid, the mixture of 2 ng/ml IL-1β+1,000 U/ml IFN-γ or 50 µM H2O2) with or 
without 500 ng/ml Interleukin-1Receptor Antagonist (IL-1Ra) or 30-50 nM linagliptin. 
Results. Linagliptin restored β-cell function and turnover, which was impaired when islets 
were exposed to elevated glucose, palmitate, cytokines or H2O2. Pre-treatment with IL-
1Ra was similarly effective, except for H2O2 treatment. Nitrotyrosine concentrations in islet 
lysates, an indicator of oxidative stress, were highly elevated under diabetic conditions, 
but not in islets treated with linagliptin or IL-1Ra. Linagliptin also reduced cytokine 
secretion and increased active GLP-1 in islet supernatants.  
Conclusions. We show that the novel DPP-4 inhibitor linagliptin protected from gluco-, 
lipo- and cytokine-toxicity and stabilized active GLP-1 secreted from human islets. This 
provides a direct GLP-1 mediated protective effect of linagliptin on β-cell function and 
survival. 
Introduction 
Dipeptidyl peptidase 4 (DPP-4) is the key enzyme responsible for cleaving and 
inactivating both incretins glucagon like peptide 1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) [1], which are released by cells in the small intestine after 
the ingestion of food and potentiate glucose stimulated insulin secretion [2]. DPP-4 is a 
ubiquitous cell-membrane protein enzyme, which is present in many tissues, including 
lymphocytes. Patients with T2DM have impaired insulin secretion, chronic hyperglycaemia 
and the effect of the incretins is significantly reduced [3]. 
Incretin-based therapies such as injectable GLP-1 receptor agonists or DPP-4 inhibitors 
are established treatments for type 2 diabetes because of their glucose-dependent 
stimulation of insulin secretion, their inhibition of glucagon secretion and their intrinsic lack 
of risk for hypoglycaemia [4], although an increased risk for pancreatitis was discussed 
recently [5]. 
Long-term clinical effects of incretin-based drugs on the β-cell are still speculative [6]. 
However, numerous in vivo and in vitro studies in rodents show that GLP-1 increases β-
cell mass, proliferation [7,8,9] and β-cell neogenesis [10]. GLP-1 inhibits β-cell apoptosis 
in human islets [11,12,13], and a protective effect was also observed in islets isolated from 
patients with T2DM [14]. 
Accordingly, stabilizing GLP-1 by DPP-4 inhibition restores glycemic control in diabetic 
animal models [2], improves β-cell survival, replication and neogenesis in the diabetic 
mouse or rat streptozotocin model [15,16] or in the VDF diabetic rat model [17].  
Several DPP-4 substrates such as CXCL10 and SDF-1 [18] are involved in immune 
regulation and influence the inflammatory response and β-cell survival [19,20]. Pro-
inflammatory factors, e.g. IL-1β directly trigger β-cell death and may be causative for 
diabetes progression. Inhibition of IL-1β by the anti-inflammatory cytokine Interleukin-1 
Receptor antagonist (IL-1Ra) improves β-cell survival, proliferation and insulin secretion 
[21,22].  
The direct effect of DPP-4 inhibitors on human β-cells has not been investigated yet. Thus, 
the aim of this study was to test whether a DPP-4 inhibitor would be are to restore β-cell 
function and survival under diabetogenic conditions in human islets. For such studies, 
linagliptin, a xanthine-based, highly potent and long-acting- DPP-4 inhibitor was used, 
which was recently approved for the treatment of T2DM [23,24]. IL-1Ra was used as a 
positive control for a β-cell protective effect. In the present study we provide evidence that 
linagliptin improves β-cell survival and function through stabilization of GLP-1, which is 
secreted during islet culture. 
 
Materials and Methods 
Cell culture. Human islets were isolated from eight pancreata of healthy organ donors at 
Lille University and cultured in CMRL-1066 medium as described previously [20,25]. Islet 
purity was greater than 95% as judged by dithizone staining (if this degree of purity was 
not achieved by routine isolation, islets were handpicked). For long-term in vitro studies 
(96h), islets were cultured on extracellular matrix–coated plates derived from bovine 
corneal endothelial cells (Novamed Ltd., Jerusalem, Israel), allowing the cells to attach to 
the dishes and spread, preserving their functional integrity [26]. In parallel, islets were 
cultured in suspension dishes, treated for 72h, and fixed with Bouin´s solution. Islet 
sections were prepared as described previously [22]. 
Human islets were exposed to a diabetic milieu (11.1-33.3 mM glucose, or 5.5 mM 
glucose+0.5 mM palmitic acid, the mixture of 2 ng/ml recombinant human IL-1β (R&D 
Systems, Minneapolis, MN) +1,000 U/ml recombinant human IFN-γ (PeProTech) for 72h 
or 50 µM H2O2 for 8h with or without 500 ng/ml Interleukin-1Receptor Antagonist (IL-1Ra), 
10 nM-1 uM linagliptin, 200 nM sitagliptin, 100 nM Exendin-(9–39) (Bachem) or 0.5 nM 
GLP-1 (Sigma). Compounds were added 1h before the exposure to the diabetogenic 
conditions and throughout the culture. Palmitic acid was dissolved as described previously 
[27]. 
Ethical approval for the use of islets had been granted by the Ethical Committee of 
University of Bremen. We received the islets from the European Consortium For Islet 
Transplantation (ECIT). Whenever an islet isolation fails to be suitable for transplantation, 
centers provide them for islet research. Thus, these research projects comply with NIH 
regulations PHS 398, exemption 4. Human pancreata are harvested from brain dead 
donors, according to the European and National regulations for organ 
procurement. Donors or their family members have given written consent to donate 
organs for transplantation and research, all documented by the transplantation centers. 
Human islet isolations are performed with the approved protocols of the centers.  
Cell turnover. For detection of β-cell apoptosis, 100 human islets were cultured in 
suspension dishes, treated for 72h, and fixed with Bouin´s solution. Islet sections were 
prepared as described previously, deparaffinized, rehydrated and incubated with 20 mg/ml 
proteinase K (Roche) for 15 minutes at 37°C before staining. In parallel, islets on ECM 
coated dishes were fixed using 4% paraformaldehyde and insulin co-stained with 
apoptosis analyzed by the terminal deoxynucleotidyl transferase-mediated dUTP nick-end 
labeling (TUNEL) technique according to the manufacturer’s instructions (In Situ Cell 
Death Detection Kit, TMR red; Roche Applied Science) [28].  
For analysis of β-cell proliferation, fixed islets on ECM coated dishes were incubated 
overnight at 4°C with mouse anti-human Ki67 (Invitrogen), followed by detection with 
donkey-rat Cy3-conjugated antibody (Jackson). Insulin was analyzed by anti guinea pig 
insulin antibody (Dako) followed by detection with donkey anti guinea pig FITC-conjugated 
antibody (Jackson). Islets and islet sections were embedded in Vectashield mounting 
medium. Fluorescence was analyzed using a Nikon MEA53200 (Nikon GmbH, Dusseldorf, 
Germany) microscope and images were acquired using NIS-Elements software (Nikon). 
Glucose stimulated insulin secretion (GSIS). Islets used to perform glucose-stimulated 
insulin secretion experiments were kept in culture medium on matrix-coated dishes. For 
each independent experiment, 20 islets were plated and exposed to the treatment 
conditions as indicated above. For acute insulin release, islets were washed and pre-
incubated (30 min) in Krebs-Ringer bicarbonate buffer (KRB) containing 2.8 mM glucose. 
The KRB was then replaced by KRB containing 2.8 mM glucose for 1 h (basal), followed 
by an additional 1 h incubation in KRB containing 16.7 mM glucose (stimulated). Islets 
were lysed in lysis buffer and whole islet protein measured by bicinchoninic acid (BCA) 
protein assay (Pierce, Rockford, IL/Thermo Scientific). Insulin was determined using a 
human insulin ELISA kit (Alpco, Windham, NH) and normalized to whole islet cell lysate 
protein content. 
Determination of nitrotyrosine. Nitrotyrosine concentration in human islets after the 4-
day culture period was determined in islet cell lysates by an adapted ELISA method as 
previously described [29,30]. At the end of the incubations, islets (a total of 30 
islets/condition) were washed in PBS, suspended, and lysed for 40 min on ice in lysis 
buffer (20 mM Tris acetate, pH 7.0, 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 50 mM 
NaF, 1 % Triton X- 100, 5 mM sodium pyrophosphate, 10 mM β-glycerophosphate (all 
Sigma Aldrich) containing 1x protease and phosphate inhibitors cocktail (Thermo 
Scientific, Rockford, IL USA). Protein concentrations of islet cell lysates were determined 
by BCA protein assay, and whole-cell lysates were stored at -80°C until assayed.  The 
standard curve samples were prepared by dissolving 1mg/ml BSA (Sigma) in 50 mmol/L 
KH2PO4. After addition of 1 mmol/L tetranitromethan (TNM), the dilution was incubated for 
30 min at 37°C and adjusted to pH10 and the amount of nitrotyrosine present was 
measured at 430 nm and moles nitrotyrosine for each mole protein was calculated directly 
using the Beer–Lambert law, ε=4300 M1cm-1 [31]. Standards of 0.05–0.6 pmol/µL were 
prepared. Maxisorp ELISA plate (BD Falcon#353279) was coated with standards and 
samples in coating buffer (50 mmol/l Na2CO-NaHCO3 buffer at pH 9.6) overnight at 4°C, 
washed 6 times with 0.05% Tween20 in PBS and incubated with IgG monoclonal anti-
nitrotyrosin (Upstate Biotechnology, Lake Placid, NY/ Millipore) for 2h RT, washed and 
incubated for 45 min at 37°C with HPR conjugated goat anti-mouse (Zymed) and washed 
again. For the peroxidase reaction, 100µl tetramethyl-benzidine microwell peroxidase 
substrate (TBM; Sigma) was added for 10 min at RT and the reaction was stopped by 
adding 50 µl stop solution (BD Opty Kit B/ 0.5 M H2SO4) and read at 492 nm on a 
microplate reader. Concentration of nitrotyrosine was normalized to whole protein content 
of islet lysates. 
Determination of cytokines, GLP-1 and DPP-4. After the 4-day culture period, human 
islet supernatants were measured for cytokine release using the Human ProInflammatory 
Tissue Culture Kit, (Mesoscale discovery, Gaithersburg, ML). Total and active human 
GLP-1 was detected by the same assay platform (Mesoscale). 
DPP-4 activity was detected using H-Ala-Pro-7-amido-4-trifluoromethylcoumarin (Ala-Pro-
AFC; purchased from Bachem) in a 200 mM stock solution in dimethylformamide which 
was diluted 1000-fold with water before the assay. The assay itself was performed in 
black flat-bottom 96-well plates by mixing 50 µl of the diluted substrate (final 
concentration in the assay 100 µM), 25 µl of supernatant and 25 µl of assay buffer (100 
mM Tris-HCl, 100 mM NaCl, pH 7.8). The plate was then incubated at room temperature 
for 1 h and fluorescence was measured at excitation/emission wavelengths of 405/535 
nm. For standards, 20 µl of appropriate compound dilutions were prepared in assay buffer 
(compound stock solutions in dimethylsulfoxide (DMSO) final concentration in the assay 
1%). 
RNA extraction and RT-PCR analysis. Total RNA was isolated from cultured human 
islets by the Trizol method (peqGOLD TriFast, PeQLab, Erlangen, Germany). For 
quantitative analysis, we used the Applied Biosystems StepOne Real-Time PCR system 
(Applied Biosystems, CA, USA) with a commercial kit (Power SYBR Green PCR Master 
Mix or TaqMan(R) Fast Universal PCR Master Mix for TaqMan assays; Applied 
Biosystems). Primers used were 5'-ggctggtcatatggagggta-3’/5’-cagggctttggagatctgag-3’  
(DPP-4), 5'-agagccaacgtcaagcatct-3’/5’-ctttagcttcgggtcaatgc-3’  (SDF1a), 5'-
tccccaactcctgagttcac-3’/5’-acatcctcgacggcatctcag-3’  (IL-6), 5'tcctcctcggcttcagacac-3’/5’-
gtaattggccgccacacagt (GLP-1R) 5'-gttggccaggctggtgtccag-3’/5’-ctgtgatgagctgctcagggtgg-3 
(tubulin), 5’-ccaaccgcgagaagatga-3’/5’-ccagaggcgtacagggatag-3’ (actin) 
5’tacgggtcctggcatcttgt3’/5’ccatttgtgttgggtccagc3’ (cyclophilin), 5’aaacggctaccacatccaag3’/ 
5’cctccaatggatcctcgtta3’ (18S). TaqMan(R) Gene Expression Assays (Applied 
Biosystems) were used for IL-1β, IL-8, cyclophylin and tubulin. 
Statistical analysis. Immunostainings were evaluated in a randomized manner by two 
investigators (P.S., S.L.) who were blinded to the treatment conditions Data are presented 
as means +/-SEM and were analyzed by paired Student’s t test or by analysis of variance 
with a Bonferroni correction for multiple group comparisons. 
 
Results 
Linagliptin, Sitagliptin and IL-1Ra improve β-cell survival 
Loss of β-cells by apoptosis and decreased β-cell mass have been recognized as major 
pathological factors for the progression of diabetes. We tested the hypothesis whether 
linagliptin can protect β-cells from damage induced by diabetogenic conditions. Isolated 
human pancreatic islets were exposed for 4 days to increasing glucose concentrations 
(5.5, 11.1, 33.3 mM), 0.5 mM palmitate, the mixture of cytokines (2 ng/ml IL-1β+1,000 
U/ml IFN-γ) or to 50 µM H2O2, for 8h, conditions which caused β-cell apoptosis and almost 
complete loss of proliferation. Islets were co-cultured with 500 ng/ml IL-1Ra, which has 
been shown to improve β-cell survival [22] or with 50 nM linagliptin, which was added 1h 
before the diabetogenic conditions and maintained throughout the 4-d culture. At basal 
culture conditions of 5.5 mM glucose for 4 days, 10-1000 nM linagliptin had no influence 
on β-cell turnover (data not shown). Elevated glucose concentrations, free fatty acids, 
cytokines and oxidative stress induced β-cell apoptosis in isolated human islets, 
compared to control (2.5-, 3.6-, 3-1-, 3.7- and 4.5-fold induction by 11.1 and 33.3 mM 
glucose and by 0.5 mM palmitate, IL-1β+IFNγ and H2O2, respectively, p<0.001, Fig.1A) in 
isolated human islets, compared to control incubations. This was reversed by co-culture 
with IL-1Ra as well as with linagliptin.  IL-1Ra reduced apoptosis 2.5, 2.0-, 2.1- and 3.0-
fold in 11.1 mM and 33.3 mM glucose, palmitate and IL-1β+IFNγ, respectively (p<0.01), 
but in H2O2, only a tendency but no significant protective effect was observed (Fig.1A). 50 
nM linagliptin reduced apoptosis 2.3-, 3.8-, 2.0-, 2.5- and 2.1-fold in all diabetogenic 
conditions (p<0.01, Fig.1A). 
Human islets on the ECM-coated dishes had a very limited capacity to proliferate in 
culture (0.4±0.1% Ki67/insulin double positive cells at 5.5 mM glucose basal condition). A 
diabetic milieu even further reduced this proliferative capacity (2.2-, 2.8-, 2.3-, 1.7- and 
1.9-fold reduction by 11.1 and 33.3 mM glucose and by 0.5 mM palmitate, IL-1β+IFNγ 
when incubated for 4 days, and H2O2 when incubated for 8 hours, respectively, compared 
to control, p<0.01, Fig.1B). In contrast, IL-1Ra and linagliptin restored proliferation (4.3-, 
5.8-, 4.0- and 3.1-fold induction by IL-1Ra and 4.8-, 6.8-, 4.4-, 2.1- and 4.1-fold by 
linagliptin in 11.1 and 33.3 mM glucose, in 0.5 mM palmitate, IL-1β+IFNγ and H2O2, 
respectively, compared to vehicle, p<0.01, Fig.1B). IL-1Ra had no protective effect on β-
cell proliferation under H2O2 exposure. This was also confirmed in mouse islets which 
were exposed for 8h to 50 µM H2O2 with or without 500 ng/ml IL-1Ra. Apoptosis was 3.6-
fold induced by H2O2, while IL-1Ra failed to show any protective effect (data not shown). 
To exclude a matrix-dependent effect, we cultured isolated human islets in suspension 
culture dishes, exposed them for 3 days or 8h (H2O2) to the above described 
diabetogenic milieu and analyzed β-cell apoptosis in bouin fixed paraffin embedded islet 
sections. A similar induction of β-cell apoptosis was observed by all diabetogenic culture 
conditions, linagliptin significantly reduced β-cell apoptosis (1.9-, 2.0-, 2.3-, 1.5 and 1.2-
fold in 11.1 and 33.3 mM glucose, 0.5 mM palmitate, IL-1β+IFNγ and H2O2, compared to 
vehicle, p<0.01; Fig.1C,D). Sitagliptin, another DPP-4 inhibitor tested in the same 
experiments had similar protective effects (Fig.1D; 1.4-, 1.9-, 4.7-, 2.5-, and 1.3-fold 
reduction of β-cell apoptosis in 11.1 and 33.3 mM glucose, 0.5 mM palmitate, IL-1β+IFNγ 
and H2O2, p<0.01).  
Linagliptin improves β-cell function and inhibits oxidative stress  
In addition to its protective effect on β-cell survival, linagliptin improved glucose stimulated 
insulin secretion (GSIS) in islets after long-term culture of 4 days. In control conditions, 
there was a 4-fold stimulatory index when glucose was increased from 2.8 mM to 16.7 
mM glucose. All diabetogenic culture conditions significantly reduced GSIS (p<0.01; 
Fig.2A,D). At basal glucose, neither linagliptin (Fig.2B,D) nor IL-1Ra (Fig.2C,D) increased 
the stimulatory index, but under the diabetogenic conditions GSIS was highly improved 
(1.9-, 2.5-, 2.1-, 2.4- and 2.5-fold by linagliptin, p<0.05, Fig.2C,D and 1.2-, 1.4-, 1.9-, 2.3-, 
and 1.8-fold by IL-1Ra, Fig.2B,D). 
To investigate the underlying mechanisms of the protective effect of the DPP-4 inhibitor, 
we hypothesized that changes in nitrotyrosine, a marker for oxidative stress, may occur 
during the long-term exposure with diabetogenic conditions. Nitrotyrosine production in 
islets during the 4-day culture period was measured and normalized to whole protein 
content of the islet lysate. Nitrotyrosine content was increased by glucose-, palmitate-, 
cytokine- and H2O2 exposure (p<0.05; Fig.2E), with the highest stimulation induced by 
33.3 mM glucose, the cytokine mixture and H2O2. Both IL-1Ra and linagliptin decreased 
nitrotyrosine under glucose, palmitate and cytokine treatment (p<0.05), but not under 
conditions of H2O2 (Fig.2E). 
Linagliptin stabilizes GLP-1 in the supernatants of human islet cells 
Since the main effect of DPP-4 is to stabilize GLP-1, we next investigated whether total 
and active GLP-1 levels in the culture medium were increased by linagliptin treatment. 
Diabetogenic conditions (increasing glucose concentrations and cytokines) induced 
accumulation of total GLP-1 (Fig.3A) in the islet supernatants, and linagliptin (30 nM) pre-
treatment resulted in approximately 2-fold higher total GLP-1 (Fig.3A) and approximately 
3-fold higher active GLP-1 (Fig.3B) in all conditions. Levels of total and active GLP-1 were 
unchanged by IL-1Ra (data not shown). 
Next, the effect of linagliptin on the stabilization of an exogenously added GLP-1 
concentration was investigated. 1h after linagliptin treatment (30 nM), 0.5 nM GLP-1 (a 
concentration similar to the secreted total GLP-1 from islets treated with Linagliptin) was 
added to the islet culture medium and immediately measured. Rapid degradation of GLP-
1 was observed during culture (Fig.3C,D), while addition of linagliptin inhibited such 
degradation of GLP-1. Total (Fig.3C) and active GLP-1 (Fig.3D) accumulated during 
culture in the linagliptin treated islet supernatants, which did not occur in the non-treated 
islets. 
GLP-1 stabilization was accompanied by restored GLP-1 receptor levels. In confirmation 
with earlier studies [32,33], GLP-1 receptor levels were decreased in response to 
glucotoxicity and cytokine exposure, compared to untreated control. In contrast, 30 nM 
linagliptin increased GLP-1 receptor levels in all diabetogenic (Fig.3E). To further prove 
whether the effect of linagliptin is GLP-1 dependent, we co-cultured linagliptin with 
Exendin-(9-39), an established inverse agonist of the GLP-1 receptor [34,35]. While 30 
nM linagliptin was effective in improving glucose stimulated insulin secretion under 
cytokine exposure, the addition of 100 nM Exendin-(9-39) inhibited the linagliptin effect 
(Fig.3F). To prove that linagliptin was active, we also measured DPP-4 activity in the islet 
cell supernatants. As expected, linagliptin inhibited DPP-4 activity in culture (Fig.3G). The 
potential GLP-1-SDF-1α synergism strongly promotes β-cell survival [19]. Since SDF-1α 
is another substrate of DPP-4 [36] and an important pro-survival factor for β-cells [37], we 
tested whether increases in GLP-1 concentration and reduction in DPP-4 activity by 
linagliptin are also paralleled with SDF1α mRNA production. Linagliptin strongly 
increased SDF1α under basal as well as under diabetogenic conditions (p<0.05, Fig.3H), 
while glucose and palmitate themselves or IL-1Ra treatment of the islets had no effect on 
SDF-1α (Fig.3H). 
  
Linagliptin inhibits cytokine secretion and production from islets under 
diabetogenic conditions 
Since pro-inflammatory cytokines and chemokines are elevated under a diabetogenic 
milieu, we tested whether IL-1Ra and linagliptin exert their protective effects through an 
inhibition of cytokine secretion. Cytokine and chemokine secretion into the culture 
medium was measured simultaneously by the MSD© technique and mRNA production by 
RT-PCR. The diabetogenic milieu which included elevated glucose concentrations and 
palmitate significantly increased IL-1β secretion (Fig.4A) and production (Fig.4B), while 
IL-6 and IL-8 were increased by the cytokine mixture IL-1β and IFNγ, but no significant 
effect was observed in the other diabetogenic conditions.  While IL-1Ra and linagliptin 
had no effect on the minimal basal IL-1β secretion and production during the 4-day culture 
period, they significantly decreased both IL-1β secretion and production (Fig.4A,B). 
Similarly, IL-6 and IL-8, which were elevated in response to IL-1β/IFNγ were decreased by 
IL-1Ra and linagliptin (Fig.4C-F).  
 
Discussion 
Orally administered DPP-4 inhibitors prevent the rapid cleavage of GLP-1, and thus 
increase levels of active GLP-1, resulting in increased insulin and reduced glucagon 
secretion, lowered glucose and reduced HbA1c levels by 0.5–1.0% [2]. Linagliptin 
improves glycemic control both as monotherapy [38] and in combination therapy, e.g. with 
metformin [39] or pioglitazone [40] and also improves insulin sensitivity [40]. DPP-4 
inhibitors mimic many of the actions ascribed to GLP-1 in rodents including preservation 
of β-cell mass through stimulation of cell proliferation and inhibition of apoptosis in 
rodents [15,16,17]. 
Besides GIP and GLP-1, many gastrointestinal hormones, neuropeptides, cytokines, and 
chemokines are substrates for DPP-4 [18], including CXCL10 and SDF1α, both of which 
have been associated with the regulation of β-cell turnover in diabetes. Since cytokines 
and chemokines are crucial for the survival of pancreatic β-cells [41], it remained to be 
investigated whether DPP-4 inhibitors in culture directly affect β-cell survival and function. 
In the present study, we clearly observed a protective effect of the DPP-4 inhibitor 
linagliptin on β-cell survival and function. At lower doses of 30-50 nM, which is 
comparable to plasma concentrations, a cmax of up to 30 nM [42] is reached with the 
therapeutic linagliptin doses and up to a concentration of 1 µM, which is 1000-fold the 
IC50 of the human enzyme and 50-fold the maximal concentration reached in serum after 
treatment of patients with the 5 mg dose, linagliptin did not affect β-cell survival at basal 
conditions in culture. It effectively restored proliferation, survival and β-cell function in a 
diabetic milieu. Linagliptin has a non-linear kinetic, which is dependent on DPP-4 and has 
not yet been tested in in vitro conditions.  
Human β-cells in culture have only a very limited if any [43] capacity to proliferate. Here 
we found 0.4% proliferating β-cells under basal conditions when islets were plated on 
extracellular matrix coated dishes, and proliferation was even further decreased by 
diabetogenic conditions of chronically elevated glucose, free fatty acids, cytokines or 
H2O2. Linagliptin improved cell survival by decreasing apoptosis, and maintained cells at 
a steady state level, even under diabetogenic conditions.  
The protective linagliptin effect seen in this study was mediated by stabilization of GLP-1 
in the islet supernatants, where total as well as active GLP-1 levels were restored and 
accumulated during islet culture, providing a similar mechanism of the protective effect of 
DPP-4 inhibition on β-cell survival as in vivo. 
Active GLP-1 can be produced from islets [44]. The α-cells, which express prohormone 
convertase PC1/3, that cleaves preproglucagon peptide to generate GLP-1, are an 
established islet source of such secreted GLP-1, and may provide a local protective 
paracrine effect for β-cell regeneration under diabetic conditions, especially during β-cell 
injury [19]. Also sorted human β-cells express PC1/3. But when GLP-1 content was 
measured in sorted human β-cells, it was under the detection limit and thus it was 
assumed that β-cells do not produce GLP-1 [45], although it was secreted from the rodent 
β-cell line INS-1E [46]. GLP-1 production from α-cells has been confirmed recently and is 
increased by IL-6, while IL-6 neutralization in rodent models of diabetes results in further 
hyperglycemia and reduces pancreatic GLP-1 [47]. High levels of active GLP-1 (~3 ng/ml 
from 50 islets over 4 days of culture) were secreted from human islets and accumulated 
only in presence of a DPP-4 inhibitor, while high DPP-4 activity could only be measured in 
the absence of linagliptin. 
GLP-1 is accumulated in the medium during the 4-day culture period and provides in turn 
a paracrine protective effect on the β-cell. Diabetogenic conditions, e.g. the cytokine 
cocktail IL-1β/IFNγ enhanced IL-6 production, which was counteracted by linagliptin, 
paralleled with increased GLP-1 in the medium. It can thus be hypothesized, that higher 
GLP-1 concentrations in the culture medium in turn inhibits elevations in IL-6.  
Hyperglycemia and a diabetic milieu decrease expression of β-cell GLP-1 receptors in 
vivo and in vitro [32,33,48]. Slightly reduced GLP-1 secretion after a meal in patients with 
impaired oral glucose tolerance and more severely impaired GLP-1 secretion in type 2 
diabetic patients was observed [49], although controversial results have been obtained in 
various studies [50]. Differences occur between tissue-specific GLP-1 levels and whether 
total or active GLP-1 was measured [51]. In islets, diabetogenic conditions significantly 
increased total GLP-1, which was also observed after-long term treatment of STZ rats 
[52]. 
Linagliptin strongly reduced DPP-4 activity in the human islet supernatant and stimulated 
GLP-1 stability. Active DPP-4 rapidly degrades SDF-1α(1-68) to inactive SDF-1α(3-68) 
[53] and thus, more active SDF1α is available upon DPP-4 inhibition. In turn SDF-1α acts 
like a cytokine and induces its own production [19]. This explains the increased SDF-
1α mRNA levels with linagliptin treatment, found in the present study. 
The regulation of DPP-4 in diabetes has not been fully clarified, both increased [54,55] 
and decreased [56] DPP-4 activity have been reported in patients with diabetes.  DPP-4 
release from adipose tissue is higher in obese individuals and correlates with parameters 
of the metabolic syndrome, where DPP-4 directly impairs insulin signaling in fat and 
muscle cells [57]. Elevated glucose exposure leads to enhanced DPP-4 activity and 
mRNA expression in endothelial cells [58]. Also in human islets, we detected elevated 
DPP-4 mRNA in response to elevated glucose and palmitate, while linagliptin inhibited an 
induction. One could speculate that in islets under diabetogenic conditions, there is more 
DPP-4 produced, which inactivates GLP-1 and thus it cannot fulfill its functions.  
Recent human studies investigating the long-term treatment with vildagliptin on β-cell 
function were somehow disappointing, because following wash out periods the observed 
β-cell sparing effects disappeared, thus questioning the disease modifying potential of this 
drug [6]. However, it remains to be elucidated whether this is caused by a limited tissue 
penetration in vivo or limited availability of the drugs in islets.  
In summary, we show that linagliptin has a protective effect on β-cell turnover and 
function, which is mediated through stabilized GLP-1 and an anti-inflammatory/anti-
oxidative stress pathway. 
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Figure legends 
Figure 1: DPP-4 inhibition improves β-cell survival 
Human pancreatic islets were cultured on extracellular matrix coated dishes (A,B) or in 
suspension (C,D) at 5.5 mM  (control), 11.1 or 33.3 mM glucose, 0.5 mM palmitate or 2 
ng/ml IL-1β/1000 IU IFN-γ for 96h (A,B) or 72h (C,D) or at 50 µM H2O2 for 8h (A-D) in  
absence (control) or presence of IL-1Ra (500 ng/ml) or linagliptin (50 nM). Apoptosis was 
analyzed either directly in the dishes (A) or in paraffin embedded islet sections (C,D: red 
nuclei) by the TUNEL assay. Proliferation was analyzed in the dishes (B) by the Ki67 
antibody. All specimens were double-stained in green for insulin and blue for nuclear Dapi 
staining. Results are means ±SEM of the TUNEL- or Ki67-positive β-cells, normalized to 
control conditions at 5.5 mM glucose (in absolute numbers: 0.4%TUNEL- and 0.37%Ki67-
positive β-cells at 5.5 mM glucose on the extracellular matrix and 1.0% TUNEL-positive β-
cells at 5.5 mM glucose in suspension culture). The average number of β-cells counted 
was 4175 for each treatment group from three different experiments from three different 
organ donors. C shows representative staining pictures (x200 magnification+TUNEL 
positive inserts 600x). *p<0.05 compared to vehicle treated control at 5.5 mM glucose, 
**p<0.05 compared to vehicle under the same treatment condition. 
 
Figure 2: Linagliptin improves β-cell function and inhibits oxidative stress 
Human pancreatic islets were cultured on extracellular matrix coated dishes at 5.5 mM  
(control), 11.1 or 33.3 mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1β/1000 IU IFN-γ for 
96h or at 50 µM H2O2 for 8h in the absence (control; A,D) or presence of IL-1Ra (500 
ng/ml; B,D) or linagliptin (50 nM; C,D). Basal and stimulated insulin secretion indicates 
the amount secreted during 1h incubations at 2.8 (basal) and 16.7 mM (stimulated) 
glucose following the culture period and normalized to protein content (A-C), stimulatory 
index was calculated as stimulated/basal insulin secretion (D). Nitrotyrosine content (E) in 
the islet lysates was normalized to whole islet protein content. Results are means ±SEM 
from triplicates from three independent experiments from three donors, *p<0.05 
compared to vehicle treated control at 5.5 mM glucose, **p<0.05 compared to vehicle 
under the same treatment condition. 
 
Figure 3: Linagliptin stabilizes GLP-1 in the supernatants of human islet cells 
Human pancreatic islets were cultured on extracellular matrix coated dishes at 5.5 mM  
glucose (control) or 11.1 and 33.3 mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1β/1000 
IU IFN-γ for 96h in the absence (control) or presence of linagliptin (50 nM, A,B) or 0.5 nM 
GLP-1 (C,D). Total (A,C) and active (B,D) GLP-1 secretion was measured in the 
supernatants during the 4-day culture period. mRNA was isolated from treated islets after 
4 days and RT-PCR analysis of GLP-1 receptor levels (E) was performed. The levels of 
gene expression were normalized to tubulin and 18S and presented as change of 5.5 mM 
glucose control.  
Human pancreatic islets were cultured at 5.5 mM (control) glucose or 2 ng/ml IL-1β/1000 
IU IFN-γ for 96h in presence of 30 nM linagliptin and an inverse agonist of the GLP-1 
receptor Exendin-(9-39) (100 nM, F). Insulin stimulatory index as the ratio of the 
stimulated and basal insulin secretion was calculated.  
(G) DPP-4 activity was measured at control conditions and with 30 and 100 nM linagliptin 
during culture. (H) mRNA was isolated from treated islets after 4 days of culture and RT-
PCR analysis of SDF-1α performed. The levels of gene expression were normalized to 
tubulin and cyclophilin (with similar results) and presented as change of control. Results 
are means ±SEM from triplicates from three independent experiments from three donors, 
except for (E): data are from one single donor and (F): from 2 donors, *p<0.05 compared 
to vehicle treated control at 5.5 mM glucose. 
 
Figure 4: Linagliptin inhibits cytokine secretion from islets under diabetogenic 
conditions 
Human pancreatic islets were cultured on extracellular matrix coated dishes at 5.5 mM  
(control), 11.1 or 33.3 mM glucose, 0.5 mM palmitate or 2 ng/ml IL-1β/1000 IU IFN-γ for 
96h in the absence (control) or presence of IL-1Ra (500 ng/ml) or linagliptin (50 nM). 
(B,D,F) mRNA was isolated from treated islets after 4 days and RT-PCR analyses of IL-
1β (B), IL-6 (D) and IL-8 (F) were performed. The levels of gene expression were 
normalized to tubulin and cyclophilin (with similar results) and presented as change of 
control. Cytokine and chemokine secretion of IL-1β (A), IL-6 (C), IL-8 (E) from the culture 
medium of the same islets were analyzed in a multiplex assay (Mesoscale Discovery©). 
Results are means ±SEM from three independent experiments from three donors, 
*p<0.05 compared to vehicle treated control at 5.5 mM glucose, **p<0.05 compared to 
vehicle under the same treatment condition. 
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Abstract
Background: Apoptosis is a hallmark of b-cell death in both type 1 and type 2 diabetes mellitus. Understanding how
apoptosis contributes to b-cell turnover may lead to strategies to prevent progression of diabetes. A key mediator of
apoptosis, mitochondrial function, and cell survival is apoptosis inducing factor (AIF). In the present study, we investigated
the role of AIF on b-cell mass and survival using the Harlequin (Hq) mutant mice, which are hypomorphic for AIF.
Methodology/Principal Findings: Immunohistochemical evaluation of pancreata from Hq mutant mice displayed much
smaller islets compared to wild-type mice (WT). Analysis of b-cell mass in these mice revealed a greater than 4-fold
reduction in b-cell mass together with an 8-fold increase in b-cell apoptosis. Analysis of cell cycle dynamics, using BrdU
pulse as a marker for cells in S-phase, did not detect significant differences in the frequency of b-cells in S-phase. In contrast,
double staining for phosphorylated Histone H3 and insulin showed a 3-fold increase in b-cells in the G2 phase in Hq mutant
mice, but no differences in M-phase compared to WT mice. This suggests that the b-cells from Hq mutant mice are arrested
in the G2 phase and are unlikely to complete the cell cycle. b-cells from Hq mutant mice display increased sensitivity to
hydrogen peroxide-induced apoptosis, which was confirmed in human islets in which AIF was depleted by siRNA. AIF
deficiency had no effect on glucose stimulated insulin secretion, but the impaired effect of hydrogen peroxide on b-cell
function was potentiated.
Conclusions/Significance: Our results indicate that AIF is essential for maintaining b-cell mass and for oxidative stress
response. A decrease in the oxidative phosphorylation capacity may counteract the development of diabetes, despite its
deleterious effects on b-cell survival.
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Introduction
Apoptosis of the insulin producing b-cells and the decline in b-
cell mass is a major mechanism of the progression of diabetes [1].
In addition, the rapid loss of b-cell function and the relative
discrepancy between insulin demand and insulin secretion worsen
the ability of the organism to maintain normoglycemia.
Important metabolites that regulate insulin secretion are
generated in the mitochondria [2,3]. The b-cell mitochondria
are key regulators of glucose stimulated insulin secretion, and
several mitochondrial pathways are disabled in type 2 diabetes
(T2DM), e.g. the glucose induced hyperpolarization of the
mitochondrial membrane and the raise in the ATP/ADP ratio
at high glucose. Diabetic islets also have increased UCP-2
expression, which uncouples mitochondrial oxidative phosphory-
lation, such that energy is wasted through heat, and cellular ATP
synthesis is decreased, probably through an increased formation of
reactive oxygen species (ROS) [4].
Besides regulating factors of insulin secretion, mitochondria play
a prominent role in apoptosis. In b-cells, elevated free fatty acids
and production of ROS have been shown to induce apoptosis
through the release of cytochrome c from the inner mitochondrial
membrane to the cytosol, which triggers caspase activation [5,6].
Mitochondria are the principal source of ROS in the b-cell [7],
which accumulates when the respiratory chain function is
defective. The low expression of an antioxidant enzyme defense
system makes the b-cells particularly susceptible to an oxidative
insult [8].
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The apoptosis-inducing factor (AIF) is a mitochondrial inter-
membrane protein, which translocates to the cytoplasm and
nucleus during apoptosis [9], where it binds to DNA triggering
DNA fragmentation and nuclear condensation [9,10]. In contrast
to cytochrome c, AIF induces apoptosis in a caspase-independent
fashion [11]. AIF is essential for mammalian development,
knocking out AIF in the mouse is lethal before birth [12].
Therefore, the role of AIF as a death executor or as an oxidative
stress scavenger is controversial. Evidence that AIF serves as free
radical scavenger to prevent apoptosis came from studies on the
Harlequin (Hq) mutant mouse. These mice have an 80% reduction
in AIF protein due to a proviral insertion in the first intron of the
AIF gene. They exhibit a reduced oxidative phosphorylation
(OxPHOS) in the retina and in the brain, which entails increased
oxidative stress and neuronal cell death through unscheduled cell
cycle reentry [13].
Defects in OxPHOS and mitochondrial energy metabolism
have been implicated in human diseases, including insulin
resistance [14,15] and diabetes mellitus [16], neurodegenerative
disorders such as Alzheimer’s disease, Parkinson’s disease, as well
as aging [17,18]. Given the different roles of AIF in maintaining a
functional respiratory chain, protecting cells from oxidative stress,
but also contributing to stress- induced cell-death and that
important mitochondrial pathways control b-cell pathophysiology,
we asked the question what role does AIF play in the regulation of
b-cell survival, mass and insulin secretion?
Materials and Methods
Animal breeding and genotyping
Harlequin (Hq) arose on a CF1 outbred stock and was
transferred to a BGCBACa-Aw-J/A (B6CBA) background. The
Hq mice were obtained from Jackson Laboratory (Bar Harbor,
ME). For controls, WT littermates which do not have the Hq
mutation (+/Y) were used. Animals were housed at 22uC with a
12-h light-dark cycle (lights on at 07:00) and allowed free access to
water and chow according to the protocol approved by the UCLA
Chancellor’s Animal Research Committee in agreement to NIH
animal care guidelines.
Islet isolation and culture
Human islets from six different donors were obtained from the
Islet cell resource center (ICR-ABCC) or the European Consor-
tium for Islet Transplantation (ECIT). Mouse islets were isolated
by bile duct perfusion and collagenase digestion as described
before [5]. The islets were cultured in suspension culture dishes.
Human islets were cultured in CMRL 1066 medium containing
5.5 mM glucose and mouse islets in RPMI 1640 medium
containing 11.1 mM glucose, both supplemented with 100 U/ml
penicillin, 100 mg/ml streptomycin and 10% FCS (Invitrogen
Ltd., Carlsbad, CA), hereafter referred to as culture medium. Islets
were pre-cultured for 48 h after the isolation before the
experiment, in some experiments, islets were transfected with
siRNA and/or treated with 50 mM H2O2 (Sigma) for 2 h.
b-cell mass analysis and immunohistochemistry
At the age of 2 and 9 weeks of age, mice were sacrificed and
pancreata dissected, weighed and fixed in formalin followed by
paraffin embedding, orienting pancreata such that sections were
cut along the head-tail axis. Sections for b-cell mass were at least
50 microns apart. Five representative sections from each pancreas
(spanning the width of the pancreas) were used in the analysis of b-
cell mass. Pancreatic and islet sections were deparaffinized in
toluene, rehydrated in grades of alcohol and washed in H2O.
Slides were exposed to antigen-retrieval using antigen unmasking
buffer according to the manufacturer’s instructions (Vector
Laboratories, Inc. Burlingame, CA). After antigen unmasking,
the sections were cooled to room temperature, permabilized in
0.4% Triton X-100/TBS for 30 min, and blocked with 0.2%
Tween 20/3% IgG-free BSA/2% Triton X-100/TBS. Primary
antibodies were diluted at the following dilutions: guinea pig anti-
insulin 1:50 (Dako, Carpinteria, CA), mouse anti-glucagon 1:1000
(Sigma-Aldrich, St. Louis, MO), rabbit anti-phosphohistone H3
1:200 (Upstate, Charlottesville, VA) followed by detection with
donkey-and goat-derived secondary antibodies conjugated to
FITC and Cy3 (Jackson ImmunoResearch Laboratories, West
Grove, PA). A montage of the whole pancreatic section was
created using OpenlabTM and ImageJ software (Improvisison,
MA) on a Leica DM6000. The relative area of b-cells (green
fluorescence) was determined by quantification of the cross-
sectional b-cell area divided by the cross-sectional area of total
tissue. b-cell mass per pancreas was estimated as the product of the
relative cross-sectional area of b-cells per total tissue and the
weight of the pancreas.
To obtain sections from isolated islets, islets were washed with
PBS, fixed in Bouin’s solution for 15 min. and resuspended in 2%
melted agarose in PBS, followed by short centrifugation and
paraffin embedding. 4 mM islet sections were cut and re-hydrated.
For detection of b-cell apoptosis, sections were incubated with
20 mg/ml proteinase K (Roche Diagnostics, Indianapolis, IN) for
12 min at 37uC and blocked with 0.2% Tween 20/3% IgG-free
BSA/2% Triton X-100/TBS. Apoptosis was analyzed by the
terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) technique according to the manufacturer’s
instructions (In Situ Cell Death Detection Kit, TMR red; Roche).
Then, sections were double-stained for insulin as described above.
Intra-peritoneal glucose tolerance test (IPGTT)
Mice were fasted for 16 h, baseline blood glucose levels were
measured in tail-vein blood from mice using a Glucometer
(Freestyle, TheraSense Inc, Alameda, CA). Glucose (2 mg/g body
weight) was injected intraperitoneally and blood glucose was
measured 15, 30, 60, and 120 min after injection.
b-cell proliferation
5-bromo-2-deoxyuridine (BrdU) incorporation: BrdU was inject-
ed intraperitoneally (0.025 mg/g body weight) 2 h before harvest-
ing the pancreata. Pancreata were isolated and processed for
histology as described above. Mouse anti-BrdU antibody/nuclease
solution (Amersham/Pharmacia) was applied for 1 h at RT and
double staining for insulin was performed as described above.
RNA extraction and quantitative RT-PCR analysis
Isolated islets were washed in cold PBS and homogenized in Tri
Reagent (Molecular Research Center Inc.), and the total RNA was
prepared according to the manufacturer’s methods. For quantitative
analysis, we used the LightCycler Quantitative PCR System
(Roche) with a commercial kit (LightCycler FastStart DNA Master
plus SYBR Green I, Roche). Primers used were: 59-AGTGGAA-
GACTGGCTGGAGA-39 and 59-TCACTCTCCGAACGGA-
TACC-39 (mouse AIF); 59-GTTGGCCAGGCTGGTGTCCAG-
39 and 59-CTGTGATGAGCTGCTCAGGGTGG-39 (tubulin).
RNA interference
A knock down of AIF mRNA and protein levels was carried out
using the small interfering RNA (siRNA) technique. The siRNA
duplex was designed against the following target sequence:
AIF in b-Cells
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GCAACCTAGTGTACTTCTT synthesized by Dharmacon.
The negative scramble siRNA #1 (Ambion, Austin, TX) was
used as control. Transfection of cultured human islets with siAIF
and control siRNA was performed by Lipofectamine2000
(Invitrogen) according to the manufacturer’s instructions. Cell
lysates were collected 72 h after transfection.
Western blot analysis
Islets were washed in PBS and lysed for 40 min on ice in 40 ml
lysis buffer containing 20 mM Tris acetate, 0.27 M sucrose, 1 mM
EDTA, 1 mM EGTA, 50 mM NaF, 1% Triton X-100, 5 mM
sodium pyrophosphate and 10 mM b-glycerophosphate. Prior to
use, the lysis buffer was supplemented with Protease- and
Phosphatase-inhibitors (Pierce, Rockford, IL). Equal amounts of
protein of each treatment group were run on NuPAGE 4–12%
Bis-Tris gels. After transfer onto PVDF filters, nonspecific binding
sites were blocked for 1 h using 5% nonfat dry milk and 0.05%
Tween 20 in Tris-buffered saline and incubated with rabbit anti-
AIF 1:1000 (Chemicon International, Temecula, CA) followed by
horseradish-peroxidase-linked anti-rabbit IgG peroxidase. The
emitted light was captured on X-ray film after adding Immobilon
Western chemiluminescent HRP substrate (Millipore, Billerica,
MA). To verify that equal amounts of protein were loaded,
membranes were stripped and re-probed with rabbit anti-b-actin
(Cell signaling, Beverly, MA).
Glucose stimulated insulin secretion (GSIS)
After treatment, islets were washed and pre-incubated (30 min)
in Kreb’s Ringer bicarbonate buffer (KRB) containing 2.8 mM
glucose and 0.5% BSA. KRB was then replaced by KRB 2.8 mM
glucose for 1 h (basal), followed by an additional 1 h in KRB
16.7 mM glucose (stimulated). Islets were extracted with 0.18 N
HCl in 70% ethanol for determination of insulin content. Islet
insulin was determined using mouse insulin ELISA (ALPCO,
Salem, NH).
Statistical analysis
All data were expressed as means+/2SE. The statistical
significance of differences was measured by Student’s t test.
Results
AIF depletion decreases b-cell mass
To understand if AIF plays a role in the regulation of survival in
b-cells, we analyzed both mRNA and protein expression of AIF in
isolated mouse and human pancreatic islets. RT-PCR analysis
showed the mRNA transcript of AIF in both human and mouse
islets. Western blot analysis confirmed the expression of AIF
protein in isolated human and mouse islets (Fig. 1A). To elucidate
if AIF played a role in the establishment of the endocrine pancreas,
we compared the islet cellular composition of WT mice and Hq
mutant mice, a hypomorphic AIF mouse model in which the
expression of AIF is reduced to 10–20% of wild type littermates.
This depletion of AIF was confirmed in isolated islets by RT-PCR
and Western Blot analysis (Fig. 1A). Immunohistochemical
evaluation of pancreata revealed normal islet morphology in the
Hq mutant mice (Fig. 1B). Islet b-cell mass was 2.7-fold reduced in
2-week (p,0.001) and 4.6-fold in 9-week-old (p,0.01) Hq mutant
mice, respectively compared to their WT littermates (Fig. 1C).
The average weight of a Hq pancreas was 53% of WT littermate
pancreas at the age of 2 weeks and 60% at the age of 9 weeks
(p,0.01). Normalization of the b-cell mass to whole body mass still
resulted in a 39% and 68% decrease in the Hq mice at the age of 2
and 9 weeks, respectively. (Fig. 1D).
Possible reasons for the decreased b-cell mass could be
increased b-cell apoptosis and/or reduced proliferation. Previous
studies show that neurons from Hq mutant mice display an
increased propensity to re-enter the cell cycle, which results in
aberrant apoptotic destruction of the neurons [13]. To determine
if cell cycle dynamics were misregulated in the Hq b-cells, we
analyzed the incorporation/expression of cell cycle markers of b-
cells in Hq mutant mice. A BrdU pulse was administered to 4 week
old Hq and WT littermates 2 h before sacrifice to mark cells that
were currently in S-phase. BrdU+insulin+ double-positive cells
were counted as b-cells in S phase. Immunohistochemistry for
phosphorylated Histone H3 (pHH3) staining allows one to
discriminate cells in G2 or M phases of cell cycle [19,20].
pHH3+insulin+ (with punctuated pattern) cells were counted as b-
cells at G2 phase. pHH3+insulin+ (with a homogeneously
condensed pattern of strong nuclear expression) cells were counted
as b-cells at M phase (Fig. 1F). Analysis of BrdU incorporation did
not reveal any significant difference in proliferating cells between
WT and Hq mutant mice (Fig. 1E). However, pHH3 staining
showed a 3-fold increase in b-cells in the G2 phase in Hq mutant
mice but no differences in M-phase (Fig. 1E, p,0.05), an example
of such punctuated staining pattern in the Hq mice is shown in
Fig. 1F. This suggests that b-cells from Hq mutant mice either stop
or prolong the G2 phase and some do not further re-enter the cell
cycle. Previous studies show that such cells are highly prone to
apoptosis [21,22]. To test this possibility, we analyzed b-cell
apoptosis in pancreatic sections from WT and Hq mutant mice at
different ages. b-cell apoptosis in Hq mutant mice was increased at
all ages compared to WT (Neonates P0: 0.4% in Hq mutant mice
versus 0.2% in WT. No apoptosis was observed in the islets from
WT mice at all further ages analyzed but the number of apoptotic
b-cell in the Hq mutant mice were at P7: 0.3%, P14: 0.1%, 4-
weeks-old: 0.2% and 9-weeks-old: 0.2%.)
AIF depletion in mice leads to increased b-cell apoptosis
Based on our in vivo results, we studied b-cell apoptosis from
isolated islets in order to further investigate the nature of the b-cell
loss in Hq mutant mice. Neurons [13] as well as cardiomycytes
[23] from Hq mutant mice are highly susceptible to cell death
induced by oxidative stress. Isolated mouse islets from mutant and
WT animals were treated with 50 mM H2O2 for 2 h and b-cell
apoptosis was analyzed by double staining for TUNEL and
Figure 1. Decreased b-cell mass in Hqmutant mice. (A). Representative Western blots (panel 1,3) and PCR analyzes (panel 2,4) of AIF expression
in isolated mouse (panel 1,2) and human (panel 3,4) islets. Actin was used as loading control/ house keeping gene. Western blots/ PCRs are
representatives of three independent experiments from three mice or from 3 organ donors, respectively. (B) Histological analysis by insulin staining
in green and glucagon staining in red show a normal islet cellular composition and smaller islets in 2-week-old Hq mutant mice. (C,D) Analysis of b-
cell mass (C) or b-cell mass divided by body weight (D) of WT and Hq mutant mice at 2 and 9 weeks of age. Values are representative of 5 slides
spanning the whole pancreas of each mouse and 4 mice for each group at each age (magnification x125). (E) Cell cycle characteristics of b-cells from
WT mice and Hq mutant mice as measured by BrdU and pHH3 staining. BrdU+insulin+ cells are counted as b-cells at S phase (see example in F, upper
panel). pHH3+ (with punctuated pattern) insulin+ cells are counted as b-cells at G2 phase (see example in F, Hq mice lower right panel). pHH3+ (with
strong nuclear expression) insulin+ cells were counted as b-cells at M phase (see example in F, WT mice lower left panel). Data are shown as
mean6SE. *P,0.05 in Hq mutant mice vs. WT mice.
doi:10.1371/journal.pone.0004394.g001
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insulin. In accordance with our in vivo observations, b-cell
apoptosis in the Hq mutant mice islets was 8-fold increased in
the untreated islets (*p,0.05). When islets were exposed to H2O2,
there was a 16.5-fold increase in b-cell apoptosis in the WT mice
(**p,0,05), and a 14-fold increase in the Hq mutant mice islets
(p,0.05). When compared to the WT mice, there was a 6.8-fold
increase in the Hq mutant mice islets (p,0.05), when islets were
exposed to H2O2 (Fig. 2A&B). Because apoptosis results in
decreased b-cell mass, we hypothesized that Hq animals would be
hyperglycemic. Contrary to our predictions, Hq mutant mice
showed significantly lower fasting blood glucose levels as well as
improved glucose tolerance during an ipGTT (Fig. 2C). Our data
confirm previously published data that AIF depletion in the liver
and/or skeletal muscle leads to increased insulin sensitivity [15].
Because Hq mice are global hypomorphs, we can only assume that
minimal insulin secretion from the reduced b-cell mass is sufficient
to maintain glucose homeostasis in insulin hyper-sensitive mice.
This indicates that hepatic and muscular defects in the oxidative
phosphorylation may counteract the development of diabetes,
despite its deleterious effects on b-cell survival.
AIF depletion leads to increased b-cell apoptosis in
human islets without affecting insulin secretion
To investigate the significance of AIF and oxidative stress in
human islets, AIF was knocked down by small interfering RNAs
(siRNA). Western blot analysis of AIF expression shows 76%
downregulation of AIF protein expression in human islets exposed
for 3 days to siRNA directed to AIF (siAIF) versus scrambled
control (siScr, Fig. 3A). In line with our observations in islets from
Hq mutant mice, exposure of isolated human islets to siAIF
resulted in a 8.8-fold increase in b-cell apoptosis (p,0,05),
analyzed by double staining for TUNEL and insulin (Fig. 3B).
After exposure to the siRNAs, isolated human islets were treated
with 50 mMH2O2 for 2 h. This resulted in a 26-fold increase in b-
cell apoptosis in the siScr islets and a 6.5-fold increase in the siAIF
treated islets (Fig. 3B, p,0.05). Furthermore, H2O2-induced b-cell
apoptosis was 2-fold higher in the AIF depleted islets compared to
siScr control (p,0.05).
To assess the effect of AIF depletion on insulin secretion, we
have performed a glucose stimulated insulin secretion assay (GSIS)
in siAIF and siScr transfected human islets. Basal and stimulated
insulin secretion (Fig. 3C) as well as the stimulatory index (Fig. 3D)
was not significantly changed in response to AIF depletion.
Despite its deleterious role in inducing b-cell apoptosis, AIF
depletion did not impair b-cell function, neither basal nor glucose
stimulated insulin secretion. Then we compared response to
H2O2. As expected, H2O2 decreased glucose stimulated insulin
secretion in control as well as in siAIF treated islets. Stimulatory
index was decreased by 23% by H2O2 in siScr islets and by 40% in
siAIF islets (p,0.05), assuming that AIF plays a role to protect the
islets from oxidative stress, but is not involved in insulin secretion
itself.
Discussion
Recent work in Hq mutant mice, which have an 80% decrease
in AIF expression, suggests that AIF depletion results in increased
neuronal cell death [13]. Under physiologic conditions, AIF acts as
a free radical scavenger in the mitochondrial respiratory chain to
prevent apoptosis. Considering the high correlation of mitochon-
drial dysfunction and oxidative stress with T2DM, we hypothe-
sized that AIF may play an important role in the regulation of b-
cell mass and survival.
In the present study, we report that AIF depletion results in a 3-
fold decrease in b-cell mass at 2-weeks of age which was further
decreased with age. This was due to the missregulation of cell cycle
control. Although there was no difference in proliferating b-cells in
the Harlequin mice, 3-fold more b-cells in the Hq mice retained in
G2 phase of the cell cycle. In accordance to previous studies we
found that Hq b-cells are highly prone to apoptosis [21,22].
A proposed mechanism for the induction of apoptosis could be
oxidative stress, which is associated with abnormal cell cycle
checkpoint function. Under normal circumstances the cell cycle
proceeds without interruptions. However, if cycling cells are
damaged by agents which induce oxidative stress, a G2 check
point response is triggered and cells pause and repair the damage
[24]. In the case of a severe damage, cells may alternatively
undergo apoptosis. Given the role of AIF in mitochondrial
respiration as a hydrogen peroxide scavenger, loss of AIF could
result in an accumulation of ROS, which would then generate a
misregulation of b-cell cycle and apoptosis. This is further
supported by the finding, that b-cells from both AIF-deficient
mice (Hq mutant mice) and human islets (AIF-siRNA-treated)
displayed increased sensitive to cell death induced by hydrogen
peroxide. b-cells are in general very sensitive to oxidative stress, in
particular with hydrogen peroxide, due to their low expression of a
peroxide scavenging system [7].
Given the role of b-cell mitochondria as key regulators of
glucose stimulated insulin secretion, we hypothesized that Hq mice
show an impaired glucose tolerance. Surprisingly, and in
accordance to a recent study, AIF deficiency in Hq mutant mice
did not impair glucose tolerance. Hq mice were rather hypogly-
cemic compared to wt. This could be due to impaired glucose
sensing as a result of selective neuron loss reported in Hq mutant
mice, but is more likely to be a result of improved insulin sensitivity
[15]. Many studies have linked changes in mitochondrial oxidative
phosphorylation to the development of insulin resistance and
diabetes [14,16,25]: Importantly, a recent study in tissue specific
muscle- and liver AIF knockout mice and Hq mice with a global
AIF deficiency shows that a primary OxPhos defect alone does not
cause diabetes, but rather increases insulin sensitivity and reduces
fat mass [15]. In line with our results, this study found that Hq
mice displayed improved glucose tolerance associated with
reduced fasting and glucose-induced insulin secretion, possibly
due to the improved insulin sensitivity. This explains, why Hq mice
still maintain normoglycemia, despite their loss of b-cell mass.
Interestingly, in the absence of oxidative stress, AIF depleted
human islets did not show any changes in insulin secretion. When
compared to WT islets, Hq islets showed a similar response to
glucose, confirming the hypothesis that AIF does not directly act
on insulin secretion. Nevertheless, when islets were exposed to
H2O2, insulin secretion was further impaired in the AIF depleted
islets, assuming that AIF plays a role in protecting the islets from
oxidative stress, but is not involved in insulin secretion itself.
Figure 2. AIF depletion in mice leads to increased b-cell apoptosis. (A, B) Triple staining for TUNEL in red, insulin in green and 49,6-
diamidino-2-phenylindole (DAPI) in blue was performed on fixed, paraffin-embedded sections from isolated islets from 9-week old mice treated for
2 h with or without 50 mM H2O2. (B) Results are expressed as percentage of TUNEL-positive b-cells6SE. The mean number of b-cells counted was 700
for each treatment condition. (C) Glucose tolerance test with 2 mg/g BW glucose: Fasting and glucose stimulated plasma glucose levels are
significantly lower in 12–16 week old Hq mutant mice (n = 9) compared to age-matched WT mice. Data are shown as mean + SE. *p,0.05 in Hq
mutant mice vs. wt mice. **p,0.05 in H2O2 treated vs. untreated control.
doi:10.1371/journal.pone.0004394.g002
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The proposed compensation mechanism involves a shift to
anaerobic glucose metabolism and increase in fuel utilization [15].
It is important to note; that the Hq mice, despite their OxPhos
deficiency, had no indication of elevated ROS levels [26].
However, our finding that AIF is necessary for maintaining b-
cell mass is in favor of a critical role of ROS signaling and
oxidative stress in the b-cells and supports the role of AIF as a free
radical scavenger in the mitochondrial respiratory chain to prevent
apoptosis.
Our data provide new insights into a protective effect of AIF on
b-cell turnover. Loss of AIF could therefore be one of the
mechanisms of b-cell apoptosis.
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Figure 3. AIF depletion leads to increased b-cell apoptosis in human islets without affecting insulin secretion. (A) Isolated human
pancreatic islets were exposed to siRNA to AIF (siAIF) or scrambled control siRNA (siScr) for 3 days. The knockdown efficiency was determined by
Western blot analysis. Actin was used as a loading control on the same membrane after stripping. This Western blot is representative of three
independent experiments from three different organ donors. The density of expression levels were quantified after scanning and normalised to actin
levels. (B–D) 3 days after transfection, islets were exposed to 50 mM H2O2 for 2 h. (B) Islet sections were prepared for analysis of b-cell apoptosis by
the TUNEL assay. Islets were double-stained for insulin in green and counterstained for DAPI in blue. Results are means6SE of the percentage of
TUNEL-positive b-cells. The mean number of b-cells counted was 3400 for each treatment condition. (C,D) GSIS: after the H2O2 treatment, islets were
washed and basal and stimulated insulin secretion analyzed during successive 1-h incubations at 2.8 mM (basal) and 16.7 mM (stimulated) glucose.
Data are normalized to insulin content. (D) Stimulatory index denotes the ratio between stimulated and basal values of insulin secretion. (B–D) All
assays were performed in triplicate or quadruplicate in three independent experiments from 3 different organ donors, respectively. *p,0.05 to siScr
control, **p,0.05 in H2O2 treated vs. untreated control.
doi:10.1371/journal.pone.0004394.g003
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